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Biologic scaffolds derived from mammalian extracellular matrix (ECM) have been extensively 
used in pre-clinical and clinical applications to promote constructive tissue remodeling in a 
number of anatomic locations. The clinical success of these technologies depends on a number of 
factors including the species and tissues from which they are derived, the efficacy of the 
decellularization process, and post-processing modifications such as crosslinking and 
solubilization, among others.  
The ECM is produced by the resident cells of every tissue and hence, it is thought to 
constitute the ideal substrate for each unique cell population. It is therefore logical to assume that 
a substrate composed of site-specific ECM would be favorable for clinical use in homologous 
anatomic locations. However, the advantages of using site-specific (homologous) ECM scaffolds 
in clinical applications is still a matter of debate. Part of the difficulty in addressing this issue 
arises from the fact that most studies have investigated the application of ECM-derived scaffolds 
in either homologous or non-homologous locations independently, but they have rarely been 
directly compared in properly designed studies.  
The present dissertation shows the development of ECM-based biomaterials derived from 
cardiac and esophageal tissues. The decellularized scaffolds are compliant with decellularization 
standards and are then used to evaluate the tissue specific effects of homologous ECM in vitro 
and in a preclinical models of cardiac and esophageal repair.  
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Ricardo Londono, PhD 
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1.0  INTRODUCTION AND SPECIFIC AIMS 
This section will introduce the mechanism of biomaterial mediated tissue repair and discuss 
current limitations in tissue engineering. The clinical need for cardiac and esophageal tissue 
repair as well as currently available regenerative medicine technologies for these applications 
will be discussed as well. Finally, the central hypothesis and specific aims of the present 
dissertation will be introduced 
 
1.1 FACTORS WHICH AFFECT THE CLINICAL OUTCOME OF BIOMATERIAL-
BASED THERAPIES 
1.1.1 Overview of the Biomaterial-Host Interaction. 
The host response to an implanted material begins immediately upon implantation and consists 
of both the response to the inevitable iatrogenic tissue injury during implantation and the 
response to the material itself. In most cases, the implantation-induced component resolves 
quickly as part of the normal wound healing process. However, the response to the material will 
last for the length of time the material is present in the host.  Materials which elicit a persistent 
proinflammatory response are likely to be associated with abundant fibrous connective tissue 
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deposition and the consequences of effector molecules secreted by recruited inflammatory cells. 
Materials which either rapidly degrade or reach a steady state of tolerance with adjacent host 
tissue are typically associated with minimal scarring, a quiescent population of resident 
inflammatory cells, and adjacent tissue types appropriate for the anatomic location. The host 
response to an implanted material can be affected by the aforementioned factors. (Table 1). 
 
Table 1. Factors that Affect the Host Response to Biomaterials 
The biomaterial-host interaction is a complex process that depends upon many different factors. These factors can be 
conceptually categorized in four different groups: Host-related and biomaterial-related factors which affect the host 
response and chapters in which they are discussed. 
 
 
 Biomaterial-Related Factors Host-Related Factors Application-Related Factors Microenvironmental Factors 
Composition (material)  Age Complexity of tissue/organ 
to be repaired 
Contamination of the 
treatment site 
Degradability  Nutritional status Performance expectations Presence of scar tissue 
Mechanical properties Immunocompetence Adjuvant therapy  Previous interventions 
Sterility  Co-morbidities Surgical placement Availability of healthy and 
vascularized adjacent tissue 
Antigenicity  Medications  Exposure to appropriate 
physiologic and mechanical 
stimuli  
 
Active ingredients (drugs)  Wound healing ability   
 
1.1.2 Biomaterial-Related Factors 
Biomaterial-related factors have been the focus of studies for many years. Such factors include 
the base composition of the material (e.g. Titanium alloy versus Poly(etherurethane urea) versus 
Extracellular Matrix, etc.), surface texture, surface ligand landscape, degradability, and device 
design parameters such as pore and fiber size among others.  At the very best, it can be assured 
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that no biomaterial is inert and the functional success of any implanted biomaterial is ultimately 
determined by the interplay between material and other factors. 
 The primary determinant of success or failure of an implanted biomaterial is the host 
response to the material itself over time (Figure 1). Although the physical and mechanical 
properties of a material at the time of implantation are obviously important, the integrity of the 
properties at one month, one year, five years and beyond is just as important for those materials 
intended to remain for the lifespan of the patient. The host response can mitigate or destroy, 
encapsulate, or otherwise alter the composition of the biomaterial over time resulting in changes 
to the form and mechanical properties of the material itself [25]. Hence, it is not the degree to 
which the physical characteristics of the material resemble the targeted anatomic location before 
implantation that determines the performance of a biomaterial, but rather the host response over 
time. 
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Figure 1. Host response to biomaterial implantation 
The host response to implanted biomaterials depends upon many factors. Although the initial stages of the 
biomaterial-host interaction are shared among all materials and include tissue damage during implantation and 
protein adsorption to the surface of the material, the host response quickly transitions into complex phases that 
depend directly upon the type of material being implanted, implantation location, and the conditions of the 
microenvironment. These phases involve cellular and molecular components of the innate immune system and the 
wound healing response, and will ultimately determine the clinical outcome (i.e. encapsulation Vs. scar formation 
Vs. constructive remodeling). 
 
The host response is initiated with the activation of the immune system as a result of cell 
and tissue damage during biomaterial implantation. Upon contact with the host tissues, the 
surface of the biomaterial is coated with blood and plasma proteins through a process known as 
the Vroman effect [415]. Depending on the type of biomaterial and surface topography (i.e. type 
I collagen vs. heparin coated polytetrafluoroethylene vs titanium), the type and amount of 
adsorbed molecules will vary, and as a result, so will the composition and arrangement of the 
interface between the host tissues and the implant.   
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As a result of the Vroman effect, host cells typically do not interact directly with the 
surface of the biomaterial, but rather with the adsorbed protein layer. This protein layer – 
sometimes in conjunction with clot formation during hemostasis, forms a temporary yet fibrin-
rich matrix that bridges and mediates the interaction between the host tissues and the biomaterial. 
With degradable materials (e.g. non-cross linked biologic scaffolds, poly (lactic-co-glycolic 
acid), polyglactin), this temporary matrix serves as a bridge that facilitates cellular access and 
promotes infiltration into the material. With non-degradable biomaterials (e.g. permanent 
titanium alloy implants, polypropylene) the adsorbed protein layer serves as an interface that 
provides sites for cell attachment and mediates the interaction between the host and the 
implanted construct [271] .     
Within minutes of implantation the cellular response becomes predominated by 
neutrophils at the host-biomaterial interface. The neutrophil response peaks within 48-72 hours 
after implantation and it is the hallmark of the acute innate immune response. In addition to 
eliminating pathogens that may be present at the treatment site, neutrophils play important roles 
in the immune response such as establishment of signaling gradients that attract and activate 
other components of the innate immune system[457], initiation of granulation tissue formation, 
and - in the case of degradable biomaterials, secretion of enzymes such as collagenases and 
serine proteases [312] that initiate the process of biomaterial degradation and remodeling of the 
treatment site[271].  
As a result of signaling gradients established by neutrophils, the innate immune response 
transitions to a macrophage dominant infiltrate that slowly replaces the accumulated neutrophils 
at the host-biomaterial interface. The type and magnitude of the macrophage response will 
depend primarily on the material and host factors identified in Table 1.  Some  degradable 
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biologic materials placed in anatomic locations within healthy, vascularized tissue can degrade 
within weeks[78, 354] and promote a pro-remodeling M2 macrophage-associated response that 
leads to functional, site-appropriate tissue deposition[27, 410]. Alternatively, certain types of 
synthetic biomaterials can promote pro-inflammatory processes that will lead to foreign body 
reaction, scar tissue formation, and chronic inflammatory processes associated with an M1 
macrophage phenotype [13, 240, 261]. Permanent, non-degradable biomaterials, such as metallic 
plates or screws, typically lead to a foreign body reaction as a result of “frustrated phagocytosis”, 
and can promote inflammation, seroma formation, and eventually encapsulation.  The degree to 
which each type of response is deemed acceptable will depend upon the type and specific 
performance expectations of the application (e.g. temporary orthopedic support vs. functional 
organ replacement vs. tissue fillers in reconstructive applications). 
1.1.3 Host-Related Factors 
Host-related factors have been underappreciated as a determinant of  the host response to 
implanted materials. As a result, host-related factors have not been thoroughly considered in the 
context of patient outcomes in existent studies. These factors include age, nutritional status, body 
mass index, co-morbidities such as diabetes, and medications being taken by the patient among 
others. As stated previously, the initial host response to implanted biomaterials is primarily 
orchestrated by plasma proteins and the innate immune system and as such, any factors or 
underlying conditions that may affect these variables will inevitably alter the biomaterial-host 
interaction.     
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1.1.3.1 Age 
The aging process affects all body systems and associated functions including 
immunocompetence. In fact, immunosenescence is thought to be one of the major predisposing 
factors to increased incidence of infection in older individuals [185]. Some of the most important 
age-related changes in the cellular component of the innate immune system are summarized in 
(Table 2). 
Table 2. Effect of age in cellular component of innate immunity 
(Adapted from [185]) Although the absolute and circulating numbers of neutrophils and monocytes/macrophages in 
the immune system is not typically affected by age, important changes including decrease phagocytosis, decreased 
chemotaxis, and decreased signaling molecule production are observed with age. In turn, these changes have the 
potential to negatively affect the host response to implanted biomaterials. 
 
Cell type Changes in Composition Changes in Function References 
    Monocytes/    
Macrophages 
No change in absolute 
number 
Decreased phagocytosis Hearps et al. 2012[186] 
McLachlan et al. 
1995[291] 
No change in circulating 
frequency 
Decreased ROS 
production 
Nguyen et al. 2005[313] 
Qian et al. 2012[350] 
Increased percentage of 
CD14+ 16++ non-
classical monocytes 
Increased TNF-α 
production via TLR-4 
Seidler et al. 2010[393]        
van Duin et al. 
2007[446] 
Reduced percentage of 
CD14+ 16- classical 
monocytes 
Decreased IL-6 and TNF-α 
production via TLR1/2 
 Neutrophils No change in circulating 
numbers  
Reduced chemotaxis in 
vitro 
Born et al. 1995[54]   
Butcher et al. 2001[72] 
No change in CD11a, 
CD11b expression 
Reduced phagocytosis Fulop et al. 2004[151]    
Tseng et al. 2012[439] 
 Impaired NET formation Wenisch et al. 
2000[459] 
 Increased/decreased ROS 
formation 
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The cellular component of the innate immune system and its role in responding to the 
presence of foreign materials is closely examined in Section 1.4.3. Although absolute numbers of 
neutrophils and macrophages are not typically affected by aging, important cellular changes 
including the ability to mobilize, establish chemical gradients, and phagocytize pathogens and 
foreign elements are usually observed with advanced age. These changes can affect the process 
of biomaterial-associated tissue repair by affecting material degradation, cell migration and 
proliferation, angiogenesis, neo-matrix deposition, and tissue remodeling.   
In addition to affecting the immune system, the aging process alters adult stem cell 
functionality and behavior [277, 327].  Stem cells are necessary for homeostasis and the wound 
healing response. These precursor cells maintain organ function and are responsible for tissue 
repair. In turn, therapeutic approaches that rely on native stem cell populations[410] for the 
organization of newly formed tissue will inevitably be affected by the aging process.   As in the 
case of age-related changes associated with the innate immune system, aging does not appear to 
decrease the absolute number of stem cells, but instead, it impairs their capacity to produce 
progenitor cells and to differentiate [404]. 
1.1.3.2 Nutritional Status  
Malnutrition is a global problem with implications for the host-biomaterial interaction. 
Malnutrition can  result in increased susceptibility to infections and co-morbidities, impaired 
healing ability, altered metabolic state, and changes to the innate immune system that directly 
affect the interaction between the host and an implanted biomaterial (Table 3). 
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Table 3. Nutritional status-related changes to innate immune system 
Although malnutrition can increase the number of leukocytes and granulocytes, this phenomenon is attributed to an 
underlying chronic pro-inflammatory state due in part to increased susceptibility to infections. As with aging, 
malnutrition causes a decrease in functionality in the cells of the immune system. These changes affect the host-
biomaterial interaction and include decreased chemotaxis, phagocytosis, and adherence among others. 
 
Parameter References 
Similar or elevated number of leukocytes  Hughes et al. (2009) [208] 
Schopfer and Douglas (1976)[387] 
Elevated number of granulocytes Najera et al. (2004)[307] 
Schopfer and Douglas (1976)[387] 
Reduced granulocyte chemotaxis Vasquez-Garibay et al. (2002)[450] 
Vasquez-Garibay et al. (2004)[451] 
Reduced granulocyte adherence to foreign material Goyal et al. (1981)[173] 
Reduced granulocyte microbicidal activity  Dougals and Schopfer (1974)[120] 
Chhangani et al (1985)[91] 
Keusch et al. (1987)[235] 
Reduce leukocyte phagocytosis Carvalho Neves Forte et al. (1984)[80] 
Shousha and Kamel (1972)[406] 
Schopfer and Douglas (1976)[387] 
Increased markers of apoptosis in leukocytes Nassar et al. (2007)[309] 
Increased signs of DNA damage in leukocytes Gonzalez et al. (2002)[167] 
Reduced levels or activity of complement system 
components 
McFarlane (1971) [290] 
Ozkan et al. (1993)[334]  
Sakamoto et al. (1992)[377] 
Kumar et al. (1984)[253]  
Sirisinha et al. (1973)[412]  
 
1.1.3.3 Comorbidities 
The host response is affected by a number of underlying pathologic conditions, particularly those 
which affect the immune system, wound healing ability, stem cell viability, and/or the state of 
the tissues adjacent to the treatment site. 
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1.1.3.4 Obesity 
Data from the National Health and Nutrition Examination Survey, 2009–2010[140, 325] 
indicates that more than 2 in 3 adults are considered to be overweight or obese in the United 
States. Obesity is a risk factor for type 2 diabetes and cardiovascular disease, and both obesity 
and diabetes are now recognized as pro-inflammatory diseases [331]. Although the inflammatory 
state present in these conditions is distinct from that of acute inflammation [249], there are a 
number of implications for the field of biomaterial-mediated tissue repair that have been often 
ignored in preclinical and clinical studies.  
Inflammation is a fundamental component of the host response to implanted bio-
materials. The innate immune system modulates the wound healing response and is a key 
mediator and determinant of the clinical outcome of biomaterial implantation[273] (Figure 1). 
Immune cells, particularly neutrophils and macrophages are the main effectors in most 
biomaterial applications. As first responders, neutrophils clear pathogens and establish chemical 
gradients that affect later stages of biomaterial–host inter-action. Macrophages, on the other 
hand, display phenotypic heterogeneity and are responsible for both positive and negative events 
during biomaterial-mediated tissue repair. Macrophage phenotype has been shown to be 
predictive of clinical outcome in the context of biologically derived biomaterials. While the 
presence of M1 macrophages is associated with pro-inflammatory processes including foreign 
body reaction, cytotoxicity, and biomaterial encapsulation, M2 macrophages are associated with 
constructive tissue remodeling and site-appropriate tissue deposition[25, 62, 65, 471]. Obesity 
has been tightly associated with M1 macrophage accumulation within adipose tissue and other 
organs [249, 458, 473]. In addition, obesity has also been shown to increase pro-inflammatory 
molecule production [206]. Hence, obesity and other underlying conditions that may promote 
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proinflammatory environments should be taken into account when considering biomaterials as 
possible treatment options.  
1.1.3.5 Diabetes 
Diabetes mellitus, a condition that affects an estimated 29 million patients in the United States 
and an additional 86 million pre-diabetic patients[1], is among the most overlooked factors that 
can affect the host–biomaterial interaction. Diabetes mellitus is considered a pro-inflammatory 
disease[249] that increases susceptibility to infections and bacteremia in the acute setting and can 
cause vascular deterioration and diabetic ulcers chronically. Increased susceptibility to infections 
and bacteremia are risk factors for bacterial engraftment on artificial heart valves and in synthetic 
vascular grafts, and both conditions are independent risk factors for infective endocarditis [93, 
239]. Vascular damage, on the other hand, can promote tissue necrosis and infection, and can 
prevent the cellular component of the immune system to access the treatment site. 
 
1.1.4 Application-Specific Factors 
1.1.4.1 Anatomical Placement 
Biomaterials are used in virtually every anatomic location for a wide variety of clinical 
applications. Each anatomic site (e.g., blood contact, musculotendinous, central nervous system, 
skin, GI tract, respiratory, pelvic floor reconstruction, bone and cartilage, total joints, etc.) is 
associated with distinctive conditions such as an air interface, blood contact, and mechanical 
loading (Figure 2). These environmental conditions affect the host response by providing stimuli 
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(e.g., cyclic stretching, load bearing, laminar flow, presence of an interface, etc.) that directly 
affect cellular processes such as migration and differentiation[127, 157, 267, 324, 374]. 
Figure 2. Anatomic placement 
Distinctive conditions such as an air interface (esophagus), blood contact (vascular grafts), and 
mechanical loading (orthopedic applications) play a role in the host response to implanted 
materials. Anatomic placement and performance expectations (e.g. temporary orthopedic support 
versus whole organ regeneration) dictate biomaterial design parameters. 
1.1.4.2 Performance Expectations 
Application-specific requirements such as electrical conductivity, biosensing (e.g., glucose 
sensors, implantable cardioverter defibrilators), enzyme/hormone production, contractility, and 
load bearing will exist depending on the target tissue/organ to be repaired. In addition, these 
conditions necessarily dictate design parameters. For example, joint replacement implants must 
be strong enough to bear weight without breaking or deformation, heparin-coated vascular 
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constructs are intended to decrease thrombus formation and improve blood flow, synthetic 
meshes used in hernia repair must possess sufficient tensile strength to withstand the 
biomechanical forces exerted by and on the abdominal wall, and semi-permeable membranes in 
dialysis and extra corporeal membrane oxygenation (ECMO) machines must selectively facilitate 
molecule traffic. 
1.1.5 Microenvironment-Related Factors 
1.1.5.1 State of Adjacent Tissue 
In addition to the aforementioned factors, the clinical outcome of regenerative strategies for 
tissue repair also depends on microenvironmental conditions such as the state of adjacent and 
surrounding tissue (i.e. healthy and vascularized versus hypoxic and necrotic), the presence 
structural damage due previous interventions and scarring, and bacterial contamination. 
Vascularized healthy tissue facilitates nutrient traffic and immune system access to the treatment 
site[273]. Granulation tissue formation and angiogenesis are both important phases of the host 
response to implanted biomaterials, and they depend on the state of the surrounding tissue and 
the microenvironment.  While healthy and vascularized surrounding tissue is typically associated 
with clinical success of biomaterial technologies, necrotic and contaminated  implantation areas 
are associated with infection and implant failure[82, 116, 156] . Furthermore, scarred tissue 
can act as a fibrotic barrier between the host and the implant, affecting the host-
biomaterial interaction, and ultimately leading to implant failure.   
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1.1.5.2 Implant Site Contamination  
Bacterial contamination can cause implant failure. For example, once engrafted in biomaterials, 
bacteria have been shown to cause artificial heart valve dysfunction [252, 258, 320], abscess 
formation[116, 129] , biofilm formation[15, 19], and sepsis[12, 306, 416]. In the case of 
degradable materials, bacterial contamination can affect degradation rates and compromise the 
biomechanical properties of the biomaterial [365, 482] . In fact, when the surgical field is 
contaminated, biomaterials derived from biologic sources are indicated for use over synthetic 
biomaterials [238] due in part to their antimicrobial properties and their degradability  [56, 378]. 
If contamination persists, further interventions including revisions and abscess drainage are 
required. The clinical performance of biomaterials has consistently been suboptimal once these 
events have occurred 
In summary, no biomaterial is biologically inert, and while it might be acceptable for 
constructs intended for temporary use to be merely biotolerable[68] , biomaterials intended for 
use in more complex applications—including those requiring functional tissue/organ 
replacement and/or constructive tissue remodeling—will inevitably have to adhere to more 
stringent design and biocompatibility criteria. Biomaterial composition, the host, the type of 
tissue/performance expectations of each specific application, and the microenvironment will 
ultimately dictate whether or not each response to implanted constructs is deemed acceptable. 
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1.2 BIOMATERIALS FOR TISSUE REPAIR 
As stated previously, the discipline of tissue engineering/regenerative medicine (TE/RM) exists, 
in part, because traditional methods of approaching some challenging medical problems have 
yielded only incremental advancements in spite of enormous investment of research time and 
resources. The treatment of pathologies such as stroke[138, 168, 381, 434, 463], Type I 
diabetes[287, 310, 478], volumetric muscle loss[175, 441], esophageal cancer[89, 142, 191, 228, 
476, 477], and inflammatory bowel disease[165, 376] has improved, but the improvement has 
been largely the result of advancements in symptomatic care, surgical technique and 
instrumentation; not as a result of curative discoveries or development of methods for replacing 
the diseased tissue with functional healthy tissue.  
The field of tissue engineering/regenerative medicine is based upon the following 
fundamental strategies to promote functional tissue replacement: cell-based therapies, scaffold-
based approaches, provision of bioactive molecules, or combinations of these strategies. The 
majority of work to date has focused upon cell-based therapies [52, 55, 86, 122, 215, 236, 248, 
286, 348, 352]. Of course, any successful approach for creation of functional tissue will require 
cells, but one strategic variable is the source of cells; i.e., exogenous delivery of harvested 
allogeneic or autologous cells to the site of interest vs. recruitment of endogenous cells to the site 
of interest. Similarly, scaffold-based strategies can include approaches in which an appropriately 
configured scaffold material is placed in-situ as a guide or inductive template for functional 
tissue replacement or, alternatively, strategies in which the scaffold is used as a substrate upon 
which cells are seeded ex-vivo, with or without selected bioactive molecules, prior to surgical 
implantation of the cell-scaffold construct. 
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Scaffold materials for TE/RM can be either synthetic or harvested from naturally 
occurring sources (Figure 3).  A wide variety of synthetic materials have been used as scaffolds 
for tissue repair and such materials have mechanical and material properties which are well 
characterized [18, 21, 35, 103, 223, 370, 407, 447, 491]. Synthetic materials are manufactured 
with high precision and generally have an identified and expected tissue response. In contrast, 
biologic scaffolds consist of either the intact extracellular matrix (ECM) following tissue 
decellularization or individual components of the ECM such as Collagen Type I, laminin, or 
hyaluronic acid [14, 28, 44, 194, 282, 346, 418, 452, 479]. Biologic scaffolds tend to elicit a 
friendlier host response than synthetic materials (i.e., less foreign body reaction and promote 
constructive tissue remodeling – the deposition of site appropriate, functional tissue) but are 
subject to biologic variability in their natural composition and mechanical properties. 
Furthermore, the methods by which naturally occurring bioscaffolds are manufactured can have 
a marked effect upon their performance. The clinical use of naturally occurring scaffolds and the 
pros and cons of such biologic materials are discussed in this section. 
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Figure 3. Biomaterials for tissue repair can be classified as synthetic, biologic, or hybrid 
1.2.1 Synthetic Biomaterials 
A vast array of synthetic biomaterials exists ranging from degradable PLGA or poly(lactic-co-
glycolic acid), to permanent titanium allow implants for orthopedic applications. For example, 
the most commonly used non-degradable synthetic mesh materials for abdominal and inguinal 
hernia repair are polypropylene (PP), polyethylene, and polyethylene terephthalate (PET)[82, 
401], and knitted polypropylene is now the most frequently used material for ventral hernia 
repair[95, 99, 189, 241]. Polypropylene's robust mechanical properties and beneficial effect upon 
the repair of ventral hernia and pelvic organ prolapse is well documented, but the host soft tissue 
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response is characterized by chronic inflammation, dense fibrous connective tissue deposition 
and complications such as erosion, exposure, and pain for patients  [137, 335]. 
 
Of particular relevance to this thesis is the synthetic biomaterial poly(ester urethane)urea 
(PEUU), a biodegradable, cytocompatible elastomer[425], a material that was used to construct 
the hybrid cardiac patch used in Specific Aim 3. Biomaterials in this class offer interesting 
characteristics for a variety of  soft-tissue remodeling applications. PEEUU enables great control 
and flexibility in design parameters including the choice of hard and soft segments, and the 
potential to be utilized as a thermoplastic elastomer[178, 177].  For this study, PEUU was 
manufactured via electrospinning, a process through which a polymer solution charged with a 
high voltage generates an electrical force strong enough to overcome surface tension of a 
pendant drop of the solution and ejecting a polymer jet. The bending and whipping instability of 
the polymer jet combined with fiber splaying and a rapidly evaporating solvent yields fibers that 
are collected on a grounded or charged collection surface. Through this process the resulting 
morphology and size of the fibers can be finely controlled by changing the voltage, feed rate, and 
collector distance, among others [178]. 
1.2.2 Biologic Biomaterials  
A detailed description of these materials is found in section 1.3. Biologic scaffolds can be 
composed of intact mammalian extracellular matrix (ECM), or individual components of ECM 
such as collagen, laminin, or hyaluronan. Such scaffold materials would ideally maintain the 
native ultrastructure and composition of the ECM. The preparation of an ECM scaffold derived 
from native mammalian tissue requires a combination of chemical and mechanical processing 
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steps that result in efficient decellularization of the source tissue. As stated above ECM scaffolds 
have been prepared from a variety of tissues including dermis, small intestine, urinary bladder, 
pericardium, liver, skeletal muscle, and adipose tissue among others. 
Most source tissue material used for derivation of ECM bioscaffolds are xenogeneic or 
allogeneic in nature, and therefore require the efficient removal of cellular antigens to prevent 
foreign body recognition and activation of an antibody-mediated rejection response by the host  
following in vivo implantation. Depending upon the tissue of interest, mechanical methods such 
an manual or automated delamination of muscle and mucosal layers is typically followed by a 
combination of physical, chemical, and enzymatic methods to achieve complete 
decellularization.  
The goal of any decellularization process is the removal of all cellular and nuclear 
material while maintaining the composition, microstructure, mechanical properties, and biologic 
activity of the remaining native ECM. A biologic scaffold material is considered efficiently 
decellularized when it meets the following criteria: (1) Lack of nuclei present within the scaffold 
material following histologic or chemical nuclear staining; (2) Total scaffold material dsDNA 
content must be less than 50 ng/mg; (3) Any remaining DNA remnants present in the scaffold 
material must be less than 200 base pairs in nucleotide length [105]. Physical treatments for 
decellularization include sonication, scraping and/or shaking, or subjection to freeze-thaw cycles. 
Such methods facilitate the disruption of cell membranes and removal of cell contents from the 
native ECM. Enzymatic treatments with detergents or ionic solutions further denature cell 
membranes and disrupt intercellular bonds. Because the ECM of different tissues varies with 
regard to composition, structure, and density, the combination of methods used to achieve 
efficient decellularization varies across tissues. 
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1.2.3 Hybrid Biomaterials 
Hybrid constructs seek to combine the tunable and versatile physical properties of synthetic 
biomaterials with the immunomodulatory properties and constructive remodeling potential of 
biologic biomaterials. For example, a method to coat a synthetic polypropylene hernia mesh with 
ECM has previously been described. [136, 466]. In these studies, the resulting hybrid mesh was 
shown to alter the default acute host response to the polypropylene mesh by delaying and 
reducing the accumulation of pro-inflammatory foreign body giant cells. This response was 
associated with a suppression of the proinflammatory M1 macrophage phenotype at the 
polypropylene/host tissue interface. The new host tissue deposition was altered after 35 days. 
The pores in the ECM coated mesh were filled with loose connective tissue rather than the dense, 
large fiber collagenous tissue noted in the uncoated mesh material pores. These differences in 
remodeling were associated with no loss of biaxial mechanical strength. Nonetheless, it is 
unknown whether these favorable outcomes persist in the long term well after the ECM 
component had fully degraded. In this study a hybrid material composed of PEEU and an 
acellular matrix derived from cardiac tissue was used to promote constructive remodeling of the 
myocardium in a preclinical model of myocardial infarction. 
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1.3 BIOLOGIC SCAFFOLDS COMPOSED OF MAMMALIAN EXTRACELLULAR 
MATRIX 
1.3.1 The Extracellular Matrix: Structure and Function First paragraph. 
The ECM is a complex milieu of both structural and functional molecules that are secreted and 
maintained by the resident cells of every tissue. Originally thought to exist with the singular 
purpose of providing structural support, it is now recognized that the ECM is a reservoir of 
information in the form of molecular and mechanical cues that contribute to the maintenance of 
cellular homeostasis, promotion of optimal tissue/organ function and, if necessary, mediation of 
wound healing and tissue repair [211]. By providing sites for cell attachment, the ECM can not 
only facilitate communication between adjacent cells but also participate directly in signal 
transduction, adapt to mechanical changes in the microenvironment, respond to signaling 
gradients, and sense and respond to disruption of tissue integrity. In turn, the response of local 
cell populations to these changes may or may not involve changes in gene expression profiles, 
cell migration, metabolic and proliferation rates, production of signaling molecules, and 
neomatrix deposition. In short, in addition to providing structural support, the ECM can 
modulate cell behavior while in turn, the local cell populations in the microenvironment can 
respond by modifying the composition and ultrastructure of the ECM. For this reason, the ECM 
exists in a highly fluidic state of dynamic reciprocity with the local cell populations and the 
microenvironment [51]. 
   
The main components of the ECM are largely conserved across multiple species and 
include bifunctional proteins such as collagen, fibronectin and laminin, glycosaminoglycans - 
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and to a lesser extent, growth factors, and cytokines (Figure 4).  This principle lays the 
foundation of biologic scaffold compatibility across multiple species and permits the use of 
biologic scaffolds derived from xenogeneic sources in clinical applications. The exact 
distribution and three-dimensional arrangement of these molecules is tissue specific and at least 
partially responsible for the diverse mechanical, functional, and structural properties observed 
across different tissues. Not surprisingly, the original in situ composition of the ECM plays an 
important role in determining composition and structure of the resulting ECM-derived biologic 
scaffolds, but the main determining factor of these properties are the methods used for 
processing and manufacture[25].   
Both the composition and the structure of ECM-based scaffolds are important aspects of 
the host-biomaterial interaction. Since the ECM is produced by the resident cells of every tissue, 
it constitutes the ideal substrate for each cell population and as such, it is logical and plausible 
that a substrate composed of site-specific ECM would be favorable for clinical use in 
homologous anatomic locations. However, the advantages and preference of site-specific 
(homologous) ECM scaffolds is still a matter of debate. Part of the difficulty in addressing this 
issue arises from the fact that most studies have investigated the application of ECM-derived 
scaffolds in either homologous or non-homologous locations independently, but they have rarely 
been directly compared in properly designed studies (Table 4). 
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Figure 4. Composition of the Extracellular Matrix: 
The extracellular matrix is composed of multiple functional molecules that are shared across multiple tissues and 
different species. For the most part, the ECM is made up of type I collagen, but other types of collagen are also 
found throughout the ECM in varying amounts depending on the source tissue. Non-collagenous molecules found in 
significant amounts include fibronectin, laminin, and glycosaminoglycans. The conformation and structure of these 
molecules enable the ECM to interact with local cell populations. The specific amount and distribution of these 
components of the ECM are partially responsible for the mechanical properties and function of the multiple organs 
and tissues. 
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Table 4. Site Specificity of ECM-Derived Scaffolds 
The final composition and ultrastructure of ECM-derived biomaterials depend on a number of factors including the source tissue from which they are derived 
and the methods of decellularization. However, it has yet to be determined whether or not differences in composition and structure offer site specific 
clinical advantages when scaffolds are used in the treatment of homologous anatomic locations. This table shows examples supporting both homologous and 
heterologous use of ECM-derived biologic scaffolds. 
Study Study details Study Study details
Sellaro, T.L., et al., Maintenance of hepatic 
sinusoidal endothelial cell phenotype in 
vitro using organ-specific extracellular 
matrix scaffolds.  Tissue Eng, 2007. 13(9): 
p. 2301-10
Liver ECM allows sinusoidal 
endothelial cells to maintain 
their differentiated phenotype in 
culture longer Vs. other ECMs
Badylak, S.F., et al., Esophageal 
preservation in five male patients after 
endoscopic inner-layer circumferential 
resection in the setting of superficial 
cancer: a regenerative medicine approach 
with a biologic scaffold. Tissue Eng Part A, 
   
SIS-ECM used to remodel the 
esophageal mucosa after 
circumferential, long segment 
en bloc removal in the setting 
of adenocarcinoma in 5 male 
patients
Lin, P., et al., Assessing porcine liver-
derived biomatrix for hepatic tissue 
engineering. Tissue Eng, 2004. 10(7-8): p. 
1046-53
Liver ECM improved 
maintenance of liver-specific 
functions of hepatocytes 
compared to adsorbed 
collagen cultures
Sicari, B.M., et al., An acellular biologic 
scaffold promotes skeletal muscle 
formation in mice and humans with 
volumetric muscle loss. Sci Transl Med, 
2014. 6(234): p. 234ra58.
UBM-ECM implantation used 
as surgical treatment
 for volumetric muscle loss in 
both a preclinical rodent 
model and five male patients
Singelyn, J.M., et al., Catheter-Deliverable 
Hydrogel Derived from Decellularized 
Ventricular Extracellular Matrix Increases 
Endogenous Cardiomyocytes and 
Preserves Cardiac Function Post-
Myocardial Infarction.  J Am Coll Cardiol, 
2012. 59(8): p. 751-63.
Injection of cardiac ECM-
derived hydrogel in a 
myocardial infarction model 
increases endogenous 
cardiomyocytes in the infarct 
area and maintains cardiac 
function without inducing 
Valentin, J.E., et al., Functional skeletal 
muscle formation with a b iologic scaffold. 
Biomaterials, 2010. 31(29): p. 7475-84
SIS-ECM used to replace 
abdominal wall muscle 
showing partial replacement 
by islands and sheets of 
skeletal muscle, able to 
generate maximal contractile 
force similar to native tissue
Medberry, C.J., et al., Hydrogels derived 
from central nervous system extracellular 
matrix. Biomaterials, 2013. 34(4): p. 1033-
40
Brain ECM hydorgels 
increased neurite length when 
compared to other ECM-
derived hydrogels 
Nieponice, A., et al., Patch esophagoplasty: 
esophageal reconstruction using biologic 
scaffolds. Ann Thorac Surg, 2014. 97(1): p. 
283-8
Four patients requiring 
esophageal reconstruction 
underwent a patch 
esophagoplasty using an 
ECM scaffold composed of 
porcine urinary bladder ECM
Crapo, P.M., et al., Biologic scaffolds 
composed of central nervous system 
extracellular matrix. Biomaterials, 2012. 
33(13): p. 3539-47
CNS ECM retains 
neurosuportive proteins and 
stimulates proliferation, 
migration, and
differentiation of PC12 cells
Kruper, G.J., et al., Salvage of failed local 
and regional flaps with porcine urinary 
bladder extracellular matrix aided tissue 
regeneration. Case Rep Otolaryngol, 2013. 
2013: p. 917183
UBM-ECM used to salvage 
flaps with extensive wound 
breakdown on the face and 
neck
Reports supporting homologous  use of ECM scaffolds Reports supporting heterologous  use of ECM scaffolds
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1.3.1.1 Composition of the ECM  
Collagen 
Collagen accounts for more than 90% of the protein found in the ECM and although more than 
25 different isoforms have been identified, the majority of collagen found within the ECM is 
type I collagen (Figure 5).  Varying amounts of collagen type III, IV, V, VI, and VII are also 
notably present in the ECM, although not ubiquitously[445]. For example, the collagen 
composition of ECMs originating from different tissues will vary depending on whether or not a 
basement membrane is present: While tendons and ligaments rely mostly on type I collagen to 
provide the tensile strength required to meet the mechanical demands placed upon these 
structures[50], tissues with a basement membrane  will have a more diverse collagen 
composition with significant amounts of type IV collagen[176]  and type VII collagen[88]. 
Whereas type IV collagen has ligand affinity for endothelial cells and it is therefore found within 
the basement membrane of vascular structures, type VII collagen is needed to facilitate fibril and 
epithelial cell anchoring, and as a result it is mostly found protecting overlying keratinocytes 
from sheer stress forces under epithelial structures. 
Collagen-based scaffolds are among the most extensively used scaffolds in clinical 
applications and are available in multiple formats including native, cross-linked, and solubilized 
gel forms. Due to its abundance and ubiquity, type I collagen is the most commonly used 
isoform, although other forms have also been used. Currently available collagen-based products 
are beyond the scope of the present manuscript, but their composition and applications have been 
thoroughly reviewed  by Chattopadhyay, S and Raines, RT [85]. 
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Figure 5. Schematic representation of the assembly of collagen I 
A, Individual collagen polypeptide chains. The polypeptides consist of the repeating sequence Gly-X-Y, where X is 
often proline and Y is often hydroxyproline; B, Collagen is made up of three polypeptide strands which are all left-
handed helixes and twist together to form a right handed coiled coil. The strands are synthesized as precursor chains 
with propeptides on the C and N ends. The propeptides are cleaved into short non-helical telopeptides; C, Collagen 
molecules self-assemble into collagen fibrils; D, Collagen fibers are formed by end to end and lateral assembly of 
collagen fibrils, resulting in a regular banding pattern that is characteristic of collagen. 
Fibronectin 
Fibronectin is the second most abundant molecule in the ECM and it is present in both soluble 
and tissue isoforms in submucosal, basement membrane, and interstitial tissues. Fibronectin is 
rich in domains that facilitate adhesion to multiple cell types via integrins, a unique property that 
makes it suitable for the coating of biomaterials and tissue culture instrumentation [197] (Figure 
6). 
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Figure 6. Structural Composition of Fibronectin 
Fibronectin is a dimeric molecule joined by two disulfide bonds at the carboxy end. Each domain of the fibronectin 
molecule has binding sites for cell receptors and ECM molecules 
 
Laminin 
Laminin is a trimeric cross-linked polypeptide that exists in multiple configurations depending 
upon the specific combination of the peptide side chains that make up its main molecule (Figure 
7). Laminin can be found throughout the body within basement membranes where it mainly acts 
as an adhesion molecule for different cell types and other components of the ECM. Laminin is an 
important molecule for the organization and maintenance of vascular structures and for 
interactions between the ECM and mesenchymal stem cells [344].   
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Figure 7. Laminin Structure 
Laminin is composed of three polypeptide chains (α, β1, and β2) organized into the shape of a cross. Laminin has 
binding domains for heparin, collagen IV, heparin sulfate, and cells. 
Second paragraph. 
Glycosaminoglycans 
Glycosaminoglycans (GAGs) present in ECM include heparin, heparan sulfate, chondroitin 
sulfate A and B, and hyaluronic acid (HA). GAGs are unbranched polysaccharides composed of 
repeating disaccharide units that possess the ability to retain water and bind growth factors and 
cytokines (Figure 8). HA possesses significant biologic activity by itself, directly influencing cell 
proliferation, migration, and differentiation. The concentration of HA within ECM is highest in 
fetal and newborn tissues and has been associated with the enhanced healing ability of the human 
body during these early stages of life[198]. 
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Figure 8. Glycosaminoglycan Structure 
Glycomsaminoglycans are long unbranched polysaccharides that are composed of a repeating disaccharide unit. The 
disaccharide unit is composed of one of two modified sugars, either N-acetylgalactosamine or N-acetylglucosamine. 
 
Matricryptic peptides 
Matricryptic peptides are molecular fragments of parent proteins within the ECM that possess 
important biologic activity [97, 301, 358]. During degradation, the ECM undergoes structural 
and conformational alterations that result in matricryptic peptide exposure, activation, and 
release into the microenvironment. The processes responsible for these events include enzymatic 
cleavage[159], protein multimerization[483], adsorption of molecules to other ECM 
components[396], cell-mediated mechanical deformation[389], and ECM denaturation[375]. As 
a whole, the processes that result in matricryptic peptide encryption, activation, and release are 
thought to have evolved as a mechanism to embed and hide these signals making them available 
only when necessary (i.e. after tissue injury). To date, several matricryptic peptides have been 
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identified, and although a thorough examination of matricryptic peptide activity is beyond the 
scope of this manuscript, comprehensive reviews of matricryptic peptide activation and function 
have been presented by Davis et al.[110] and Ricard-Blum et al. [361] .   
Growth factors and Cytokines 
As previously mentioned, some components of the ECM such as GAGs and proteoglycans can 
bind to and sequester growth factors and cytokines, a process that allows the ECM to serve as a 
reservoir of signaling molecules [246, 417] - storing them after secretion by resident cells, and 
releasing them when needed and appropriate stimuli are provided[34]. The mechanisms that 
mediate the process of growth factor and cytokine release are complex and rely upon a number 
of strategies including binding affinity, conformational changes, and degradation of the ECM 
during normal and pathologic processes. For instance, perlecan can function as a low-affinity co-
receptor for bFGF, a property that makes it an important component of processes such as bFGF-
mediated mitogenesis and angiogenesis. Degradation of either the perlecan protein core or the 
heparan sulfate chains releases ECM-bound bFGF in its active form and allows it to participate 
in these processes in a controllable fashion[214].  
In addition to regulating storage, availability, and biological activity of these molecules, 
binding to the ECM also influences cytokine diffusion and adequate presentation to receptors on 
the cell surface[475]. Other important signaling molecules that bind to and associate with 
perlecan include G-MCSF, IL-3, INFγ, and hepatocyte growth factor[213]. In addition, there is 
evidence that the activity of TGF-βs may be controlled through binding to ECM components 
such as decorin and biglycan[385, 386]. Adequately designed decellularization protocols can 
preserve growth factors and cytokines during the manufacturing process in such a way that they 
are still detectable in significant amounts in the resulting scaffolds [460]. 
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1.3.2 The Extracellular Matrix as a Bioscaffold for Tissue Repair. 
ECM-derived scaffolds are subject to natural variability in their biologic composition and 
mechanical properties depending on the species, age, [409], and anatomic location [106, 230, 
422, 468] from which they are derived. However, a great degree of variability depends upon the 
exact methods of manufacture[26], the efficiency of the decellularization process[67, 231], and 
any post-processing modifications to which the materials might be subjected depending on the 
specific intended application. Commonly used post-processing modifications include different 
degrees of chemical cross linking, powdering, and manufacture of multi-laminate constructs 
[444].  Solubilization into hydrogel forms has recently become increasingly popular [218, 219, 
292, 379, 395, 467] (Figure 9).   
 
Figure 9. ECM-Derived Hydrogels for Tissue Repair 
ECM-derived hydrogels can be prepared by placing lyophilized powdered ECM into a 0.01 N HCl solution of 
1mg/mL pepsin and stirring at room temperature for 48hrs. The pre-gel ECM solution is then brought to pH 7.4 
using 0.01 N NaOH and diluted to the desired volume/salt concentration using 10× and 1 × PBS. Pepsin is 
irreversibly inactivated at pH above 7.5ECM at which point the material gels. Hydrogels provide advantages such as 
injectability, the ability to fill an irregularly shaped space, and possess the inherent bioactivity of native matrix. 
 
The specific composition and three-dimensional architecture of scaffolds composed of 
decellularized tissues vary significantly depending on the source tissue and the methods used for 
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decellularization. Scaffolds manufactured from the ECM of small intestinal sub-mucosa (SIS-
ECM) and urinary bladder matrix (UBM-ECM) have been most extensively characterized, and 
will therefore serve as the exemplars.  Like the ECM from the tissues they originate from, SIS-
ECM and UBM-ECM are composed of more than 90% collagen, the majority of which is type I 
[26, 282] with varying amounts of collagen type III, IV, V, VI, and VII also present. The ECM 
derived from the esophageal mucosa (EM-ECM) [230], skeletal muscle (SM-ECM), and dermis 
(D-ECM) show similar composition [230, 347, 357, 468]. The collagen composition of ECM-
derived bioscaffolds originating from different tissues will vary depending on whether or not a 
basement membrane is present.  Tissues with a basement membranes such as UBM-ECM, EM-
ECM and SM-ECM contain collagen type IV, type VII and other basement membrane associated 
adhesion proteins such as laminin and fibronectin, while other ECMs have much less of these 
collagen types [61, 197, 230, 282].  Originally described as a purely structural biomolecule, 
evidence has shown that cryptic peptide motifs with important biological activity to the 
constructive remodeling processes including mitogenesis, chemotaxis, and differentiation of 
stem cells are still present and active in biologic scaffolds after decellularization [8, 358, 437, 
453]. Some matricryptic peptides have been shown to be antimicrobial [56] and antiangiogenic 
[361]. In the context of biomaterial-mediated tissue repair, these matricryptic peptides are 
released as a consequence of cleavage and degradation by phagocytic cell populations recruited 
to the zone of injury and release of matrix metalloproteases (MMPs) and other proteases (See 
section 1.4.5) [110, 192, 361].    
 
In addition to the various types of collagen and other basement membrane-associated 
molecules, ECM-derived bioscaffolds contain a mixture of glycosaminoglycans (GAGs) 
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including heparin, heparan sulfate, chondroitin sulfate and hyaluronic acid [198]. It is now well 
established that the specific methods of decellularization particularly affect GAG content [161], 
the details of which will be discussed in the next section. 
1.3.3 Tissue and Whole Organ Decellularization 
The objective of the decellularization process is to remove cell associated antigens while 
preserving the ultrastructure and composition of the ECM. When properly manufactured, the 
resulting scaffold can serve as a cell-guiding template that contains the necessary cues and 
adequate three-dimensional configuration to facilitate cell infiltration, modulate the immune host 
response, and mediate tissue repair upon implantation and subsequent degradation[27, 410]. 
However, even the gentlest methods of tissue decellularization will inevitably alter the 
composition and ultrastructure of the ECM and remove some of these desirable components. 
Hence, the decellularization process is better described as a balancing act between thorough 
decellularization and conservation of biologically active molecules that favorably modulate the 
host response. In fact, adequate decellularization can only be achieved in some instances at the 
expense of losing important molecular components of the ECM and dramatically disrupting its 
original structure. Therefore, a thorough understanding of the properties and application of the 
various decellularization agents is necessary for the systematic optimization of decellularization 
protocols.   
A number of decellularization methods that are suitable and appropriate for the source 
tissues have been described [105, 106, 161, 230, 468] (Table 5). The type and amount of 
bioactive molecules that remain in the scaffolds vary significantly depending on the specific 
methods of decellularization and other processing steps. 
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Table 5. Published Protocols for Tissue Decellularization 
 
Source Tissue Species Report 
Central nervous 
system 
Porcine Crapo, P.M., et al., Biologic scaffolds composed of central nervous system extracellular matrix. Biomaterials, 2012. 33(13): p. 
3539-47. 
Dermis Human Wainwright, D.J., Use of an acellular allograft dermal matrix (AlloDerm) in the management of full-thickness burns. Burns, 
1995. 21(4): p. 243-8. 
Esophagus Murine 
(Rat) 
Sjoqvist, S., et al., Experimental orthotopic transplantation of a tissue-engineered oesophagus in rats. Nat Commun, 2014. 5: 
p. 3562. 
Esophageal 
mucosa 
Porcine Keane, T.J., et al., Preparation and characterization of a biologic scaffold from esophageal mucosa. Biomaterials, 2013. 
34(28): p. 6729-37. 
 Ovine Ackbar, R., et al., Decellularized ovine esophageal mucosa for esophageal tissue engineering. Technol Health Care, 2012. 
20(3): p. 215-23. 
Heart Porcine Wainwright, J.M., et al., Preparation of cardiac extracellular matrix from an intact porcine heart. Tissue Eng Part C Methods, 
2010. 16(3): p. 525-32. 
 Porcine French, K.M., et al., A naturally derived cardiac extracellular matrix enhances cardiac progenitor cell behavior in vitro. Acta 
Biomater, 2012. 8(12): p. 4357-64. 
 Murine 
(mouse) 
de Castro Bras, L.E., et al., Texas 3-step decellularization protocol: looking at the cardiac extracellular matrix. J Proteomics, 
2013. 86: p. 43-52. 
Lung Porcine Price, A.P., et al., Automated Decellularization of Intact, Human-Sized Lungs for Tissue Engineering. Tissue Eng Part C 
Methods, 2014. 
Skeletal Muscle Porcine Wolf, M.T., et al., Biologic scaffold composed of skeletal muscle extracellular matrix. Biomaterials, 2012. 33(10): p. 2916-25 
Trachea Porcine Haykal, S., et al., The effect of decellularization of tracheal allografts on leukocyte infiltration and of recellularization on 
regulatory T cell recruitment. Biomaterials, 2013. 34(23): p. 5821-32. 
 Porcine Kutten, J.C., et al., Decellularized Tracheal Extracellular Matrix Supports Epithelial Migration, Differentiation and Function. 
Tissue Eng Part A, 2014. 
Small intestinal 
submucosa 
Porcine Lindberg, K. and S.F. Badylak, Porcine small intestinal submucosa (SIS): a bioscaffold supporting in vitro primary human 
epidermal cell differentiation and synthesis of basement membrane proteins. Burns, 2001. 27(3): p. 254-66 
Urinary Bladder Porcine Lindberg, K. and S.F. Badylak, Porcine small intestinal submucosa (SIS): a bioscaffold supporting in vitro primary human 
epidermal cell differentiation and synthesis of basement membrane proteins. Burns, 2001. 27(3): p. 254-66 
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The use of harsh detergents can thoroughly decellularize tissues and successfully remove 
undesirable cellular remnants and epitopes, but such methods also disrupt the native 
ultrastructure and remove or decrease the availability of bioactive molecules that are favorable 
for the constructive remodeling response in vivo. In turn, milder treatments conserve more 
bioactive molecules, but may fail to remove all cell remnants and pro-inflammatory epitopes that 
can cause chronic inflammation leading to scar tissue formation , and dense collagenous non-
functional tissue deposition [65, 67, 474, 485]. Consequently, tissue processing methods, 
including decellularization and terminal sterilization techniques are critical determinants of the 
clinical performance of these scaffolds [69, 169, 362]. The optimal processing methods represent 
a balancing act of thorough decellularization vs. maintenance of ECM ultrastructure and 
favorable bioactive molecules. 
The most effective methods for tissue decellularization are determined by multiple 
factors, including the tissue’s cellularity (e.g. muscle vs. tendon), density (e.g. dermis vs. adipose 
tissue), lipid content (e.g. brain vs. small intestinal submucosa), and thickness (e.g. dermis vs. 
pericardium) (Figure 10). Inevitably, all methods will alter the composition of the ECM and will 
cause some degree of ultrastructure disruption. Thus, the objective of every decellularization 
protocol is to minimize these undesirable effects while meeting the criteria for decellularization. 
A brief summary of some commonly used decellularization agents (e.g. chemical, enzymatic, 
and physical) and their effects on cellular and extracellular tissue components is provided below: 
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Figure 10. Methods of Decellularization are Determined by the Source Tissue: 
A, Small Intestinal Submucosa (SIS) is mechanically decellularized by scarping and chemically decellularized by 
peracetic acid. The resultant acellular material is white in appearance. B, Example decellularization protocols for (1) 
thin laminates such as pericardium, (2) thicker laminates such as dermis, (3) fatty, amorphous tissues such as 
adipose, (4) composite tissues or whole simple organs such as trachea, and (5) whole vital organs such as liver. 
Arrow lengths represent relative exposure times for each processing step. ((Figure adapted from (Crapo et al., 
2011)[105])). 
1.3.3.1 Detergents:   
Detergents are important decellularization agents because they are very efficient at solubilizing 
lipid-containing cellular components such as cell walls and nuclear and mitochondrial 
membranes. In addition, detergents effectively dissociate proteins from DNA[105]. Disruption of 
nucleic acids facilitates the removal of genetic material from the ECM. However, detergents are 
non-specific, and therefore also disrupt and dissociate desirable proteins from the ECM, a side 
effect that can potentially minimize or eliminate the constructive remodeling response in vivo.  
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Non-ionic detergents such as Triton X-100, can effectively remove cellular material from 
most tissues and can therefore decrease potentially adverse immune responses following in vivo 
implantation. However, decellularization of dense tissues requires longer treatments and higher 
concentrations of such agents, both of which are associated with progressively greater disruption 
of the ECM ultrastructure and content. In contrast, ionic detergents such as sodium dodecyl 
sulfate (SDS) can efficiently and thoroughly remove cellular material from dense tissues 
including solid organs, but have the disadvantage of removing growth factors and significantly 
altering the ultrastructure of the ECM. Because of its cytotoxicity and ability to penetrate deeper 
into denser tissues even at low concentrations, multiple washes are necessary to ensure all SDS 
residues are removed from the scaffolds. Zwitterionic detergents such as 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) are preferred when the 
objective is the preservation of the ECM ultrastructure, but these detergents are only effective in 
decellularizing less dense tissues such as the lungs.  In summary, while non-ionic and 
zwitterionic detergents are better for ultrastructure preservation, ionic detergents are better cell 
removal agents[105] .  
1.3.3.2 Acids and Bases:  
Acids are commonly used agents that catalyze the hydrolytic degradation of multiple 
biomolecules.  For example, peracetic acid is frequently used as a disinfecting agent in the later 
stages of the decellularization process, but it also doubles as a decellularization agent that 
removes residual nucleic acids with minimal effect on the ECM composition and structure [163, 
193, 195]. Acetic acid can disrupt the structure of collagen within an ECM and therefore affect 
its biomechanical properties, but it has minimal effect upon sulfated glycosaminoglycan 
composition (sGAG) [119]. Bases on the other hand, are almost exclusively used to remove hair 
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from dermis samples during the early stages of decellularization [347, 357]. Bases have been 
shown to completely eliminate growth factors from the ECM [357], cleave collagen fibrils, and 
disrupt collagen crosslinks [170]. 
1.3.3.3 Hypertonic and Hypotonic solutions:  
Hypertonic solutions aid in the dissociation of DNA from proteins[104]. Hypotonic solutions 
have the ability to cause cell swelling and lysis with osmotic pressure without markedly 
modifying the ultrastructure of the ECM [472]. For optimal results, hyper- and hypotonic 
solutions are often alternated through several cycles. This process can facilitate removal of cell 
remnants and chemical residues left from the decellularization process. 
1.3.3.4 Alcohols:  
Alcohols contribute to the decellularization process by dehydrating and lysing cells [347], and 
extracting phospholipids [126, 264]. Isopropanol, ethanol, and methanol have been shown to be 
more effective than lipase in removing lipids from tissue and are therefore widely used in 
adipose tissue decellularization [64, 141]. Methanol in combination with chloroform has also 
been used during delipidation of tissues. However, some alcohols such as methanol and ethanol 
are commonly used as tissue fixatives in histology, and to precipitate proteins in molecular 
biology [78], and therefore they can potentially damage ECM ultrastructure [170, 171]. 
1.3.3.5 Enzymes:  
The use of enzymes in decellularization protocols provides high specificity for the degradation 
and removal of specific types of molecules. However, complete decellularization solely via 
enzymatic treatment is not possible, and enzymatic residues, even at low concentrations, can 
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impair recellularization and potentially cause an undesirable inflammatory response [105]. 
DNases and RNases are very useful in the removal of nucleotides, but only after cells have been 
lysed and lipid membranes have been disrupted with detergents and other agents [342] [128]. 
Endonucleases [342] may be more suitable for decellularization than exonucleases because they 
cleave nucleotides mid-sequence and are therefore more effective at fragmenting long strands of 
nucleic acids in preparation for removal. 
1.3.4 Criteria for Tissue Decellularization  
The Food and Drug Administration has not established standards for tissue decellularization. As 
a result, commercially available ECM-derived scaffolds (Table 6) contain different amounts of 
cell associated antigenic material. Studies have shown that cellular debris within biologic 
scaffold materials can have a pro-inflammatory effect that has in turn been associated with poor 
remodeling outcomes[67, 231]. Therefore, establishment of decellularization criteria have been 
suggested and include the following: 1) No visible nuclei per histologic evaluation via eosin & 
hematoxylin and 4',6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI) stains, 2) Any 
remaining DNA content should not exceed 200 base pair in length, and 3) the amount of double 
stranded DNA should not exceed 50ng per mg of dry weight of the material (Figure 11). 
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Table 6. Commercially Available Biologic Scaffolds for Tissue Repair 
 Source 
Species Source Tissue Product Company Post-Processing Form 
Bovine Fetal  skin DurepairTM TEI Biosciences Natural Dry scaffold 
 
Fetal  skin PriMatrixTM TEI Biosciences Natural Dry scaffold 
 
Fetal  skin SurgiMend® TEI Biosciences Natural Dry scaffold 
 
Fetal  skin TissueMend® TEI Biosciences Natural Dry scaffold 
 
Fetal  skin XenformTM TEI Biosciences Natural Dry scaffold 
 
Pericardium Dura-Guard® Synovis® Surgical Innovations Cross-linked Hydrated scaffold 
 
Pericardium Peri-Guard® Synovis® Surgical Innovations Cross-linked Dry scaffold 
 
Pericardium Vascu-GuardTM Synovis® Surgical Innovations Cross-linked Dry scaffold 
 
Pericardium Veritas® Synovis® Surgical Innovations Cross-linked Hydrated scaffold 
Equine Pericardium DurADAPTTM Pegasus Biologicals Cross-linked Dry scaffold 
 
Pericardium OrthADAPTTM Pegasus Biologicals Cross-linked Dry scaffold 
Human Dermis AxisTM Dermis Mentor Natural Dry scaffold 
 
Dermis Bard Dermal Allograft ® Bard Natural Dry scaffold 
 
Fascia lata AlloPatch ® MTF Natural Dry scaffold 
 
Fascia lata FasLata® CR Bard Natural Dry scaffold 
 
Fascia lata SuspendTM Mentor Natural Dry scaffold 
 
Skin AlloDerm ® LifeCell Natural Dry scaffold 
 
Skin Graft Jacket ® Wright Medical Tech Natural  Dry scaffold 
Porcine Dermis PelvicolTM CR Bard Cross-linked Hydrated scaffold 
 
Dermis Zimmer Collagen PatchTM Tissue Science Laboratories Cross-linked Hydrated scaffold 
 
Myocardium Ventrigel  Ventrix Gelation Hydrogel 
 
Skin PermacolTM Tissue Science Laboratories Cross-linked Hydrated scaffold 
 
Small intestinal submucosa (SIS) CuffPatchTM Biomet Sports Medicine Cross-linked Hyrdated scaffold 
 
Small intestinal submucosa (SIS) Durasis® SIS Cook Natural Dry scaffold 
 
Small intestinal submucosa (SIS) Oasis® Cook Biotech/Healthpoint Natural  Dry scaffold 
 
Small intestinal submucosa (SIS) Restore® DePuy Natural Dry scaffold 
 
Small intestinal submucosa (SIS) StratasisTM Cook Biomedical Natural Dry scaffold 
 
Small intestinal submucosa (SIS) Surgisis® Cook Biomedical Natural Dry scaffold 
 
Urinary bladder matrix (UBM) MatristemTM Acell Natural  Dry scaffold 
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Figure 11. Criteria for Tissue Decellularization 
The objective of the decellularization process is to remove all immunogenic cellular material while maintaining 
components of the ECM that are shared across species. Although official standard criteria for decellularization have 
not been established, proposed standards in (a) seek to avoid cellular remnants that might initiate or prolong 
detrimental inflammatory processes and potentially transmit zoonotic and/or prion-based diseases upon 
implantation. When properly decellularized according to these criteria, ECM-derived biologic scaffolds have 
consistently shown superior performance in vivo and in vitro. (b) H&E and DAPI stains of properly decellularized 
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ECM-based scaffolds with no visible nuclei. (c) In contrast, poorly decellularized scaffolds contain visible nuclei per 
H&E and/or DAPI stains (arrows). (d) Ethidium bromide gel showing that when properly decellularized, scaffolds 
contain DNA remnants below 200 bp in length (arrow), and (e) promote a quick transition to the favorable M2 pro-
remodeling macrophage phenotype upon in vivo implantation (M1 macrophages in orange and M2 macrophages in 
green). (f) On the other hand, poorly decellularized scaffold contain relatively large fragments of DNA above 200 bp 
(Arrow) and (g) promote a robust and prolonged M1-proinflamatory macrophage phenotype upon in vivo 
implantation. Scale bars 100µm. 
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1.4 BIOMATERIAL-HOST INTERACTION 
1.4.1 Default Mammalian Wound Healing Response 
The adult mammal has a few privileged tissues such as the epidermis, the intestinal epithelium, 
and the bone marrow which have the ability to regenerate, at least to a certain extent; however, 
this regenerative response is the exception rather than the rule in most adult mammals, and it 
only occurs after mild to moderate injury. In contrast, the more common wound healing response 
eventually and inevitably leads to fibrotic tissue formation through a process that involves a 
variety of cell types acting in highly coordinated spatial and temporal processes that eventually 
organize into dense scar tissue.  For example, myocardial fibrosis is the usual sequela following 
infarction, liver fibrosis is a downstream consequence of chronic hepatic disease, and esophageal 
scarring with associated clinical stricture is the expected outcome of extensive surgical ablation 
of the diseased esophageal mucosa. Even though the mechanisms underlying these processes are 
tissue-specific and not entirely understood, it is generally recognized that wound healing occurs 
in several complex phases [216, 296, 321, 366, 382, 461].  
 
Similarly, the response to the presence of foreign materials, including those materials of 
which biological scaffolds are composed, involves some of the same general components of the 
inflammatory and remodeling phases. However, regenerative medicine strategies seek to modify 
this default response by shifting the outcome of tissue injury and loss from an evolutionary 
derived process of hemostasis and scar tissue formation to one of well-orchestrated constructive 
remodeling and functional tissue restoration. Not surprisingly, such fundamental changes are not 
trivial, and they necessarily involve the mechanisms by which stem cell recruitment is initiated, 
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cell growth is controlled, cell fate is determined, and site appropriate parenchymal and non-
parenchymal tissue components are organized, vascularized, and innervated when necessary. 
Interestingly, signals to control most, if not all such processes exist within the naturally occurring 
ECM ECM [5, 8, 40, 282, 295, 296, 358, 435, 437, 484] 
1.4.2 Biomaterial-Host Interaction: Overview  
Most tissues in the human body do not have the ability to regenerate and as a result, an insult of 
sufficient magnitude will invariably lead to scar tissue formation and loss of tissue function. The 
steps responsible for tissue damage repair are defined as the wound healing response and have 
been traditionally classified into a number of complex and overlapping phases that include 
hemostasis, inflammation, cell proliferation, and tissue remodeling[10, 118, 288, 298]. When  
properly configured, biologic scaffolds have the ability to modify the outcome of the wound 
healing response from a process of scar tissue formation to one of constructive tissue 
remodeling, a term that implies the deposition of newly formed, site appropriate, functional 
tissue.  
Depending on a number of factors including the efficacy of decellularization, the use of 
chemical crosslinking agents, and the age of the source tissue from which ECM scaffolds are 
harvested, the host response to implanted ECM-derived biomaterials may vary from 
unacceptable to excellent[25]. Multiple studies have shown that constructive tissue remodeling 
consistently occurs when the following conditions are met: 1) The scaffold is thoroughly 
decellularized[67, 231], 2) Cross linking via chemical agents is avoided[444], 3) The scaffold is 
free of endotoxin and bacterial contamination[109], and 4) The scaffold is placed in contact with 
healthy surrounding tissue[32] and subjected to appropriate physiologic mechanical loads[11].  
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When these conditions are met, the host response consists of an initial neutrophil infiltrate 
followed by a mononuclear cell response that quickly transitions from an early M1 pro-
inflammatory phenotype to an M2 immunomodulatory, pro-remodeling phenotype within days 
of implantation[66]. As the scaffold degrades, endogenous stem/progenitor cells are recruited to 
the treatment site, neomatrix deposition occurs, and the remodeling process eventually 
culminates with the deposition of newly formed site-appropriate tissue that is at least partially 
functional and devoid of  chronic inflammatory processes[25] (Figure 12). In contrast, the host 
response to an ECM-derived scaffold that has not been properly configured is characterized by a 
process of chronic inflammation and scar tissue formation. Known causes of such a response 
include the presence of immunogenic cellular debris due to poor decellularization, the use of 
chemical crosslinking agents that may inhibit or delay scaffold degradation and matricryptic 
peptide release, and lack of adequate contact with viable, vascularized, innervated tissue upon 
surgical placement[25].   
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Figure 12. Overview of biomaterial-host Interaction (properly configured biologic scaffolds): 
The biomaterial-host interaction is a complex process that is composed of overlapping phases that resemble the 
traditionally described wound healing response. Within minutes of implantation, hemostasis and the formation of 
temporary fibrin-rich matrix that facilitates cellular access into the scaffold occurs. When the scaffolds are properly 
configured, this process is quickly followed by activation of the innate immune response, composed of sequential 
neutrophil and macrophage infiltrates that remove pathogens, clear cellular debris, and begin the process of scaffold 
degradation and matricryptic peptide release. As the macrophage infiltrate transitions into the M2 proremodeling 
phenotype, signaling molecules produced by the innate immune system and scaffold degradation products act 
synergistically to recruit stem/progenitor cells from adjacent tissues and the bone marrow. This heterogeneous cell 
population containing immune cells and stem/progenitor cells is referred to as the constructive cell infiltrate, and is 
responsible for further scaffold degradation, neomatrix deposition, and ultimately constructive functional tissue 
remodeling. 
 
Although the initial stages of the host response to both properly and poorly configured 
scaffolds are histologically indistinguishable from one another, the host response to poorly 
configured scaffolds quickly shows signs of a chronic inflammatory process and foreign body 
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reaction including the presence of multinucleate giant cells, a persistent M1-proinflammatory 
macrophage phenotype, and in some cases, serous effusion. The presence of these early signs 
invariably leads to an outcome of dense scar tissue formation. 
 
1.4.3 Biomaterial- Host Interaction: The Innate Immune Response 
As previously stated, the initial stages of the host response to implanted materials are very 
similar regardless of the quality and exact configuration of the material used. The host response 
invariably starts with activation of the innate immune system as a result of surgical trauma 
during implantation. Within seconds of scaffold placement, blood and plasma proteins are 
adsorbed to the surface of the scaffold - a process known as the Vroman effect [415].  In 
combination with hemostasis, the Vroman effect results in the formation of a temporary fibrin-
rich matrix. This transitional matrix bridges the gap between the host tissue and the implanted 
material facilitating cellular access into the scaffold. Simultaneously, cellular injury and the 
presence of a foreign material result in the activation of the innate immune response, a phase that 
begins with a neutrophil infiltrate within minutes of implantation. The extent and persistence of 
the neutrophil response depend upon a number of variables including contamination of the 
surgical field, the type of scaffold used, and the exact anatomic location being treated[20, 25, 
272].   
As first responders neutrophils are not only important for phagocytosis of cellular debris 
but are also the first line of defense against invading pathogens that might be present in the 
surgical field[312]. In addition to phagocytosis, and perhaps more relevant to the process of 
biomaterial-mediated tissue repair, neutrophils have the ability to secrete digestive enzymes 
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including collagenases, elastases, and serine proteases[312]. These enzymes allow neutrophils to 
initiate the processes of scaffold degradation and tissue remodeling, an important step that 
facilitates angiogenesis, promotes cellular infiltration into the scaffolds, and mediates 
matricryptic peptide release into the treatment site.  An equally important component of the 
neutrophil response is their ability to secrete a number of inflammatory mediators that include 
cytokines, chemokines, leukotrienes, and prostaglandins. This array of signaling molecules is 
controlled in great part by immunoregulatory cytokines such as interferon (INF)-gamma, IL-4, 
IL-10, and IL-13[440], allowing neutrophils to modulate both acute and chronic inflammatory 
processes and the process of tissue remodeling.  Pro-inflammatory cytokines such as tumor 
necrosis factor (TNF)-α and IL-1β[363] play an important role in the recruitment of other cell 
types of the immune system, particularly macrophages, and thus, are necessary for the initiation 
of the next phases of the innate immune response[457].  
The subsequent remodeling events are characterized by a mononuclear cell infiltrate that 
overlaps with the later stages of the neutrophil response.  During this phase, macrophages 
quickly become the predominant cell type at the treatment site by 7 days post-implantation.  The 
macrophage response is an important determinant of the outcome of the constructive remodeling 
process and is in fact necessary for a favorable outcome[66, 444]. Studies have shown that in 
vivo macrophage depletion after scaffold implantation inhibits the process of scaffold 
degradation and matricryptic peptide release, both of which are necessary steps for constructive 
remodeling to occur[444]. In addition to scaffold degradation, macrophages are key 
immunoregulatory mediators and play both positive and negative roles during wound healing and 
in the response to implanted materials due to their functional plasticity.  
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Macrophages are a heterogeneous cell population with diverse functional phenotypes 
ranging from M1 (classically activated, pro-inflammatory) to multiple subtypes of M2 (anti-
inflammatory, immunoregulatory, remodeling). M1 pro-inflammatory macrophages can be 
activated by mediators such as IFN-γ and LPS, and produce traditional pro-inflammatory 
cytokines including IL-1β, IL-6, IL-12, IL-23 and TNF-α, among others [281]. In addition, M1 
macrophages produce reactive oxygen species (ROS), can present antigens, and promote a Th1 
pro-inflammatory pathway[303]. In contrast, M2 immunoregulatory macrophages are activated 
by signals such as IL-4, IL-13, IL-10, and matricryptic peptides released from ECM-derived 
scaffolds[298]. M2 macrophages show increased expression of scavenger, mannose and 
galactose receptors, produce ornithine, polyamines, and promote Th2 type reactions [297].  
Despite their contrasting differences and heterogeneity, macrophage phenotype is highly plastic 
and dynamic, and ultimately determined by all factors that affect their microenvironment. In 
reality, macrophage phenotype exists along a spectrum between the M1 and M2 extremes - 
where any given cell may express or co-express different components of the M1 or M2 
phenotypes, rather than as a discrete functional state with clearly defined boundaries. 
In the context of ECM-derived biologic scaffolds, macrophage phenotype has been 
suggested to be a major determinant factor of the host response and clinical outcome [65-67]. 
ECM scaffold materials that promote constructive functional remodeling consistently show a 
higher percentage of M2 macrophages within weeks of implantation than those that promote scar 
tissue formation and encapsulation. These findings suggest that strategies to promote 
macrophage phenotype modulation toward a favorable M2 phenotype after implantation of 
ECM-derived scaffolds might improve clinical outcomes [66] (Figure 13).    
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Figure 13. Innate immune response to ECM-derived scaffolds 
the innate immune response to ECM-derived scaffolds is characterized by an initial neutrophil infiltrate as a result of 
tissue injury during the implantation process and the presence of a foreign material. (a) The neutrophil response 
becomes histologically apparent at the interphase between the scaffold and the native tissue as early as 1 day post 
implantation. (b) By day ten the constructive cell infiltrate is primarily composed of mononuclear cells that infiltrate 
deep into the scaffold as the material is degraded and matricryptic peptides are released. (c) By 2 weeks post 
implantation, the innate immune response is composed primarily of macrophages that have transitioned into the M2 
pro-remodeling phenotype. However, transition into the M2 phenotype is not always observed. When scaffolds are 
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not properly configured, a persistent M1 pro-inflammatory occurs which results in scar tissue formation. (d) M1 
macrophages are characterized by expression of CCR7 and CD86 surface cell markers among many others and the 
expression of pro-inflammatory signaling molecules. In contrast, M2 macrophages have been identified by CD206 
surface marker expression and can contribute to the remodeling process by participating in important processes 
including angiogenesis, immunoregulation, and stem cell recruitment and proliferation. (e) Factors known to 
contribute to the M1 pro-inflammatory macrophage phenotype, and the M2-proremodeling macrophage phenotype. 
 
1.4.4 Biomaterial- Host Interaction: Degradation of Extracellular Matrix Bioscaffolds 
The process of scaffold degradation serves two purposes: 1) As the scaffold degrades it is rapidly 
infiltrated by host cells and eventually replaced with functional, site-appropriate tissue, and 2) 
Enzymatic scaffold degradation is one of the most important methods by which matricryptic 
peptide release occurs in vivo. Both of these steps are necessary for a constructive remodeling 
process to occur. Inhibition of scaffold degradation either by chemical cross-linking or by 
methods of in vivo macrophage depletion inhibits the remodeling process [444]. 
The rate of scaffold degradation varies depending on a number of factors including the 
source tissue from which the scaffolds are derived, the use of cross-linking agents during 
manufacturing, and the metabolic and physiologic demands of the treatment site. For example, 
dermal ECM-scaffolds are characterized by a dense and compact ultrastructure that makes them 
difficult to fully decellularize and prolongs the in vivo degradation process. In contrast ECM-
scaffolds derived from less dense tissues such as the small intestinal submucosa can be easily 
decellularized and are rapidly degraded in vivo, generally by 10 weeks post-implantation. 
Degradation rates have been traditionally assessed via histologic examination. However, 
histologic identification of biologic scaffold ECM versus host tissue can be difficult, particularly 
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during the later stages of the remodeling process. An alternative to this approach is the use 
radioactively labeled ECM scaffolds that allow for tracking as they degrade in vivo. The basis of 
this approach is the integration of benign 14C into the collagen triple helix as a result of 14C-
proline weekly injections into the source animals. Over time, all tissues become rich in 14C, and 
liquid scintillation counting (LSC) can be used to quantitatively measure the in vivo degradation 
profile of various types of ECM scaffolds derived from these animals. Using this technique, 
studies have shown that SIS-ECM is completely degraded by 10 weeks post implantation[162, 
354], whereas in the case of dermal ECM biologic scaffolds at least 50% of the scaffold material 
still remains present at 24 weeks post implantation [77]. 
 
1.4.5 Biomaterial- Host Interaction: Stem Cell Recruitment 
Matricryptic peptide activation and release during scaffold degradation has potent effects on 
macrophage polarization and stem cell behavior, both important components of the remodeling 
response.  When generated in vitro via enzymatic degradation, matricryptic peptides have been 
shown to increase migration and proliferation rates of perivascular stem cells and endothelial 
cells [6, 358, 453], and favorably polarizing naïve macrophages (MØ) into and M2-like, pro-
remodeling phenotype.  
The in vivo study of matricryptic peptide release is a challenging task, as the effect 
observed in host tissues is confounded by multiple paracrine effector molecules. In vivo studies 
have shown that in addition to perivascular stem/progenitor cells originating from adjacent 
tissues [410], stem cells populations originating from the bone marrow can also contribute to the 
process of biomaterial-mediated tissue repair [317].   
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1.4.6 Clinical Applications 
Commercially available biologic scaffolds (Table 6) vary widely in their composition and 
methods of manufacture. As a result, the clinical performance of these scaffolds can vary widely. 
Some of the clinical applications in which these scaffolds have been successfully used are 
summarized in (Figure 14). For example, due to their antibacterial properties [56, 378], biologic 
scaffolds are preferred over synthetic meshes for hernia repair when the operative field is 
contaminated [238]. In reconstructive surgery, acellular tissue scaffolds have been widely used 
for breast reconstruction[73], although side effects including increased risk of seroma formation, 
foreign body reactions, and scarring have been observed [438]. The use of biologic scaffolds in 
fields such as vascular [255] and cardiothoracic surgery [383] is becoming increasingly popular, 
and to a lesser degree in applications including facial [383]  and esophageal repair[27, 315], 
among others.  
 
The process of biomaterial-mediated tissue repair is inherently different from true tissue 
regeneration. However, when appropriately manufactured, an implanted biologic scaffold can 
lead to constructive tissue remodeling and significant clinical success. The performance of 
biologic scaffold-based therapies is dependent upon a variety factors that ultimately affect the 
wound healing response. Although the set of criteria that have been historically identified to 
describe the ideal biomaterial focus upon the physical characteristics of the material (e.g., 
uniaxial or multidirectional strength, surface topology, suture retention strength, and 
compliance), the primary determinant of success of an implanted biomaterial is the host response 
to the material over time. The ability to understand and control the factors that play a role in 
modulating the host response will guide the design of the next generation biomaterials.    
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Figure 14. Clinical applications of ECM-derived scaffolds 
To date, ECM-derived biologic scaffolds have been used in multiple clinical applications with various degrees of 
success. For example, a number of multi-center clinical studies of ventral hernia repair have shown superior 
performance of ECM-derived biomaterials when applied to contaminated fields. In esophageal repair after mucosal 
resection in the setting of superficial non-invasive neoplastic disease, ECM-derived biomaterials have proven to be a 
viable alternative to radical esophagectomy. The use of ECM-derived biomaterials in applications such as neural 
tissue repair is still in very early stages and as a result, clinical studies have not yet been initiated. 
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1.5 REGENERATIVE MEDICINE APPROACHES FOR ESOPHAGEAL REPAIR 
1.5.1 The Human Esophagus 
The human esophagus is a tubular organ that extends from the epiglottis in the pharynx to the 
stomach. Structurally, it is composed of four concentric layers: the mucosa, the submucosa, the 
muscularis externa, and the adventitia [414]. The mucosa lines the lumen of the esophagus and is 
composed of a stratified squamous epithelium that serves as a protective layer for the deeper 
layers of the esophagus during deglutition. The submucosa consists of vascular, connective, and 
glandular tissues that provide mucous secretions to facilitate the passage of food. The muscularis 
externa is composed of two distinct muscular layers organized in circumferential and 
longitudinal directions that function in tandem to generate esophageal peristalsis. The muscularis 
externa transitions from skeletal muscle in the proximal end of the esophagus, to smooth muscle 
in the distal two thirds of the esophagus. The skeletal muscle portion of the esophagus is 
innervated by lower motor neurons that course through the vagus nerve and allow voluntary 
initiation of the deglutition process. The distal two thirds of the esophageal muscularis externa is 
composed of smooth muscle and is innervated by fibers originating from the sympathetic trunk 
and the vagus nerve. Once the deglutition process is voluntarily initiated, esophageal peristalsis 
is mediated by the sympathetic and parasympathetic innervation via a series of well-orchestrated 
muscle contractions, including opening and closing of the lower esophageal sphincter, that allow 
the process of food intake to occur[3, 205] (Figure 15). 
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Figure 15. The Human Esophagus 
(A) The majority of the esophagus resides in the mediastinum anteriorly to the vertebral column and the descending 
aorta and posteriorly to the trachea, lungs, and heart. The esophagus has three natural narrowings: at the cricoid 
cartilage, at the tracheal bifurcation, and as it passes through the diaphragm. (B) The esophagus and the stomach are 
separated by the gastroesophageal sphincter. While the esophagus is lined by a stratified squamous epithelium, the 
stomach is lined by a columnar epithelium. (C) The esophagus comprises four concentric layers: starting from the 
lumen, the mucosa (stratified squamous epithelium), submucosa (glands and connective tissue), muscularis externa 
(two layers: circumferential and longitudinal), and adventitia (connective tissue). UES, upper esophageal sphincter; 
LES, lower esophageal sphincter. 
1.5.2 Need for Esophageal Repair  
Pathologies that involve the structure and/or function of the esophagus are often life threatening. 
While damage to the mucosa can result in scar tissue formation and clinical stricture, damage to 
the muscularis externa, or injury to the innervation of the esophagus or lower esophageal 
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sphincter can compromise peristalsis and result in achalasia [323]. Damage to the lower 
esophageal sphincter itself can result in gastroesophageal reflux disease (GERD), a condition 
that can lead to Barrett’s esophagus and progress to adenocarcinoma [454]. Trauma, iatrogenic 
injury, and congenital malformations can have a variety of adverse consequences depending on 
the anatomic structures that are compromised. The most common of these adverse consequences 
include fistula and stricture formation [209].  
There is currently an unmet clinical need for effective methods of esophageal repair. The 
esophagus is a complex organ composed of non-redundant tissue that does not have the ability to 
regenerate. Currently available interventions for esophageal pathology have limited success and 
are typically associated with significant morbidity. An understanding of the different diseases 
that affect the esophagus, the anatomic and functional consequences of each pathologic process, 
and the shortcomings associated with currently available therapies is necessary for the 
development of successful strategies for esophageal repair (Table 7). 
Table 7 Anatomic Involvement of Esophageal Pathologies 
  
Anatomic Involvement 
Condition  Incidence  Mucosa  Submucosa Muscularis  Proximal Esophagus 
Distal 
Esophagus  LES* 
Adenocarcinoma 
52,000/year 
[16] (world) Always 
Upon 
invasion 
Upon 
invasion Rarely Mostly Mostly 
Squamous cell 
carcinoma 
398,000/year[16] 
(world) Always 
Upon 
invasion 
Upon 
invasion Mostly Rarely Rarely 
Caustic injury 5000/year [237] (US)  1st degree 2nd degree 3rd degree Possible Possible Possible 
Congenital 
deformity 
1 in 3000 births[112, 172, 
232] Possible Possible Possible Possible Possible Possible 
Perforations 
(trauma)  Very rare [102, 154, 421] Usually If severe If severe Mostly Rare Rare 
 
1.5.2.1 Esophageal Cancer 
The incidence of esophageal cancer has shown a recent dramatic increase in the US[130, 201] 
and worldwide[217]. This recent increase in esophageal cancer incidence is associated with a 
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change in the epidemiology of the two major types of esophageal cancer:  adenocarcinoma and 
squamous cell carcinoma [16, 308] (Table 8).  As recently as 30 years ago, squamous cell 
carcinoma was responsible for more than 90% of esophageal neoplasia in the United States. 
However, adenocarcinoma is now more prevalent in the United States and accounts for more 
than 80% of esophageal cancer cases[340]. Squamous cell carcinoma remains the most prevalent 
form of esophageal cancer in the rest of the world [100]. Despite advances in detection, 
diagnosis, and treatment, the 5-year survival rate for all patients diagnosed with esophageal 
cancer ranges from 15% to 20% [340]. 
Table 8. Esophageal Cancer: Comparative Characteristics of Adenocarcinoma Versus Squamous 
Cell Carcinoma 
  Adenocarcinoma Squamous cell carcinoma 
Overall incidence  Increasing  Decreasing 
Geography Predominant in the U.S. Predominant outside U.S. 
Demographics White males mostly African American males mostly 
Anatomic locations affected Distal esophagus Middle esophagus  
Risk factors GERD, Barrett's esophagus Alcohol and tobacco  
 
Adenocarcinoma 
Esophageal adenocarcinoma has one of the highest rates of increased incidence among neoplastic 
diseases worldwide [217, 338]. Esophageal adenocarcinoma is not only the most common form 
of esophageal cancer in the United States, but its increase in incidence is only matched by that of 
obesity [343, 480] (Figure 16). 
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Figure 16. Increase in incidence of esophageal adenocarcinoma and obesity 
(A) Esophageal adenocarcinoma has one of the highest rates of increased incidence among neoplastic diseases. (B) 
The increase in the incidence rate of esophageal adenocarcinoma is only matched by that observed in obesity. *Data 
for 2005–2020 are extrapolated. Figures adapted from Pohl and Welch 2005[343] and Sturm et al., 2004.[430] 
 
Esophageal adenocarcinoma develops primarily in the distal portion of the esophagus including 
the gastroesophageal junction as a consequence of Barrett’s esophagus, a pathologic process that 
is a downstream complication of GERD. The most common cause of GERD is lower esophageal 
sphincter relaxation or insufficiency, a condition that can be caused by mechanical factors such 
as obesity, pregnancy, or increased gastric volume and by non-mechanical factors such as central 
nervous system depressants and alcohol and tobacco abuse [340].  Barrett’s esophagus develops 
in approximately 10% of patients with GERD as a result of chronic exposure to the acidic 
contents of the stomach [454]. Over time, the esophageal epithelium adapts to the new acidic 
environment by transforming from squamous epithelium to columnar epithelium through a 
process known as metaplasia. Barrett’s esophagus is more common in white males over the age 
of 40 than in the rest of the population, and once it develops, 10% of those patients will further 
develop high grade dysplasia and adenocarcinoma[341]. Hence, the increased incidence of 
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esophageal adenocarcinoma is attributed in great part to obesity-related GERD and Barrett’s 
esophagus [355, 371]. 
Squamous cell carcinoma 
Squamous cell carcinoma is less common than adenocarcinoma in the United States and it 
typically occurs in patients over 45 years of age. It is four times more frequent in males than in 
females and it is eight times more frequent in Blacks than in Caucasians[486]. In the rest of the 
world, however, particularly in rural and underdeveloped areas, squamous cell carcinoma 
remains the most common cause of esophageal cancer[166]. As with many cancers, the main risk 
factors associated with squamous cell carcinoma are alcohol and tobacco use. Other factors such 
as poverty, caustic injury, achalasia, human papilloma virus[423], and consumption of hot 
beverages and mutagenic compounds (i.e. polycyclic hydrocarbons, nitrosamines) have also been 
associated with the disease [221].  
Squamous cell carcinoma has an insidious onset that typically presents with dysphagia, 
odynophagia, and/or esophageal obstruction [160, 429]. Although both adenocarcinoma and 
squamous cell carcinoma begin as superficial lesions in the esophageal mucosa, squamous cell 
carcinoma tends to localize to the middle third of the thoracic esophagus. Early lesions typically 
begin as patchy thickenings that slowly develop into polyps or exophytic tumors that eventually 
obstruct the lumen of the esophagus, or as ulcerated and infiltrative lesions that progressively 
invade all layers of the esophagus and eventually infiltrate the surrounding organs in the 
mediastinum (Figure 17). Whereas invasion of the trachea, bronchi, or lungs can lead to 
pneumonia usually resulting in detection of the disease, invasion of the aorta and pericardium 
can lead to catastrophic exsanguination [328].   
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Figure 17. Esophageal Cancer Staging 
The TNM (tumor, node, and metastasis) staging system takes into consideration a number of variables, including 
tumor invasion (T), the presence or absence of metastatic disease (M), and nodal invasion (N). Tumor staging will 
determine the clinical approach to the disease. Staging for adenocarcinoma of the esophagus is shown as an 
example. HGD, high-grade dysplasia. Figure adapted from Pennathur et al.[340] 
Standard of care  
Although recent improvements in screening, staging, surgical technique, adjuvant therapy, and 
patient selection have reduced morbidity and prolonged postoperative survival[53, 300, 304], 
significant controversy remains over the optimal management of esophageal carcinoma [38, 
302].  
As with many neoplastic processes, the primary objective following detection is surgical 
removal of the neoplastic tissue with or without adjuvant therapy. In the case of advanced 
disease, an esophagectomy followed by gastric pull up into the mediastinum and anastomosis of 
the gastric cardia and the proximal esophagus remains the only viable alternative [181]. 
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However, this procedure is associated with high morbidity, decreased quality of life, and high 
mortality rates [251, 402, 481].  
A number of novel alternatives for the treatment of non-invasive early stage disease are 
under investigation to ultimately replace the traditional watchful wait approach that inevitably 
leads to esophagectomy. Minimally invasive endoscopic ablation techniques for the treatment of 
Barrett’s esophagus with high grade dysplasia and superficial carcinoma are among the most 
studied approaches. Radiofrequency ablation is now an accepted treatment for flat Barrett’s 
esophagus. This technique offers significantly lower rates of stricture formation than other 
ablative techniques [233]. In cases where nodularity exists, endomucosal resection with or 
without ablation has been shown to be an effective treatment that prevents recurrence [400]. 
These procedures have shown improved survival rates and quality of life [125, 289]. However, 
the development of metachronous lesions after these procedures remains a common finding 
(21.5%). Risk factors for the development of metachronous lesions include piecemeal resection, 
no ablation therapy following endomucosal resection, multifocal neoplasia, and long segment 
Barrett’s esophagus [476]. Stepwise radical endoscopic resection (SRER), a technique being 
investigated for the treatment of recurrent Barrett’s esophagus after radiofrequency ablation or 
endomucosal resection, has shown to be effective, although it usually requires a large number of 
therapeutic sessions and complications such as esophageal stenosis require dilation in 50% of 
cases [403]. 
In summary, limitations associated with these techniques include the requirement for 
numerous interventions, incidence of metachronous lesions, absence of a suitable tissue 
specimen for histologic assessment, and the unavoidable sampling error that occurs in patients 
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with long segment disease [275].  Furthermore, even with successful treatment there is need for 
repeated postsurgical dilation in more than 50% of cases [329, 403]. 
1.5.2.2 Congenital Abnormalities  
Every year, 1 in 3000 births presents with esophageal pathology (Table 7). Congenital 
abnormalities can compromise all layers of the esophagus and include esophageal atresia, 
tracheo-esophageal fistulas, and esophageal agenesis (Figure 18). Without exception, these 
defects are incompatible with life. 
 
Figure 18. Esophageal Congenital Abnormalities 
The most common congenital abnormalities of the esophagus include (A) esophageal atresia and (B) 
tracheoesophageal fistula. These conditions result in mechanical obstruction of the esophagus and are incompatible 
with life. Detection occurs shortly after birth 
 
Esophageal atresia is characterized by the replacement of a portion of the esophagus with 
a non-patent esophageal segment that results in mechanical obstruction. This segment of the 
esophagus is typically present at or near the carina of the trachea and usually associated with a 
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fistula connecting either the upper or lower fully developed esophageal segments to the trachea 
[111].  Agenesis of the esophagus is a very rare condition [74, 399].  
The survival rate for patients with esophageal atresia has been approximately 95% in the 
last ten years [114, 369]. Depending on the specific underlying pathology, congenital 
abnormalities may be surgically addressed with synthetic prosthetics, flaps, or grafts. One of the 
major issues with congenital abnormalities is that pediatric patient outgrow prosthetic devices 
such as stents, and as result often require further intervention.    
1.5.2.3 Esophageal Injury 
Despite decades of clinical experience, most perforations of the esophagus are iatrogenic and 
occur during endoscopy. The esophagus is a highly vascularized organ, particularly in the gastro-
esophageal junction. Hence, mortality from esophageal perforations is close to 20% [92].  Other 
important causes of esophageal injury include Mallory Weiss tear, ingestion of foreign body, and 
acute trauma.   
1.5.3 The Esophagus and Regenerative Medicine  
The ultimate goal of regenerative medicine is the functional restoration of lost or damaged 
tissues. To date, strategies for functional tissue repair have included delivery of bioactive 
molecules, cell-based therapies, biomaterials-based therapies, and combinations thereof [46, 227, 
234]. The delivery of these technologies and their effect upon host tissues have been investigated 
in various anatomic locations and have shown different degrees of success. This section focuses 
on progress made in the field of regenerative medicine with respect to strategies for esophageal 
repair, from benchtop to bedside.   
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In vitro studies and preclinical animal studies are necessary steps toward the development 
of novel strategies for tissue repair. Well-designed experiments permit the isolation of test 
variables and the establishment of necessary parameters for optimal pre-clinical study design. In 
the field of regenerative medicine, important aspects of preliminary studies include the cellular 
composition and architecture of target tissues and organs, the mechanical properties of 
biomaterials and scaffolds, the assessment of cytotoxicity and cytocompatibility of new 
technologies, and the biochemical properties of novel constructs. Pre-clinical studies permit the 
evaluation of new technologies in-situ including the different components of the host response 
such as the type and magnitude of the immune response, and important cellular processes such as 
stem cell migration, proliferation and differentiation. Scar tissue formation, resistance to 
infection, angiogenesis, and functional tissue remodeling are important processes that are also 
evaluated during the pre-clinical stage.  
1.5.3.1 Esophageal architecture and stem cell populations 
 
Several differences across multiple species have been identified in the microarchitecture of the 
esophagus including the presence of a keratinized epithelium in mice, rats, pigs, and 
domesticated animals [188, 294, 353], and a different distribution of striated versus smooth 
muscle within the muscularis externa. While striated muscle is only present in the proximal one 
third of the human esophagus, striated muscle can be found in virtually the entire length of the 
esophagus in other mammalian species. This configuration allows these species to voluntarily 
regurgitate gastric contents to chew cud and/or to feed the young[427]. The differences in the 
cellular composition and tissue architecture of the esophagus among different species should be 
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taken into consideration when choosing an animal model for preclinical study design and when 
interpreting the results from these studies.  
 
Several groups have further characterized the esophageal epithelium as a high turnover 
tissue comprised of two layers: a basal layer composed of a single sheet of cells in direct contact 
with the basement membrane that have self-renewal capacity, and a supra-basal layer that 
contains progressively more differentiated cell populations and lines the lumen of the 
esophagus[293]. The basal layer is composed of two distinct zones: the papillary basal layer 
(PBL) which extends along papillae that invaginate the epithelium, and the interpapillary basal 
layer (IBL) which is located at the flat interface between papillae [158] (Figure 5a).   The IBL 
cells constitute the stem cell compartment of the esophageal epithelium and proliferate 
infrequently and asymmetrically [391, 392].  Recent studies in the mouse esophagus have 
identified these cells to be Itgb4High, CD73+ and having the greatest stem cell potential, 
whereas CD73- transit-amplifying cells show variation in their degree of maturation. Esophageal 
stem cells have been used in vitro to show three-dimensional organoid forming capacity (Figure 
5b-e)  and the participation of Sox2, Wnt, and bone morphogenetic protein signaling pathways in 
the process of esophageal epithelium self-renewal [115]. 
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Figure 19. The Esophageal Epithelium 
(A) The architecture of the esophageal epithelium includes papillary structures located at regular intervals (PBL) 
separated by flat interpapillary zones (IBL). The basal cells comprise a heterogeneous population of epithelial cells 
with cells located in the IBL constituting the stem cell compartment (blue) and transit-amplifying cells residing in 
the PBL (orange). Epibasal layers (purple) are undergoing differentiation and can no longer divide. The arrow 
indicates the direction of differentiation. (B) When isolated and cultured, esophageal stem cells have shown 
organoidforming capacity114 and show similar organization to native tissues through (C) hematoxylin and eosin 
staining and (D) Cytokeratin 14 and (E) Cytokeratin 13 stains. Native tissue shown in inset for comparison (D, E). 
1.5.3.2 Biomaterials for Esophageal Repair 
The ideal biomaterial for esophageal repair remains to be determined and it is unlikely that a one 
size fits all approach will be optimal.  A number of synthetic and biologic materials have been 
proposed for esophageal repair (Table 8). While synthetic scaffolds can be manufactured with 
precision and their mechanical properties can be fine-tuned for specific applications, these 
materials tend to cause a well characterized foreign body reaction[13]. In contrast, biologic 
materials are subject to natural variability and have less tunable properties, but tend to produce a 
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friendlier host response and promote constructive tissue remodeling, a term that implies the 
deposition of site-specific, functional tissue[271].  
Biologic scaffolds composed of acellular esophageal tissue have been proposed by a 
number of groups. Work by Bhrany et al. [47] presented an SDS-based method for 
decellularization of murine esophagi. The resulting scaffold showed ECM protein preservation, 
the ability to support esophageal cell proliferation in vitro, and neovascularization with minimal 
inflammation after subcutaneous implantation. Although studies have shown that constructive 
tissue remodeling consistently occurs when chemical crosslinking of biologic scaffolds is 
avoided, the same group crosslinked the developed acellular matrix in additional studies with the 
intent of reducing antigenicity and improving collagen stability to prolong in vivo durability. As 
expected, results showed increased stability in crosslinked scaffolds, and while minimal 
inflammatory response was also reported upon in vivo implantation, inflammation was assessed 
only by quantification of macrophages and multinucleate giant cells at the treatment site, and did 
not take into consideration macrophage phenotype. Interestingly, while genipin-crosslinked 
scaffolds supported esophageal epithelial adhesion and proliferation in this study, 
glutaraldehyde-crosslinked scaffolds did not support epithelial cell adherence or proliferation 
[48]. Inhibition of biologic scaffold degradation has been shown to prevent matricryptic peptide 
release and inhibit constructive scaffold remodeling in other studies. [271, 444] 
Recognizing the potential benefits of using biologic scaffolds derived from homologous 
tissues in regenerative medicine applications, a protocol for the decellularization of the porcine 
esophageal mucosa was developed for the treatment of noninvasive disease by Keane et al.[230]. 
The protocol developed in this study avoids the use of SDS and other harsh decellularization 
agents and is compliant with previously established criteria for decellularization [231, 271]. The 
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resulting scaffold maintained important proteins and ultrastructure consistent with the basement 
membrane complex including laminin, collagen IV, and fibronectin. Perivascular stem cells 
remained viable when seeded upon the porcine esophageal ECM scaffold in-vitro, and the in-
vivo host response showed an increased number of M2 pro-remodeling macrophages and an 
associated pattern of constructive remodeling when used to repair striated muscle defects in rats. 
 
Table 9. Biomaterials for Esophageal Repair 
  
Biomaterial  Summary of Results  Reference 
Synthetics    
 poly(L-lactide-co-caprolactone) Fibronectin grafted on PLLC scaffold greatly promotes epithelium 
regeneration 
Zhu, 2007 (130) 
 Poly(3-hydroxybutyrate-co-3-
hydroxyvalerate)-based 
nanofibrous scaffolds (PHBV)   
Human esophageal epithelial cells seeded on PHBV present higher 
proliferation than those seeded in PHBV-gelatin after 7 days of culture 
Kuppan, 2014 
(63) 
 Polyvinylidene (PVDF) and 
absorbable Vicryl surgical meshes 
Mucosal regeneration after 3 month. Vicryl treatment group showed 
leakage 
Lynen Jansen, 
2004 (70) 
 poly-ε-caprolactone Ingrowth of epithelial and smooth muscle cells was observed one month 
post operatively 
Diemer, 2014 
(32) 
Biologics   
 Small intestine submucosa  ECM 
(SIS) 
Used in different defect models with different degrees of success Lopes, 2006 (68) 
Badylak, 2000 
Badylak, 2001 
 Urinary bladder  ECM (UBM) Used in different defect models with different degrees of success Badylak, 2000  
Badylak, 2005 
Nieponice, 2006 
Nieponice, 2009 
Nieponice, 2013 
 Esopahgeal ECM SDS-based decellularization protcol. Supports esophageal cell 
proliferation in vitroand neovascularization upon subcutaneous 
implantation 
Bhrany, 2006 
(13) 
 Gastric  ECM No stenosis or dilatation. Regeneration of keratinized stratified squamous 
epithelium only, not other layers.  
Urita, 2007 (116) 
 Crosslinked esophageal ECM Increased stability in genipin-crosslinked vs non-crosslinked scaffolds. 
Glutaraldehyde crosslinking was detrimental. 
Bhrany, 2008 
(14) 
 Esophageal mucosa ECM Protocl avoids SDS, and is compliant with decellularization criteria. Host 
response showed increased numbers of M2 macrophages when 
implanted in striated muscle defects.  
Keane, 2013 (54) 
 Acellular dermal matrix Superior epithelial organization and stratification compared to synthetic 
scaffolds.  
Beckstead, 2005 (11) 
Hybrids   
 Collagen-coated Vicryl tubes Mediastinitis within days of implantation, stenosis and granulation tissue 
formation  
Purushotham, 1991 (94)  
 Collagen-modified PLGA Collagen-modified PLGA increases the proliferation of the ESMCs and 
promotes extended morphology 
Zhu, 2005 (129) 
 Colalgen-coated silicone stents Segemental defects showed stricture formation and inability to swallow 
when the stent was removed at 2-3 weeks. When removed at 4 weeks no 
stricture was observed 
Natsume,1993 (80) and 
Takimoto, 1998 ( 115)  
 Complete decellularized 
esophagus with allogeneic 
mesenchymal stromal cells 
All animals survive the 14-day study period, with patent and functional 
grafts. Explanted grafts show regeneration of all the major cell and tissue 
components 
Sjöqvist, 2014 
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Commercially available biologic scaffold materials such as AlloDerm have been 
evaluated for use in esophageal repair. In a study by Beckstead et al. [41], rat esophageal 
epithelial cells were isolated and characterized for epithelial identity, adhesion protein 
preference, and in vitro interaction with both AlloDerm and synthetic scaffolds. Various factors 
including calcium concentration, scaffold composition, and pore size were evaluated by 
measuring their influence on epithelial growth and differentiation. Results from this study 
showed superior epithelial organization and stratification on AlloDerm compared to synthetic 
scaffolds such as poly(lactic-co-glycolic acid) (PLGA), poly-L-lactic acid (PLLA), and 
polycaprolactone (PCL)/PLLA. The authors concluded that modification of the synthetic 
scaffold’s surface properties and pore size may be necessary to improve cell behavior in these 
constructs. 
 
Studies of esophageal epithelial cells have also been performed with other materials 
including fibronectin grafted poly(L-lactide-co-caprolactone)[489] and Poly(3-hydroxybutyrate-
co-3-hydroxyvalerate)-based nanofibrous scaffolds (PHBV)  [254]. These studies showed that 
human esophageal epithelial cells seeded on PHBV present higher proliferation than those 
seeded in PHBV-gelatin after 7 days of culture. Cells seeded on both scaffolds present epithelial 
cobblestone morphology after 3 days of culture. However, extracellular matrix proteins including 
collagen type IV and laminin, and expression of phenotypic markers including cytokeratin-4 and 
14 were significantly higher in cells cultured in PHBV-gelatin scaffolds than in cells cultured in 
PHBV scaffolds without gelatin. 
Zhu et. al.[488] studied the effect of covalent immobilization of collagen onto poly(DL-
lactideco-glycolide) (PLGA) surfaces  on cell behavior by seeding porcine esophageal smooth 
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muscle cells (ESMC) on collagen-PLGA vs. unmodified PLGA and tissue culture plastic. The 
authors found that collagen-modified PLGA increases the proliferation of the ESMCs and 
promotes extended morphology. 
The unifying findings of these in-vitro studies is that although a number of materials have 
been found to be cytocompatible, naturally occurring biomolecules provide superior substrate 
properties for esophageal cells compared to synthetic materials. 
1.5.3.3 Animal models for esophageal repair 
A number of animal models are available for the study of regenerative medicine strategies for 
esophageal repair (Table 10). The use of small animal models - particularly murine species, 
offers a number of advantages including cost efficiency, the ability to adequately statistically 
power studies, the availability of genetic modification tools that facilitate mechanistic studies, 
and the possibility to evaluate multiple innate physiologic variables that cannot be mimicked in-
vitro. However, small animal models are technically challenging and a great degree of expertise 
is required to perform surgical procedures in the murine esophagus. Large animal models, on the 
other hand, are technically easier to implement and permit the evaluation of technologies at their 
intended therapeutic physical dimensions. As a result, large animal models are a valuable tool for 
the optimization of surgical approaches and evaluation of feasibility and delivery of these 
technologies. However, large animal models are expensive and genetic modification tools are 
usually not available to the same degree as they are in small animal models.  
 
Esophageal mucosal resection models have been described in the dog [32, 318], pig [135, 
339, 384, 464], and in rodents (Figure 20)[317]. These models are particularly important for 
modeling the treatment of non-invasive neoplastic disease, as a mucosectomy alone can 
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oftentimes entirely remove early stage neoplastic tissue without compromising the remaining 
layers of the esophagus. Caustic esophageal burn models [179, 278] also study pathology 
localized to the mucosa and focus on integrity of the epithelium. Injury or removal of the 
esophageal mucosa invariably leads to stricture formation, and as a result, regenerative medicine 
strategies aimed towards mucosal regeneration usually focus on stricture prevention as one of the 
primary objectives. 
Table 10 Animal Models for Esophageal Repair 
 
Full thickness defects including part or the full circumference of the esophagus have been 
described in the pig[220], dog[23], and rat[413].  Full thickness defect models permit the 
investigation of treatment options for invasive neoplastic disease, congenital abnormalities 
involving all layers of the esophagus (e.g.. tracheoesophageal fistulas), and acute trauma. In 
addition to full thickness defects, anastomosis reinforcement is an important aspect of 
esophageal repair in these scenarios, particularly after esophagectomy. Anastomosis 
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reinforcement models focus on leaks and dehiscence, and have been described at different 
anatomic locations in the esophagus in the dog[316]. 
 
Figure 20. Esophageal Mucosal Resection in  the Rat Model 
(A) Mucosal resection in the rat is performed by exposing the esophagus around the trachea and performing a 
mucosectomy through a horizontal incision in the muscularis layer of the esophagus. (B) Once the mucosa is 
removed, an extracellular matrix (ECM)-derived biomaterial is delivered in situ to facilitate constructive tissue 
remodeling. (C) Masson’s trichrome stain of native esophageal mucosa (arrow) and (D) remodeled esophageal 
mucosa after biomaterial-mediated repair showing intact keratinized epithelium (arrowhead). 
 
The Levrat procedure is a well-established model  involving an esophagojejunostomy, a 
procedure that produces retrograde flow of gastrointestinal contents into the distal part of the 
esophagus resulting in Barrett’s esophagus and eventually progressing to esophageal 
adenocarcinoma[71, 90, 247, 268, 299] (Figure 21). The Levrat procedure will be a valuable tool 
in the study of regenerative medicine strategies for esophageal repair after neoplastic tissue 
resection with or without adjuvant radiation therapy and chemotherapy. 
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Figure 21. Levrat Model 
(A, B) An esophagoduodenal anastomosis is performed by ligating the gastroesophageal junction and (C) 
anastomosing the distal end of the esophagus to the jejunum, creating a patent conduit that induces 
gastroduodenojejunal reflux.  (D, E) The gastroesophageal sphincter is ligated and remains attached to the 
stomach (arrow head). The anastomosis between the distal end of the esophagus and the jejunum forms a 
patent conduit that allows free retrograde flow (double arrow). 
1.5.3.4 Pre-clinical Studies 
Molecular Therapies 
Molecular therapies focus on the delivery of bioactive molecules that aim to modify one or 
several steps of the wound healing response.  Poly(adenosine diphosphate-ribose) polymerase 
affects the repair of DNA in damaged cells, but its activation can lead to ATP depletion and 
death in damaged cells[84]. With this in mind, Guven et al. [179] evaluated 3-amino benzamide, 
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a poly(adenosine diphosphate-ribose) polymerase inhibitor, in the context of caustic esophageal 
burn and the prevention of stricture-formation in rats. This group reported a decreased stenosis 
index and histopathologic damage in the treatment group and concluded that 3-amino benzamide 
has a preventive effect in the scarring of the esophagus and decreases tissue damage by 
increasing antioxidant enzyme activity. 
Growth factors are among the most commonly investigated molecular therapies for tissue 
repair.  In the context of esophageal disease, the effect of basic fibroblast growth factor (bFGF) 
on vascularization was evaluated in the canine esophagus. In this study, Hori et al. [204] 
compared an acellular collagen in sponge and gel formats supplemented with bFGF. The 
scaffolds were implanted in the cervical esophagus and evaluated one month after implantation. 
Histologic analysis confirmed the presence of blood vessels in significantly higher number in the 
bFGF-containing collagen gel group compared to the bFGF (-) control group. However, in the 
collagen sponge groups, no difference was observed between the bFGF (+) group and the bFGF 
(-) group. This study highlights the fact that structure, in addition to composition, is an important 
determinant of the host response to implanted biomaterials.  
Synthetically-Derived Biomaterials 
A number of synthetic materials have been used in preclinical studies for esophageal repair with 
limited success.  In a study by Lynen Jansen et al. [279] ,non-absorbable polyvinylidene (PVDF) 
and absorbable Vicryl surgical meshes were used to repair 1cm by 2cm semi-circular defects in 
the rabbit and resulted in mucosal regeneration after 3 months without stricture and initial 
muscular regeneration in the PVDF group. However, three patch failures with consecutive 
anastomotic leakage were reported in the Vicryl treatment group.  
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In a similar study performed in the rabbit by replacing smaller, 0.6cm by 1cm windows, 
in the abdominal esophagus with poly-ε-caprolactone, ingrowth of epithelial and smooth muscle 
cells was observed one month post operatively with an almost completely degraded mesh. 
However, the study had a 75% survival rate, and more than half of the surviving animals 
developed pseudo-diverticula[117].  
The use of hybrid constructs that seek to combine the biomechanical properties of a 
synthetic material with the biocompatible properties of a biologic material, typically as a coating 
agent, is becoming increasingly popular in regenerative medicine[136, 465, 469]. This type of 
construct has been investigated in esophageal repair. Purushotham et al. [349], investigated the 
replacement of complete esophageal segments in the thoracic esophagus with collagen-coated 
Vicryl tubes. Preliminary experiments resulted in mediastinitis within days of implantation due 
to prosthetic leakage secondary to acid reflux and digestion of the construct. The complication 
was addressed thereafter by crosslinking the constructs with glutaraledehyde, which increased 
the resistance of the material. The animals, however, developed stenosis at a mean of 11 days 
post-operatively and considerable granulation tissue and scar formation was found histologically.  
In addition to coating Vicryl tubes, collagen has been used to coat silicone stents by Natsume et 
al., and Takimoto et al. [311, 433] In these studies, this group reports the use of collagen-coated 
silicone tubes to replace 5 cm esophageal segmental defects in dogs followed by endoscopic 
removal of the inner silicone stent at weekly intervals from 2 to 4 weeks. Results showed 
stricture formation and inability to swallow when the stent was removed at 2-3 weeks. In the 
dogs in which the stent was removed at the 4 week time point, a regenerated esophagus with 
stratified flattened epithelia, striated muscle, and esophageal glands was observed. 
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In summary, a variety of synthetic materials have been used to attempt to repair 
esophageal defects with different degrees of success. However, due to the synthetic nature of the 
materials, recurrent problems include stricture formation, inflammation, foreign body reaction, 
and leakage.  
Biologically-Derived Biomaterials 
The advantage of using biologically derived biomaterials for esophageal repair is based on the 
premise that unlike synthetically derived materials, biologic scaffolds  composed of extracellular 
matrix have the ability to promote constructive tissue remodeling [25, 24]. The mechanisms of in 
vivo tissue remodeling upon biologic scaffold implantation are reviewed elsewhere[271]. 
Briefly, appropriately configured biologic scaffolds have the ability to modulate different phases 
of the wound healing response and induce a shift from a process of inflammation and scar tissue 
formation to one of constructive tissue remodeling and functional tissue repair.  
The factors that facilitate this process during the biomaterial-host interaction are complex 
and involve both host-related factors (i.e. age, immunocompetence, native stem cell populations, 
and overall health state of the patient), and biomaterial-related factors (i.e. source and 
composition[106, 230, 456, 468], efficacy of the decellularization process [67, 231], post-
processing modifications such as crosslinking and solubilization [113, 218, 292, 394, 411, 444, 
467], source animal age[409],and surface topography [37, 63]). 
 
Biologic scaffolds have been used in multiple large animal models to study the feasibility 
of biomaterial-mediated esophageal repair. Initial studies by Badylak et.al., [23] utilized porcine-
derived acellular small intestinal submucosa (SIS) and urinary bladder matrix (UBM) to repair 
patch defects in the dog model. The ability of these materials to repair defects measuring 5cm in 
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length and encompassing either 40% to 50% of the esophageal circumference or the entire 
circumference of the esophagus was shown as the xenogeneic scaffolds used to repair the patch 
defects were replaced by appropriately oriented skeletal muscle within 30 to 60 days and showed 
complete and intact squamous re-epithelialization without signs of clinical dysfunction. 
However, the scaffolds used to repair full circumference segmental defects showed stricture 
formation within 45 days of implantation.   
Given the results of stricture formation when attempting a full thickness, full 
circumference defect repair, subsequent experiments by Badylak et. al. [32] addressed the 
necessity of a native (i.e., host) tissue component for adequate esophageal repair without stricture 
formation. In these experiments esophageal defects encompassing different portions of the 
esophageal circumference were repaired with UBM-ECM. Treatment groups included full 
circumference, full thickness defects; full circumference mucosal resections; and full thickness 
defects with 30% intact muscularis externa. This study concluded that UBM-ECM scaffolds plus 
autologous muscle tissue, but not UBM-ECM scaffolds alone or muscle tissue alone, can 
promote constructive tissue remodeling of segmental defects in the esophagus. Biologic scaffolds 
have also been shown to be effective in the reinforcement of surgical anastomoses of the 
esophagus in a dog model[316].  
Following these studies, endoscopic-deployment of biologic scaffolds was investigated 
for mucosal repair after endomucosal resection (EMR) in the dog. EMR is an accepted technique 
for the treatment of and high-grade dysplasia and early neoplasia, but often leads to stricture 
formation when used to treat extensive (i.e., long segment) areas. In this study by Badylak et al. 
[318], endoscopic placement of a biologic scaffold was shown to effectively prevent esophageal 
stricture formation after EMR.  Together, the results from these pre-clinical studies formed the 
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basis for initial clinical trials of biomaterial-mediated tissue repair after neoplastic tissue 
resection.  
Biologically-derived biomaterials have also been studied in small animal models. In 
contrast to large animal models, the focus of small animal studies is usually to determine 
mechanisms of tissue repair, screen large numbers of potential therapies, and optimize treatment 
options by systematically modifying design parameters. For instance, a murine model of 
esophageal reconstruction with chimeric mice constitutively expressing green fluorescent protein 
(GFP) in the bone marrow was used by Nieponice et.al.[317] to study the contribution of bone 
marrow-derived stem cells to biomaterial mediated esophageal repair. In this study, animals were 
subjected to partial mucosal resection followed by ECM scaffold implantation. The authors 
found GFP labeled bone marrow stem cells at the treatment site, and concluded that stem cells 
originating from the bone marrow participate in ECM remodeling process during tissue repair 
after esophageal injury. However, the low number of GFP labeled cells argues against the 
significant involvement of these cells in the constructive remodeling process. 
In a different study, Lopes et. al [276] performed  semi-circumferential esophageal 
defects and  segmental esophageal defects in a rat model and repaired them with a SIS-patch 
graft and a SIS-tube interposition graft, respectively. Similarly to results obtained in large animal 
studies by Badylak et al., all animals in the segmental defect group died within the first post-
operative month. Surviving animals in the semi circumferential defect group showed no signs of 
esophageal dysfunction and returned to normal weight. There was no evidence of fistula, 
significant stenosis or diverticula. No hematologic or serum biochemistry abnormalities were 
found. By month 5 the SIS patch had been replaced by esophageal-derived tissues. 
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A similar study was performed by Urita et al. [442] in the rat model using gastric 
acellular matrix for the repair of patch esophageal defects created in the abdominal esophagus. In 
this study, rats were sacrificed 1 week to 18 months after implantation and showed an implant 
site free of stenosis or dilatation. Keratinized stratified squamous epithelium had regenerated in 
the entire construct after the 2 week time point. However, regeneration of the muscle layer or 
lamina muscularis mucosa was not observed. 
1.5.3.5  Clinical studies 
Properly designed clinical studies for regenerative medicine approaches to esophageal repair are 
scarce.  In 2008, a case study presented by Knorr et. al.[242], reported a 16-year-old female with 
perforated esophagus after accidental ingestion of a toothbrush. Inspection of the esophagus after 
retrieval of the brush revealed a near total perforation of the esophageal wall below the upper 
esophageal sphincter measuring approximately 1.5 × 2 cm which was treated with antibiotics and 
no oral ingestion. Two days after the primary treatment, an area measuring 1 × 2 cm covered with 
fibrin was found via endoscopy and the area was treated with factor XIII in all four quadrants of 
the lesion. Eight weeks after the incident esophagogastroduodenoscopy (EGD) showed a 
completely healed wound at the site of the rupture. Coagulation factor XIII was first used by 
Laki and Lóránd in 1948 as fibrin-stabilizing factor [256] and has been used since as therapy for 
ulceration due to pressure, large burns, sepsis, and acute liver disorders [75].  
In 2011, Badylak et. al. [27] reported results of five male patients with adenocarcinoma 
of the esophagus treated by an entirely endoscopic technique for long segment en bloc resection 
of the mucosa and submucosa followed by placement of a biologic scaffold. Results from this 
study reported at 4 to 24-month follow-up showed restoration of normal, mature, K4+/K14+, 
squamous epithelium, and return to a normal diet. These patients had no significant 
 81 
complications from the procedure. Two of five patients showed recurrent Barrett's esophagus 
confined to the gastroesophageal junction after 12 months, while the rest of the reconstituted 
esophageal mucosa remained intact. This study provided evidence that a biomaterial-based 
regenerative medicine approach may enable aggressive endoscopic resection of early stage 
neoplastic disease avoiding the traditional approach of watchful wait followed by radical 
esophagectomy (Figure 22). 
 
 
Figure 22. Esophageal preservation in human patients after endomucosal resection in the setting of 
superficial cancer 
The current standard of care for esophageal neoplasia is esophagectomy, a procedure associated with high morbidity 
and mortality. As an alternative, Badylak et al.174 have implemented an entirely endoscopic method for removal of 
the mucosa and submucosa with subsequent placement of a biologic scaffold to promote constructive mucosal 
remodeling and minimize stricture formation in the setting of superficial cancer. To date, the method has been 
successfully used to treat eight human patients. (A) Diagnostic biopsy showing high-grade dysplasia. (B) 
Postoperative biopsy showing replacement of the ECM scaffold with mature, differentiated squamous epithelium. 
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Representative endoscopic views of each stage in the procedure and follow-up: (C) Muscularis externa being 
exposed during inversion and resection of the entire sleeve of mucosal and submucosal layers (arrow). (D) Stent 
placed to gently compress the ECM scaffold (arrow) against the exposed muscularis layer. (E) Thirteen-month 
follow-up showing complete coverage of the resected area by normal esophageal epithelium without stricture 
formation. 
In 2014, Nieponice et al. [315]  proposed the use of an ECM scaffold as a reconstructive 
patch for the augmentation of esophageal diameter during primary repair. In this study, four 
patients requiring esophageal reconstruction underwent patch esophagoplasty with a UBM-ECM 
scaffold. The full thickness of the esophagus was replaced by the scaffold by securing it to the 
edges of the remaining esophagus. All patients had a favorable clinical recovery and resumed 
normal oral intake after 7 days. One of the patients presented a micro leak that closed 
spontaneously after drainage. Follow-up studies including barium swallow and EGD showed 
normal esophageal emptying in all patients. Complete mucosal remodeling was observed at 2 
months and was indistinguishable from surrounding healthy tissue. Implant sites presented 20% 
area contraction and biopsy of the treatment site showed normal esophageal epithelium.  
 
In summary, the esophagus is a complex organ composed of multiple tissues that do not 
have the ability to regenerate. Esophageal pathologies that effect the esophagus are life 
threatening and currently available treatment options are very limited. This problem is 
compounded by the default inflammatory and scarring response of the esophagus following 
surgical intervention, even in the case of minimally invasive endoscopic approaches. 
Regenerative medicine strategies that utilize cell based, scaffold based, and bioactive molecule 
based approaches for tissue repair show promise as effective alternatives for the treatment of 
esophageal disease. However, esophageal pathologies are diverse, and a single regenerative 
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medicine approach is unlikely to prove effective in all settings of esophageal pathology. A 
thorough understanding of different pathologies that affect the esophagus, the anatomic and 
functional consequences of each disease, and the shortcomings associated with currently 
available therapies is necessary for the development of successful regenerative medicine 
strategies for esophageal repair. 
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1.6 REGENERATIVE MEDICINE APPROACHES FOR CARDIAC REPAIR 
 
1.6.1 The Human Cardiovascular System 
The cardiovascular system provides the vital function of pumping and distributing blood 
throughout the body to provide oxygen, vital nutrients, and to facilitate waste removal from 
tissues and organs.  At the core of the cardiovascular system is the heart, a muscular pump 
composed of four structurally and functionally distinct chambers.  The two atria receive blood 
from the peripheral and pulmonary circulation through the pulmonary vein and vena cava, 
respectively. Blood is then pumped it into the ventricles through the mitral and tricuspid valves, 
respectively. Once the blood is in the ventricles, coordinated myocardial contractions pump it out 
of the heart into the peripheral and pulmonary circulations through the aortic and pulmonary 
valves that serve to prevent retrograde blood flow back into the heart. The coronary vessels 
originate from the base of the aorta above the cusps of the aortic valve and supply the 
myocardium itself with oxygen and nutrients.  The pumping action of the heart is achieved 
through coordinated myocardial contractions that are generated and distributed by a highly 
specialized conduction system composed of the sinoventricular node, the atrio-ventricular node, 
and purkinje fibers. The pericardium is an epithelial tissue that encloses all components of the 
heart and separates them from the rest of the mediastinal organs. The endocardium is continuous 
with the vascular endothelium [364]. 
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 The cardiomyocytes in the left ventricle are arranged circumferentially in a spiral 
orientation. This organization helps generate a highly coordinated contraction wave that starts at 
the apex in the bottom of the heart and spreads upwards to squeeze blood in that direction out of 
the aortic valve into the aorta and the peripheral tissues. Cardiomyocytes in the right ventricle are 
less organized, and as a result, less powerful contractions are generated. The coordinated beating 
of cardiac myocytes depends on intercalated discs —specialized intercellular junctions that 
facilitate cell-to-cell mechanical and electrical (ionic) coupling [262, 390, 428]. In addition with 
total muscular ventricular mass, this arrangement serves to pump the same amount of blood 
through different circuits having different resistance and pressure.  
 Atrial myocytes, on the other hand, are randomly organized, and as a result, contractions 
generated by the atria are very weak comparted to ventricular contractions[364]. A subset of 
atrial cells possess storage granules containing atrial natriuretic peptide [419, 420]. In addition to 
contributing to arterial vasodilation, this hormone stimulates salt and water elimination through 
the kidneys. This is one of the many mechanisms by which blood pressure is regulated [83, 448].  
1.6.2 Cardiovascular Disease  
Cardiovascular disease is the leading cause of death in the United States with about 80% of the 
worldwide burden occurring in third world[145, 155, 164, 225, 432]. In the United States alone, 
a third of all deaths are caused by cardiovascular disease, totaling about 800,000 patients—or 
roughly 1.5 times the number of deaths caused by all types of cancer combined [134]. A non-
functional cardiovascular system is incompatible with life. Cardiac function is so imperative for 
human body that under normal circumstances, tissue and organ death will occur within minutes 
if the heart stops. 
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Most occurrences of cardiovascular disease manifests as structural or functional damage 
in one or more anatomic cardiac components. This set of conditions includes congenital heart 
abnormalities such as tetralogy of Fallot [81, 337, 345] and septal defects[36, 42, 123, 283, 285], 
arterial hypertension [2, 79, 132, 326, 388], diseases of the valvular disease [76, 96, 184, 280], 
and ischemic or coronary heart disease[45, 70, 98, 265, 373]. Of these, coronary heart disease is 
a major cause of death and disability in developed countries.  
 
1.6.3  Coronary Artery Disease and Myocardial Infarction 
Although mortality rates for coronary artery disease (CAD) have declined worldwide over the 
past four decades, CAD it remains responsible for more than one-third of all mortality in 
individuals over 35 years of age[269, 314, 372]. Furthermore, recent estimates suggest that as 
much as one-half of all middle-aged males and nearly one-third of middle-aged females in the 
United States will develop at some point a form of coronary artery disease [270]. 
The two main risk factors that contribute to coronary artery disease are hypertension, 
cigarette smoking, and diabetes mellitus, of which hypertension and diabetes mellitus are also 
associated with an increased tendency toward unrecognized myocardial infarction (MI)[405]. 
Hypertension is the most important risk factor for cardiovascular disease, scoring even above 
diabetes, cigarette smoking and dyslipidemia. In fact, hypertension is responsible for more than 
half of all cerebral ischemic events, and about 50% of all ischemic heart disease [260]. On the 
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other hand, diabetes mellitus has been confirmed as a risk factor for silent infarction, but only in 
males [224]. 
  Interestingly, even though the incidence of CAD has decreased steadily in the United 
States [87, 131, 152, 368], studies indicated the incidence of myocardial infarction in has not 
deacrease d[131, 152, 367, 368]. These findings are attributed, at least in part, to the use of the 
more sensitive tests that allow for better detection and diagnosis of MIs, even when a smaller 
region of the myocardium is infarcted [336]. 
1.6.4 Cardiac Regenerative Medicine 
The main objective or regenerative medicine approaches to cardiac repair is the replacement or 
regeneration of damaged myocardial tissue with functional, site appropriate cell types that can 
synchronize and act together to generate myocardial contraction and maintain the heart’s ability 
to adequately perfuse peripheral tissues.   
Early approaches to cardiac tissue repair included the localized delivery of stem cell and 
progenitor cell populations directly into affected myocardial tissue [305]. Although such an 
approach was reported to be partially successful in increasing cardiac function [59, 380], 
additional studies suggested that the actual number of surviving cells is in fact dramatically low. 
The high percentage of nonviable cells is attributed to a number of factors, including the lack of 
adequate substrate for cell delivery, and the lack of an appropriate microvasculature within the 
transplanted mass of cells to support cellular metabolism and function [200, 351]. As a result, the 
benefits of this approach have not been thoroughly exploited.     
The use of biomaterials in cardiac repair has been motivated by a number of observations 
including the lack of cell survival in cardiac stem cell delivery applications, and the ability of 
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some biologic materials to promote constructive tissue remodeling. Synthetic biomaterials have 
been used in cardiac repair applications in the form of overlaying patches aimed to prevent 
ventricular remodeling following myocardial infarction.  These materials include collagen [490], 
alginate [263], and [178, 182, 183]. 
An approach that is becoming increasingly popular is the use of biomaterial-derived 
hydrogels. These materials offer a number of advantages over solid scaffolds including the 
possibility of non-invasive delivery in a liquid phase that polymerizes in situ.  This property 
allows hydrogels gives hydrogels flexible geometry and permits them to conform to the shape of 
multiple defects.  In addition, biomaterial-derived hydrogels can be used as injectable substrates 
for drug and/or cell delivery. For instance, myoblast have been delivered to the myocardium 
using an injectable scaffold composed of fibrin that can increase cell survival after 5 weeks [94]. 
Synthetic constructs offer additional advantages, such as the ability to finely control 
polymerization and degradation rates as in the case of hybrid constructs composed of fibrinogen 
conjugated with poly-ethylene glycol [462].  
Finally, whole organ decellularization offers great potential for the development of novel 
biologic scaffolds for organ repair. Cardiac perfusion decellularization as a method for the 
preparation of such scaffolds has been described by a number of groups [333, 360, 456].  As with 
traditional sheet scaffolds derived from natural tissue sources, the objective of this method is to 
remove the cellular compartment while maintaining the structure and components of the 
extracellular matrix. Once decellularized, these scaffolds can be repopulated with cells from 
different sources, including perfusion seeding of endothelial cells and transmural seeding 
cardiomyocytes. Using this technique constructs have recovered 2% of normal cardiac function 
[333]. 
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1.7 CENTRAL HYPOTHESIS 
 
The central hypothesis of the present dissertation states: biologic scaffolds composed of 
extracellular matrix from derived homologous anatomic structures have the ability to modulate 
cell processes associated with constructive remodeling and the host response in preclinical 
models of cardiac and esophageal injury.   
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1.8 SPECIFIC AIMS 
Aim 1: To develop and characterize extracellular matrix based bioscaffolds from the 
mucosal layer and muscularis externa of the porcine esophagus.  
 Sub-Aim: To characterize the host response to implanted esophageal ECM-
derived bioscaffolds in a preclinical murine model of abdominal wall defect.  
 
Aim 2: To evaluate the tissue specific effects of biologic scaffolds derived from 
esophageal tissues in vitro and in a preclinical murine model of esophageal mucosal resection.  
 
Aim3: To evaluate the ability of cardiac-ECM to modify the host response to an 
implanted cardiac patch in a preclinical murine model of myocardial infarction. 
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2.0  DEVELOPMENT AND CHARACTERIZATION OF ECM-DERIVED 
BIOMATERIALS FROM ESOPHAGEAL TISSUES  
Aim 1: To develop and characterize extracellular matrix based bioscaffolds from the mucosal 
layer and muscularis externa of the porcine esophagus.  
 Sub-Aim: To characterize the host response to implanted esophageal ECM-derived 
bioscaffolds in a preclinical murine model of abdominal wall defect.  
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2.1 BACKGROUND 
 
The default mechanism of mammalian tissue repair typically results in scar tissue deposition, a 
protective and favorable response in most tissues. However, this scar tissue formation is 
associated with adverse clinical consequences including stricture in select anatomic locations 
such as the esophagus. Preclinical studies have shown that placement of an extracellular matrix 
(ECM) scaffold derived from heterologous tissue is capable of restoring a functional esophagus 
with minimal stricture and normal esophageal motility following circumferential mucosal 
resection [32]. A clinical report involving patients with stage 1 esophageal adenocarcinoma 
corroborated this finding and provided proof-of-concept in the clinical setting[27] and [203]. 
While heterologous ECM was successful in reducing stricture formation, the remodeled tissue 
did not fully reconstitute all components of normal esophageal tissue; for example, glandular 
tissue was absent. Delivery of the scaffold also required temporary placement of an intraluminal 
stent to allow integration of the scaffold with the subjacent tissue. A possible advantage of a site-
specific, homologous ECM could be more rapid integration and faithful remodeling of the 
esophageal mucosa. 
 
Recent work has described potential benefits of ECM scaffold materials derived from 
homologous tissue versus heterologous tissue when used in selected anatomic locations [9, 39, 
58, 101, 106, 143, 292, 397, 398, 487]. While tissue specificity is not necessary for all 
therapeutic applications [27, 30, 468], some studies have shown that site-specific ECM can 
preferentially maintain tissue-specific cell phenotypes [9, 143, 397, 398], promote cell 
proliferation [9] and [487], induce tissue-specific differentiation [101], and enhance the 
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chemotaxis of lineage-directed progenitor cells [58, 106, 180]. It is plausible therefore that a site-
specific esophageal mucosal ECM may promote similar effects and further improve clinical 
outcomes in esophageal mucosa repair. The harvesting and preparation of an ECM scaffold 
requires tissue-specific methodologies for optimal outcomes [149, 174, 180, 195, 196]. 
Biologic scaffolds composed of ECM, when prepared by methods designed to preserve structure 
and composition of the native source tissue, contain bioactive molecules including growth 
factors (e.g., vascular endothelial growth factor (VEGF) [199][21], basic fibroblast growth factor 
(bFGF) [455]) and glycosaminoglycans (GAGs) [198][23]. The composition, ultrastructure, and 
mechanical properties of an ECM construct are affected by the methods used to decellularize the 
source tissue as well as the methods of sterilization and storage of such bioscaffolds [105, 146, 
149]. Therefore, the methods of preparing ECM scaffolds intended for use in the repair and 
reconstruction of the esophageal mucosa must be carefully considered as regenerative medicine 
strategies are developed for this intended therapeutic application. 
 
The objective of Specific Aim 1 was to prepare, characterize, and determine the in-vitro 
cytocompatibility of two ECM bioscaffolds derived from 1) the esophageal mucosa and 2) the 
esophageal muscularis externa. Porcine esophagi were collected and the mucosa and muscularis 
layers were independently decellularized by methods sufficient to meet stringent 
decellularization criteria: specifically no visible intact nuclei by hematoxylin and eosin staining, 
remnant DNA concentration less than 50 ng/mg dry weight, and DNA fragment length less than 
200 basepairs [105]. Biochemical and mechanical properties of the ECM were then characterized 
by quantitative and qualitative measures, and the in vivo host response to the mucosal ECM 
bioscaffold was evaluated in a murine model of abdominal wall defect.  
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2.2 MATERIALS AND METHODS 
2.2.1 Harvest and preparation of ECM bioscaffolds from porcine esophagus 
Esophageal mucosal decellularization: Esophagi were harvested from market weight (240–260 
lbs) pigs. The mucosa and submucosa were isolated by mechanical separation from the 
muscularis propria. The luminal of the mucosa surface was gently abraded to remove squamous 
epithelium. The tissue that remained was composed primarily of the basement membrane, lamina 
propria, muscularis mucosa, and submucosa. The mucosa was then subjected to a series of 
immersion treatments as follows: 1% trypsin/0.05% EDTA (Invitrogen, Carlsbad, CA) for 1 h at 
37 °C on a rocker plate, deionized water for 15 min, 1.0 m sucrose (Fisher Scientific, Pittsburgh, 
PA) for 30 min, deionized water for 30 min, 3.0% Triton X-100 (Sigma Aldrich, St. Louis, MO) 
for 48 h, deionized water for 15 min, PBS (Fisher Scientific) for 15 min, 10% deoxycholate 
(Sigma Aldrich) for 4 h, deionized water for 30 min, 0.1% peracetic acid (Rochester Midland 
Corp., Rochester, NY) in 4.0% ethanol for 4 h, 100 U/mL DNAse (Invitrogen) for 2 h on a 
rocker plate, followed by 15 min washes with PBS, deionized water, PBS, and deionized water. 
All treatments were performed at room temperature with agitation on a shaker plate at 300 RPM 
unless otherwise stated. For cytocompatibility evaluation and in-vivo remodeling evaluation, 
chemically cross-linked emECM (XL-emECM) scaffolds were used as negative controls. 
Chemically cross-linked bioscaffolds have been shown to consistently inhibit a constructive 
remodeling response [443] and [31]. Cross-linking was achieved by immersion in 0.01 m 
carbodiimide for 24 h with multiple subsequent washes in PBS over 48 h. The esophageal 
mucosa ECM (emECM) was lyophilized and sterilized using ethylene oxide. 
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Muscularis Externa decellularization: In contrast to the esophageal mucosa, the 
esophageal muscularis externa was decellularized via perfusion decellularization in an attempt to 
conserve the ECM ultrastructure of its two layers. Each esophagus was placed in a 2 L container 
with 1 L of hypotonic type 1 water and connected in a close circuit to a peristaltic pump (L/S® 
Drive EW-07550-30; Cole-Parmer, Vernon Hills, IL) for 15 min at 800 mL/min. The type 1 
water was replaced with fresh solutions 3 times and then with 2 × phosphate-buffered saline 
(PBS) at for 15 min and two fresh solution washes. Two liters of 0.02% trypsin/0.05% 
ethylenediaminetetraacetic acid/0.05% NaN3 solution was warmed to 37°C using a digital 
hotplate and then perfused through the esophageal muscularis at 800 L/min for 3 h. Two DI 
water washes followed by two-2 x PBS washed were used before a 6 h, 2% Triton X-100/0.05% 
ethylenediaminetetraacetic acid/0.05% NaN3 solution was followed by washes of DI water and 
PBS and a 4% deoxycholic acid solution at for 6 h at room temperature. Disinfection was 
accomplished by perfusion of 0.1% peracetic acid/4% ethanol for 2 h. The acid was neutralized 
and removed from the ECM by perfusing the intact matrix with PBS (pH 7.4) two times and type 
1 water three times for 15 min each at 800mL/min. The resulting muscularis externa ECM 
(meECM) was then lyophilized until dry for characterization and analysis. 
2.2.2 Assessment of DNA content 
DNA was extracted from representative samples (n = 6) of emECM and (n = 3) of meECM. For 
DNA extraction, lyophilized ECM scaffolds were powdered using a Wiley Mill and filtered 
through a 60-mesh screen. One hundred milligrams of lyophilized, powdered emECM was 
digested with proteinase K digestion buffer (100 mm NaCl, 10 mm Tris–HCl (pH = 8), 25 mm 
EDTA (pH = 8), 0.5% SDS, 0.1 mg/mL proteinase K) at 50 °C for 24 h. The digest was 
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extracted twice using 25:24:1 (v/v/v) phenol/chloroform/isoamyl alcohol. DNA was precipitated 
from the aqueous phase at −20 °C with the addition of 2 volumes of ethanol and 0.1 volume of 3 
m sodium acetate (pH = 5.2). The DNA was then centrifuged at 10,000 g for 10 min and 
resuspended in 1 mL of TE buffer (10 mm Tris (pH = 8), 1 mm EDTA). 
The concentration of each extracted DNA sample was determined using Quant-iT 
PicoGreen dsDNA Assay Kit (Invitrogen) following the manufacturer's recommended protocol. 
A standard curve was constructed by preparing samples of known DNA concentrations from 0 to 
1000 ng/mL and concentration of DNA was found by linear interpolation of the standard curve. 
Samples were read using SpectraMax M2 Plate Reader (Molecular Devices, Sunnyvale, CA). 
DNA samples were diluted to ensure their absorbance properties fell within the linear region of 
the standard curve. 
To determine the fragment size of remnant DNA, equal concentrations of extracted DNA 
from each sample were separated on a 2% agarose gel containing 0.5% ethidium bromide and 
visualized with ultraviolet transillumination using a reference 100-bp ladder (New England 
BioLabs, Ipswich, MA). All assays were performed in quadruplicate. 
 
2.2.3 Immunolabeling and histochemistry 
Slides (n = 6 for each bioscaffold) were stained to visualize the extent of cell removal with a 
hematoxylin and eosin (H&E) protocol. Antigen retrieval was performed for immunolabeling 
studies using a 0.01 m citrate buffer (pH = 6) heated to 95–100 °C. Slides were placed in hot 
buffer for 20 min and rinsed in PBS (3 × 5 min). Sections were placed in pepsin solution (0.05% 
pepsin/0.01 m HCl) at 37 °C for 15 min. After rinsing in PBS (3 × 5 min), the samples were 
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blocked in blocking buffer (2% goat serum/1% bovine serum albumin/0.1% Triton X-100/0.1% 
Tween) for 1 h at room temperature. The sections were incubated in blocking buffer with rabbit 
polyclonal collagen IV antibody (1:500 dilution, Abcam, Cambridge, UK), rabbit polyclonal 
laminin antibody (1:200 dilution, Abcam), or mouse monoclonal fibronectin (1:200 dilution, 
Abcam) overnight at 4 °C in a humidified chamber. Sections were subsequently rinsed in PBS (3 
× 5 min). Peroxidase activity was quenched by rinsing sections in a 3% hydrogen peroxide in 
methanol solution for 30 min followed by rinsing in PBS (3 × 5 min). Biotinylated goat anti-
rabbit or goat anti-mouse secondary antibodies (Vector Laboratories, Burlingame, CA) were 
diluted 1:200 in blocking buffer and added to the sections for 30 min at 25 °C and sections were 
rinsed in PBS (3 × 5 min). The slides were incubated in detection solution (VectaStain® Elite 
ABC Reagent, Vector Laboratories) for 30 min at 37 °C. Peroxidase substrate, 3,3′-
diaminobenzadine (ImmPACT™ DAB, Vector Laboratories) was prepared and sections were 
incubated while being visualized under a microscope to time the color change for subsequent 
section staining intensities. Tissues were rinsed in water (3 × 5 min). Sections were dipped in 
hematoxylin (Thermo Shandon, Pittsburgh, PA) for 1 min for a nuclear counterstain and 
subsequently rinsed in PBS (3 × 5 min). 
2.2.4 Sulfated glycosaminoglycan assay 
Sulfated glycosaminoglycan (sGAGs) concentration in emECM samples was determined using 
the Blyscan Sulfated Glycosaminoglycan Assay Kit (Biocolor Ltd, Belfast, Northern Ireland). 
For extraction of sGAGs, lyophilized ECM scaffolds were powdered using a Wiley Mill and 
filtered through a 60-mesh screen. Samples were prepared by digestion of 50 mg/mL dry weight 
of each sample with 0.1 mg/mL proteinase K in buffer (10 mm Tris–HCl, pH 8, 100 mm NaCl, 
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25 mm EDTA) for 48 h at 50 °C. Digested samples were assayed following the manufacturer's 
protocol, and the assay was performed in duplicate on three different emECM sample. 
 
2.2.5 Growth factor assay 
The concentration of basic fibroblast growth factor (bFGF) and vascular endothelial growth 
factor (VEGF) in urea-heparin extracts of emECM samples was determined with the Quantikine 
Human FGF basic Immunoassay, Human VEGF Immunoassay (R&D Systems, Minneapolis, 
MN). Each assay for bFGF and VEGF was performed in quadruplicate. The ELISA assays are 
cross-reactive with porcine growth factors and do not measure activity. 
2.2.6 Scanning electron microscopy 
Scanning electron micrographs were taken to examine the surface topology of emECM. Prior to 
final lyophilization, samples were fixed in cold 2.5% (v/v) glutaraldehyde (Electron Microscopy 
Sciences, Hatfield, PA) in PBS for at least 24 h, followed by three washes in PBS. Fixed samples 
were then dehydrated using a graded series of alcohol (30, 50, 70, 90, 100%) for 15 min each, 
followed by 15 min in hexamethylenediamine (Fisher) and subsequent air-drying. The dried 
samples were sputter coated with a 3.5 nm layer of gold/palladium alloy using a Sputter Coater 
108 Auto (Cressington Scientific Instruments, Watford, UK) and imaged with a JEOL JSM6330f 
scanning electron microscope (JEOL, Peabody, MA) at 100× and 500× magnifications. 
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2.2.7 Perivascular stem cell (PVSC) culture 
Perivascular stem cells isolated by flow cytometry from fetal muscle [107] and [108] were used 
in all experiments. These cells (CD146+/NG2+/CD34−/CD144−/CD56−) have been previously 
shown to represent a distinct population of perivascular cells obtained after positive selection and 
stringent exclusion of hematopoietic, endothelial, and myogenic cells, and which are able to 
differentiate into mesodermal lineages [108] and [437]. Isolated cells were cultured in high-
glucose Dulbecco's modified Eagle's medium (Invitrogen) containing 20% fetal bovine serum 
(Thermo), 100 U/mL penicillin, and 100 μg/mL streptomycin (Sigma Aldrich) at 37 °C in 5% 
CO2. 
In-vitro cell viability assays were performed using single layer sheets of ECM. PVSCs 
(0.5 × 106) were cultured for 48 h on 2 cm diameter circular sheets of emECM or XL-emECM. 
Cell viability was compared to growth on tissue culture plastic (TCP) using LIVE/DEAD® 
Viability/Cytotoxicity Kit (Invitrogen) following manufacturer's guidelines. Capturing 4 random 
fields across the emECM scaffold, the live and dead cells were imaged with green fluorescent 
calcein-AM (cAM) and red fluorescent ethidium homodimer-1 (EtH1), respectively. 
Quantification of live and dead cells was achieved using a custom image analysis algorithm 
developed using the cell profiler image analysis package [222] and [257]. This custom algorithm 
identified and quantified the number of cAM+ (live) and EtH1+ (dead) cells present on the 
emECM scaffolds. These results were then expressed as a percentage of total cells. 
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2.2.8 In-vivo Biocompatibility 
All procedures were performed in accordance with the National Institute of Health (NIH) 
guidelines for care and use of laboratory animals and with approval of the Institutional Animal 
Care and Use Committee (IACUC) at the University of Pittsburgh. Sprague Dawley rats (female; 
250–350 g) were anesthetized with 1.5–3% isoflurane and maintained at a surgical plane of 
anesthesia. The surgical site was shaved, disinfected with a betadine solution, and an incision 
was made into the ventrolateral abdominal wall. Bilateral partial thickness abdominal body wall 
defects [109]  were created by excision of a 1 cm2 piece of tissue comprising the internal and 
external oblique muscles but leaving the transversalis muscle intact [443]. Size matched emECM 
or XL-emECM scaffolds were then sutured into the defect site using nonresorbable 4-0 proline 
sutures at each of the 4 corners of the device. The skin was closed using 3-0 resorbable vicryl 
sutures. Rats were euthanized at 14 or 35 days post-implantation and implant sites were 
identified by nonresorbable sutures. The implant site containing emECM devices and adjacent 
tissue site were isolated and placed in 10% neutral buffered formalin. Fixed samples were 
paraffin embedded and cut into 6 μm sections. 
The sections obtained at 14 and 35 days post-op were stained with H&E for a qualitative 
and semiquantitative histomorphologic analysis that evaluated cell infiltration, multinucleated 
giant cells, vascularity, connective tissue, encapsulation, and scaffold degradation. Two blinded 
investigators scored the sections according to a previously established and validated 
semiquantitative scoring method [443]  and [65]. Using quantitative scoring criteria (Table 11), 
biologic scaffolds can be grouped according to chronic inflammation and foreign body response 
(quantitative score < 5), early inflammatory cell infiltration with decreased cellularity and little 
evidence of constructive remodeling at later time points (5 < quantitative score < 10), and early 
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infiltration by inflammatory cells and signs of constructive remodeling at a later time point 
(quantitative score >10). 
Table 11. Semiquantitative scoring criteria for day 14 and day 35 explants. 
         
  3 2 1 0 
Day 14 scoring criteria 
    Cellular infiltration (per 
40× field) 
>150 cells 75–150 cells 1–75 cells 0 cells 
Connective tissue 
organization 
Highly organized 
connective 
tissue present 
Moderately 
organized 
connective 
tissue present 
Unorganized 
connective tissue 
throughout 
disrupted original 
scaffold 
Original scaffold 
intact 
Degradation No scaffold 
present 
Some scaffold 
present 
Mostly present No degradation 
Encapsulation No 
encapsulation 
Minimal 
encapsulation 
Moderate 
encapsulation 
Dense 
encapsulation 
Multinucleated giant 
cells (per 40× field) 
0 cells 1 cell 2–5 cells >5 cells 
Vascularity (per 40× 
field) 
>10 vessels 6–10 vessels 2–5 vessels 0–1 vessel 
Day 35 scoring criteria     
Connective tissue 
organization 
Highly organized 
connective 
tissue present 
Moderately 
organized 
connective 
tissue present 
Unorganized 
connective tissue 
throughout 
disrupted original 
scaffold 
Original scaffold 
intact 
Degradation No scaffold 
present 
Some scaffold 
present 
Mostly present No degradation 
Encapsulation No 
encapsulation 
Minimal 
encapsulation 
Moderate 
encapsulation 
Dense 
encapsulation 
Multinucleated giant 
cells (per 40× field) 
0 cells 1 cell 2–5 cells >5 cells 
Muscle ingrowth Organized 
muscle 
throughout 
scaffold 
Muscle cells 
present in 
scaffold center 
Muscle cells 
present at scaffold 
periphery 
No muscle 
ingrowth 
 
 
 
 
 102 
Immunolabeling of macrophages was performed on tissue sections from day 14 explants. 
Paraffin embedded sections were deparaffinized with xylene and rehydrated through a graded 
ethanol series. Heat-mediated antigen retrieval was performed with 0.01 m citrate buffer (pH = 
6) at 95–100 °C for 25 min. The tissue sections were subjected to Tris-Buffered Saline Tween-20 
(TBST) for 15 min, followed by incubation in blocking buffer (2% horse serum albumin/1% 
bovine serum albumin/0.05% Tween-20/0.05% Triton X-100) for 1 h. The primary antibodies, 
diluted in blocking buffer, were added to the slides for 16 h at 4 °C in a humidified chamber. The 
slides were then washed three times in PBS prior to the addition of the secondary antibody for 1 
h in a humidified chamber at room temperature. DAPI was used as a nuclear counterstain. The 
primary antibodies used in this study were mouse anti-rat CD68 (1:150, AbD Serotec, Raleigh, 
NC), goat polyclonal CD206 (Santa Cruz Biotech, Santa Cruz, CA), rabbit anti-rat CD86 (1:150, 
Abcam) and mouse anti-rat CD68 (1:50, Serotec, Raleigh NC). The secondary antibodies used 
were Alexa Fluor® donkey anti-mouse 594 (1:200, Invitrogen), Alexa Fluor® donkey anti-goat 
488 (1:200, Invitrogen) and donkey anti-rabbit IgG-PerCP-Cy5.5 (1:300, Santa Cruz). CD68 is a 
pan-macrophage marker. CD86 is an M1 marker. CD206 is an M2 marker. All primary 
antibodies were confirmed to cross-react with rat epitopes. The sections were imaged at random 
fields along the interface of the native tissue and ECM scaffold. Quantification of M1/M2 
polarization was achieved using a custom image analysis algorithm developed using the cell 
profiler image analysis package[222, 257]. This algorithm identified and quantified the number 
of CD68+CD86+ (M1 phenotype) and CD68+CD206+ (M2 phenotype) cells present within the 
tissue sections. Any cells that co-expressed these markers were not counted. These numbers were 
then expressed as a ratio of M2/M1. 
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2.2.9 Biomechanical testing 
The passive biaxial mechanical properties were characterized for the native esophageal mucosa 
and emECM (n = 8). A detailed description of the testing device and methods used for planar 
biaxial testing has been reported previously [49]. Briefly, samples were affixed to 250 g load 
cells (Model 31, Honeywell, Columbus, OH) with two loops of suture attached to each side with 
four hooks, and deformation was measured from a four-marker array. Samples were tested in 
PBS at room temperature under an equibiaxial stress protocol from a 0.5 g tare load to 250 kPa 
after 10 cycles of preconditioning with a cycle time of 30 s. All data was referenced to the post-
preconditioned free-float state. The maximum strain for each sample was then defined as the 
strain at the maximum tested stress of 250 kPa. 
 
The suture retention analysis we performed according to a previously described 
protocol[148]. Briefly, a 2-0 prolene suture with a taper needle was passed through the specimen 
with a 2 mm bite depth, and tied with a square knot and the loop attached to an Instron machine, 
and pulled at a constant rate of 10 cm/min[148]. Two locations were tested per sample and eight 
samples were tested per group. Samples were thoroughly rehydrated prior to testing. 
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2.2.10 Statistical analysis 
An independent samples t-test was used to determine whether the DNA, growth factor, and GAG 
content, and mechanics of the emECM were different than that of native esophagus (p < 0.05). A 
one-way analysis of variance (ANOVA) was used to determine differences in the percentage of 
viable cells in culture. Macrophage phenotype ratio between XL-emECM and emECM was 
compared using an independent samples t-test. A two-way ANOVA with post-hoc Tukey test 
was performed to determine differences in biomechanical properties with the two independent 
variables being axIs and material. All data are reported as mean ± standard error. 
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2.3 RESULTS 
 
2.3.1 Decellularization efficacy 
The degree of decellularization following the described method was assessed using previously 
established guidelines for decellularization [105]. No intact nuclei were visible by H&E or DAPI 
staining following decellularization (Fig. 1C). The concentration of remnant DNA in emECM 
and was (48 ± 6.4 ng/mg) and (43.3 ± 4.1ng/mg) in meECM.  Both markedly less (p < 0.001) 
than that in native esophageal tissue (855 ± 24 ng/mg) (Fig. 23A). Residual DNA was present 
only in fragments less than 200 bp in length (Fig. 23B and 23C). 
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Figure 23. Decellularization Efficacy 
Decellularization of emECM and meECM was assessed by the amount and size of remaining DNA and 
histologically by hematoxylin and eosin (H&E). The amount dsDNA in emECM was less than 50 ng/mg, which was 
significantly less (asterisk; p < 0.001) than native tissue (A). DNA fragment length was assessed by gel 
electrophoresis using a reference 100 bp ladder (B). No intact nuclei were visible after decellularization by H&E 
staining (C). Data represented as mean ± standard error. Scale bar = 100 μm. 
2.3.2 Ultrastructural characteristics of esophageal ECM 
SEM images of the luminal and abluminal surface of emECM showed a smooth surface on the 
luminal surface of the emECM (Figure. 24A,C). The abluminal surface, however, had a more 
textured and fibrous structure (Figure. 24B,D). Cross sectional images of meECM show that 
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perfusion decellularization maintains the ultrastructure of the muscularis layer and preserves the 
orientation of the two different layers (Figure 25). 
 
Figure 24. Scanning electron micrographs (SEM) of emECM surface. 
The luminal surface of the emECM scaffold was characterized by a smoother surface (A, C) Compared to the 
abluminal surface which was more textured and fibrous (B, D). 
 
 108 
 
Figure 25. Scanning electron micrographs (SEM) of meECM surface. 
The cross sectional surface of the meECM scaffold was characterized by a distinct transition between longitudinally 
oriented, and circumferentially oriented layers of the muscularis externa that was preserved with perfusion 
decellularization (red dotted line). 
 
2.3.3 Biomechanical Properties 
The equibiaxial stress response of the native esophageal mucosa showed anisotropic behavior 
with a maximum strain of 83% and 18% in the circumferential and longitudinal direction, 
respectively (Figure. 26A,B). The emECM showed similar anisotropy, but had a lower 
compliance along both axes, with the circumferential strain reaching only 10.5% (Figure. 
26A,B). The decellularized tissue had 30% lower suture retention strength than the native 
esophagus. Results for meECM ae shown in (Figure 27) 
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Figure 26. Native and decellularized esophageal mucosa mechanical characterization. 
The equibiaxial stress response was characterized along the circumferential and longitudinal axes (A). The 
maximum strain defined at a stress of 250 kPa for both circumferential (C) and longitudinal (L) axes (B). Significant 
differences (p < 0.05) between the circumferential and longitudinal axes of the same sample are denoted as the 
following: (*) as different from circumferential. Significant differences between samples in each axis are denoted as 
the following: (ˆ) as different from native. Data represented as mean ± standard error. 
 
Figure 27. Native and decellularized esophageal muscularis mechanical characterization. 
The equibiaxial stress response was characterized along the circumferential and longitudinal axes (A). The 
maximum strain defined at a stress of 250 kPa for both circumferential (C) and longitudinal (L) axes (B). Significant 
differences (p < 0.05) between the circumferential and longitudinal axes of the same sample are denoted as the 
following: (*) as different from circumferential. Significant differences between samples in each axis are denoted as 
the following: (^) as different from native. Data represented as mean standard error. 
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2.3.4 Cytocompatibility and Immunomodulation in vitro 
When cultured on emECM, XL-emECM, and meECM quantification of PVSC cell viability in-
vitro showed no difference when compared to tissue culture plastic (p = 0.67). All conditions 
resulted in over 98% viability following 48 h in culture (Figure. 28A,B, and C). Results for 
meECM are shown in (Figure 29A and B). 
 
Figure 28. Cytocompatibility of emECM and XL-emECM. 
The viability of perivascular stem cells (PVSCs) after 48 h culture on emECM (A), XL-emECM (B), and tissue 
culture plastic (TCP) was assessed. Percentage of live cells was quantified and compared across groups (C). Data 
represented as mean ± standard error. Scale bar = 50 μm. 
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Figure 29. Cytocompatibility of meECM 
The viability of perivascular stem cells (PVSCs) after 48 h culture on TCP and meECM (A) was assessed. 
Percentage of live cells was quantified and compared across groups (B). Data represented as mean ± standard error. 
Scale bar = 50 μm. 
 
Primary monocytes isolated from murine bone marrow and matured into macrophages 
showed expression of M2 macrophage phenotype-associated marker Fizz1 after exposure to 
esophageal mucosa ECM and esophageal muscularis ECM digests. The same populations did not 
show expression of M1 macrophage phenotype-associated marker iNOS  (Figure 30) 
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Figure 30. Immunomodulatory effects of esophageal ECM in vitro 
Esophageal mucosal ECM and esophageal muscularis ECM pepsin digests promote an immunomodulatory 
macrophage phenotype when exposed to murine macrophages in vitro.  iNOS: M1 macrophage marker, Fizz1: M2 
macrophage marker. Both biomaterials derived from esophageal tissues promote an M2 pro-remodeling macrophage 
phenotype. 
 
2.3.5 Host Response and In vivo Cytocompatibility 
In-vivo host response to emECM was examined at both 14 and 35 days post-implantation in a rat 
abdominal body wall model. The host response to emECM scaffolds showed a robust 
mononuclear cell response throughout the partially degraded scaffold at 14 days (Figure 31A) 
and yielded a histologic score of 11.4. Along the interface between the emECM scaffold and 
native tissue, the macrophage response was predominantly of the M2 phenotype (Figure 32A) 
with a ratio of M2/M1 macrophages of 1.29 ± 0.21 (Figure 32C). By 35 days post-implantation, 
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the original material was not identifiable by histologic evaluation and the remodeling site was 
composed of organized host connective tissue and islands of skeletal muscle at the periphery that 
extended into the center of the remodeling site (Figure 31B). Semiquantitative histomorphologic 
analysis of emECM at day 35 resulted in a total score of 12. In contrast, the host response to XL-
emECM was characterized by little to no cellular infiltration or vasculature within the chemically 
cross-linked bioscaffold, a dense population of mononuclear macrophages at the host–scaffold 
interface, the deposition of disorganized connective tissues surrounding the implanted test 
article, and little to no degradation of the material at 14 days (Figure 31C). The cellular response 
along the scaffold and native tissue interface was shown to be predominantly macrophages of the 
M1 phenotype (Figure 32B) with an M2/M1 ratio of 0.19 ± 0.03, which was less than (p < 0.001) 
the M2/M1 ratio in emECM. By 35 days, the XL-emECM was still largely intact and showed no 
infiltration of skeletal muscle (Figure 31D). 
 114 
 
Figure 31. In-vivo Cytocompatibility 
Tissue sections were stained with H&E at 14 and 35 days after implantation of emECM (A,B) and XL-emECM 
(C,D). Histomorphologic sections were evaluated and scored according to previously established criteria (E). Scale 
bar = 100 μm. 
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Figure 32. In-vivo macrophage response 
Macrophage immunolabeling in emECM (A) and XL-emECM (B) in explants 14 d after implantation was quantified 
and represented as a ratio of M2/M1 phenotype (C). Dashed line indicates the interface of native tissue (marked by a 
triangle) and the surgical site. Data represented as mean ± standard error. Scale bar = 50 μm. 
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2.4 DISCUSSION AND CONCLUSIONS 
2.4.1 Discussion  
While ECM-derived materials were manufactured and characterized from both the muscularis 
layer and the mucosa layer of the esophagus, due to the clinical higher relevance of mucosal 
repair in the setting of neoplastic tissue resection, only the biocompatibility of ECM-derived 
scaffolds from the esophageal mucosa was assessed in vivo using the abdominal wall defect 
model, and subsequently in aim 2.  
Although current clinical applications of ECM-based biologic scaffolds have included the 
use of devices originating from heterologous tissue sources, recent studies have suggested there 
may be an advantage to using ECM derived from homologous tissue (i.e., site-specific) [9, 58, 
397, 398]. This concept is based upon the fact that ECM from different tissue sources have 
distinct and specific properties, including the ultrastructure and composition; i.e., a tissue-
specific microenvironmental niche. 
The necessity or preference for site-specific ECM remains unknown for many therapeutic 
applications. Zhang et al. have shown that ECM derived from liver, skin, and skeletal muscle 
increases the proliferation and differentiation potential for site-matched cell types [487]. Sellaro 
and colleagues have shown that ECM derived from liver improves the maintenance of sinusoidal 
endothelial cell phenotype [398] and the function of hepatocytes in-vitro [397]. More recently, 
porcine myocardial ECM has been shown to improve cardiac progenitor cell function in-vitro 
[143]. Seif-Naraghi et al. have shown that injection of a hydrogel form of cardiac ECM after 
myocardial infarct improves cardiac function and results in increased cardiac muscle mass [395]. 
Although the present study showed that the emECM facilitates a constructive remodeling 
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response in a heterologous location and excellent in-vitro cytocompatibility, any site-specific 
benefit in the esophageal mucosa (homologous) location has not yet been tested. 
 
The importance of effective decellularization is well recognized [105, 231]. While 
protocols for decellularizing the esophagus have been reported, little has been described with 
focus on the esophageal mucosa. Bhrany et al. developed a rat full thickness esophageal scaffold 
that was able to support epithelial cell growth [47]. Marzaro et al. decellularized intact porcine 
esophagus and seeded with autologous smooth muscle cells for repair of an esophageal 
muscularis defect [284]. Using a similar protocol, Totonelli et al. decellularized intact esophagus 
using luminal perfusion [436]. These groups reported decellularization of the entire esophagus, 
including both muscularis externa and mucosa. However, the efficacy of these decellularization 
protocols, characterization, and cytocompatibility of the scaffold were not investigated in a 
comprehensive manner. 
 
Protocols for esophageal decellularization have been reported but have been conducted 
using non-porcine species and/or have used harsh detergents such as sodium dodecyl sulfate 
(SDS) [41, 243]. SDS, as an ionic detergent, destroys the cell membrane and denatures protein—
altering the collagen structure in ECM [105]. Thus, SDS has the associated drawback of 
ultrastructure disruption [124, 226, 332] and growth factor elimination [357]. A loss of ECM 
structure is also associated with variability in biomechanical properties [322]. Therefore, the use 
of SDS was avoided in the present study. 
Studies have shown the requirement for retention of at least a portion of the submucosal 
tissue to promote constructive remodeling of the esophagus over stricture and scarring [4]. The 
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use of emECM would therefore appear a more logical strategy for clinical translation. The 
methods of the current study thoroughly decellularized esophageal mucosa with the use of mild 
detergents while preserving the anisotropic mechanical properties and bioactive molecules. The 
described method effectively removed cellular components while maintaining ECM constituents 
and basement membrane proteins, collagen IV and laminin, in a contiguous pattern at the surface 
of the emECM material. Scanning electron micrographs of the luminal surface of emECM 
showed a smooth contour that was also consistent with an intact basement membrane surface. 
The basement membrane complex may be of importance to esophageal mucosal remodeling 
because of its natural function of supporting the growth of epithelial cell populations [60, 330, 
431]. The emECM scaffold was cytocompatible with perivascular stem cells, which were shown 
to survive and proliferate when cultured on the scaffold. 
 
The role of the host response to biologic ECM scaffolds is a topic of interest and has been 
reviewed in detail elsewhere [62]. Briefly, the successful therapeutic efficacy of biologic 
scaffolds is attributed largely to the ability of these ECM-derived materials to modulate the 
innate immune response in favor of a constructive remodeling outcome over 
scarring/encapsulation. Key mediators of the innate immune response are macrophages—a 
highly plastic and heterogeneous cell population [65, 426]. Appropriately prepared biologic 
scaffolds have been shown to elicit a macrophage response that is predominantly of an anti-
inflammatory (M2) phenotype which has been associated with a downstream constructive 
remodeling response (i.e., formation of functional, site-appropriate tissue) [31, 65, 67]. However, 
when biologic scaffolds are prepared using harsh decellularization methods, are chemically 
cross-linked, or are inadequately decellularized, a robust proinflammatory (M1) macrophage 
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phenotype is observed at the in-situ interface of host tissue and ECM scaffold and ultimately 
results in chronic inflammation, encapsulation, and fibrosis [65, 243]. In the present study, 
implantation of emECM scaffolds in an established rodent model was associated with a 
predominant M2 macrophage response after 14 days and was shown to remodel in a constructive 
fashion with a histomorphologic score comparable to urinary bladder matrix (UBM-ECM) and 
small intestinal submucosa ECM (SIS-ECM) [65, 410, 443]. These findings are consistent with 
the predictive association of the M2 phenotype with constructive remodeling outcomes [65]. 
 
The objective of the present specific aim was to develop and characterize two distinct 
esophageal ECM scaffolds originating from the different layers of the esophagus, but was limited 
by a number of factors. The effects of  the resulting ECM scaffolds on esophageal cells were not 
studied. Instead, perivascular stem cells were used because they are well-characterized [108] and 
have been used in a number of studies to evaluate the cytocompatibility of a variety ECM 
scaffolds [437]. In addition, while retention of growth factor proteins was used as an indicator of 
the relative mildness of the decellularization protocol, the activity of the growth factors was not 
determined and the effect of the presence of these growth factors in the overall remodeling 
process is unknown. While the M2/M1 macrophage phenotype ratio has been shown to be 
strongly associated with a constructive remodeling response in several anatomic locations, a 
direct cause–effect relationship has yet to be established. Finally, the present study observed the 
in-vivo compatibility and constructive remodeling response of the emECM scaffold in a well-
characterized abdominal wall defect model, a heterologous anatomic site. Thus, the potential 
benefits of ECM derived from homologous tissue (i.e., the use of emECM in an esophageal 
mucosal resection model) remain unknown. 
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2.4.2 Conclusions 
 
Porcine esophageal mucosa was effectively decellularized with the use of a relatively mild 
detergent-based protocol. The emECM scaffold maintained structural proteins and an 
ultrastructure consistent with a basement membrane complex. Likewise, retention of sGAGs and 
bFGF was shown. Compared to native esophageal mucosal tissue biomechanics, the emECM 
scaffold was expectedly less compliant but retained similar anisotropy. The emECM biologic 
scaffold was conducive to stem cell viability in-vitro and was associated with a host innate 
immune response consisting predominantly of M2 macrophages and a more robust constructive 
remodeling response when compared to XL-emECM biologic scaffolds in-vivo. Future studies 
aimed at investigating the specific physical and/or biochemical factors responsible for the 
constructive remodeling outcome and the utility of an emECM biologic scaffold in an 
esophageal location are warranted. 
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3.0  TISSUE SPECIFIC EFFECTS OF BIOLOGIC SCAFFOLDS DERIVED FROM 
ESOPHAGEAL TISSUES 
Aim 2: To evaluate the tissue specific effects of biologic scaffolds derived from esophageal 
tissues in vitro and in a preclinical murine model of esophageal mucosal resection.  
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3.1 BACKGROUND 
 
ECM-derived scaffolds have been extensively used in multiple clinical applications for their 
ability to promote constructive tissue remodeling in several organ systems including the 
gastrointestinal tract [27, 274, 275, 315]. Furthermore, ECM-derived  bioscaffolds have been 
produced via tissue decellularization[105]  from virtually every tissue and organ [22, 106, 147, 
272]. Once implanted, the host response is initiated with the Vroman effect followed by a series 
of complex and overlapling phases that involve the cellular component of the innate immune 
system and the exposure and release of matricryptic peptide fragments.  Matricryptic peptides 
have been shown to modulate cell behavior and tissue remodeling events[4, 6, 7, 97, 110, 159, 
361, 396], and ultimately lead to constructive tissue remodeling. 
 
The ECM represents the structural and functional molecules secreted by the resident cells 
of every tissue and organ. Hence, the biochemical composition and mechanical properties of an 
ECM bioscaffold vary according to the tissue source from which the ECM is isolated and the 
methods of processing and manufacture [105, 271]. It stands to reason that the ideal substrate for 
cell survival, proliferation, differentiation, and functional tissue remodeling is the native ECM of 
the homologous tissue or organ. Recent work has described potential benefits of ECM scaffold 
materials derived from homologous tissue versus heterologous tissue when used in selected 
anatomic locations [9, 57, 101, 106, 144, 292, 397, 398, 487]. ECM bioscaffolds derived from 
homologous tissues can preferentially maintain tissue-specific cell phenotypes [9, 144, 397, 
398], promote cell proliferation [9, 487], induce tissue-specific differentiation [101], and 
enhance the chemotaxis of stem cells [40, 57, 106].  However, these preferences have only been 
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shown in the context of in vitro experiments, and the role of tissue-specificity remains to be 
determined in vivo and in all ECM all therapeutic applications [27, 29, 468].  
 
The objective of this Specific Aim was to study the cellular behavior and tissue 
remodeling events in response to esophageal mucosa ECM (emECM) versus small intestinal 
submucosa (SIS-ECM) and urinary bladder matrix (UBM) in vitro and in vivo. Previous studies 
have demonstrated that when cultured in a emECM-derived hydrogel, esophageal stem 
cells[115] have an increased capacity for organoid formation in comparison to other 
matrices[274] (Figure 33).  Hence, in this aim, the chemoatractive and mitogenic properties of 
emECM were studied and compared to SIS-ECM and UBM-ECM, as well as their ability to 
promote constructive tissue remodeling in a murine model of esophageal mucosal resection. 
 
Figure 33. Organoid Forming Capacity 
Esophageal stem cells show greater organoid-forming capacity when cultured in ECM hydrogels derived from 
esophageal tissues when compared to hydrogels derived from SIS-ECM and UBM-ECM 
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3.2 MATERIALS AND METHODS 
3.2.1 Overview of experimental design 
Porcine esophageal mucosa was decellularized to produce emECM. Using a population of 
heterogeneous esophageal primary cells, the ability for emECM to promote migration and 
proliferation was evaluated and compared to two benchmark ECM scaffolds; specifically urinary 
bladder matrix (UBM) and small intestinal submucosa (SIS). To assess the role of site specificity 
of ECM bioscafolds in esophageal repair applications, emECM and UBM scaffolds were 
subsequently implanted into a rat model of esophageal mucosa resection and the remodeling 
response was evaluated at 14 days post-surgery. 
3.2.2 Animals 
Female Sprague Dawley rats (350 – 400 g at implantation) were purchased from Harlan 
Laboratories and housed in the Division of Laboratory Animal Resources facility at the 
University of Pittsburgh McGowan Institute for Regenerative Medicine. Experimental protocols 
followed NIH guidelines for animal care and were approved by the Institutional Animal Care and 
Use Committee at the University of Pittsburgh. 
3.2.3 Harvest and Preparation of ECM scaffolds and hydrogels 
The esophagus, urinary bladder, and small intestine were isolated from market weight pigs and 
frozen at -20 °C until use. All ECM scaffolds were prepared according to established 
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decellularization protocols (Fig 1). Briefly, esophageal mucosal ECM (eECM) was prepared by 
mechanically separating the mucosa and submucosa from the muscularis externa and subjecting 
the mucosal layers to 1% trypsin/0.05% EDTA (Invitrogen, Carlsbad, CA) for 1 h at 37 °C on a 
rocker plate, deionized water for 15 min, 1 M sucrose (Fisher Scientific, Pittsburgh, PA) for 30 
min, deionized water for 30 min, 3.0% Triton X-100 (Sigma Aldrich, St. Louis, MO) for 48 h, 
deionized water for 15 min, PBS (Fisher Scientific) for 15 min, 10% deoxycholate (Sigma 
Aldrich) for 4 h, deionized water for 30 min, 0.1% peracetic acid (Rochester Midland Corp., 
Rochester, NY) in 4.0% ethanol for 4 h, 100 U/mL DNAse (Invitrogen) for 2 h on a rocker plate, 
followed by 15 min washes with PBS, deionized water, PBS, and deionized water [230]. All 
washes were at 300 rpm unless otherwise specified.  
 
Small intestinal submucosa (SIS) was prepared by mechanically removing the superficial 
layers of the tunica mucosa, tunica serosa, and tunica muscularis externa from the intact small 
intestine, leaving the submucosa, muscularis mucosa, and basilar stratum compactum intact. 
Urinary bladder matrix (UBM) was prepared by mechanically removing the tunica serosa, tunica 
muscularis externa, the tunica submucosa, and majority of the tunica muscularis mucosa from 
the intact bladder, leaving the lamina propria and basement membrane intact. The SIS and UBM 
were then subjected to 0.1% peracetic acid in 4.0% ethanol for 4 h, followed by 15 min washes 
with PBS, deionized water, PBS, and deionized water as described above. All treatments were 
performed at room temperature with agitation on a shaker plate at 300 RPM unless otherwise 
stated. 
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For implantation studies, the ECM scaffolds were lyophilized using an FTS Systems 
Bulk Freeze Dryer (Model 8-54) and sterilized with ethylene oxide. For studies using a hydrogel 
form of the ECM, the decellularized ECM sheets were lyophilized and comminuted to a 
particulate form using a Wiley Mini Mill. One gram of lyophilized ECM powder and 100 mg of 
pepsin (Sigma) were mixed in 100 ml of 0.01 M HCl and kept at a constant stir for 48 h at room 
temperature.  
3.2.4 Isolation and Culture of Esophageal Primary Cells 
The esophagus was removed from Sprague Dawly rats followed by physical separation of the 
mucosa using forceps. The muscularis was minced into small pieces and digested with 1mg/ml 
Collagenase and 1mg/ml Dispase for 1 h each and remaining tissue were passed through a 70 µm 
filter to obtain a single cell suspension. The heterogeneous cell population was then placed in 
tissue culture flasks and cultured in high glucose DMEM media containing 10% fetal bovine 
serume (FBS) and 1% penicillin streptomicin. The cells were then expanded in culture and 
passaged for use in the experiments. Cells used for the experiments consisted of pasages 1 and 2.  
3.2.5 Preparation of ECM Digestion Products 
ECM from different groups (esophageal, UBM, and SIS) was harvested from porcine tissues as 
previously described. Decellularized material was digested at 10 mg/mL dry weight with 
1 mg/mL pepsin (Sigma) in 0.01N HCl for 48 h at 20°C before dialysis at 4°C into phosphate-
buffered saline (PBS). Protein concentration was quantified using the BCA protein assay 
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(Thermo) against bovine serum albumin. The resultant material was referred to as ECM 
degradation products. 
3.2.6 Migration Assay 
Migration assays were performed using a 48 well chemotaxis chamber with polycarbonate filters 
containing 8 μm pores (Neuro Probe, Gaithersburg, MD). The filters were coated with 20 μg/ml 
collagen (Sigma) and dried prior to use. The bottom wells of the chamber were loaded with 30 μl 
containing 25 or 100 μg/ml of emECM digest and the top wells were loaded with 50 μl 
containing 7×104 esophageal cells. Control wells consisted of serum free media and media 
containing 10% FBS.  Following a 3 h incubation, the top filter surface (non-migratory) was 
scraped and the bottom of the filter was fixed in 95% methanol for 5 min and then mounted on a 
glass slide with mounting media containing DAPI (Vector Laboratories Inc, Burlingame, CA) 
and imaged. Migrated cells were quantified using ImageJ (NIH) to set the threshold and count 
cells, with binning to resolve cell clusters of various counts. The same ImageJ macro was used to 
analyze all images. Experiments were performed using 4 technical replicates with 3 separate 
biologic replicates (n=3). 
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3.2.7 Proliferation assay 
Cells isolated from esophageal tissues were inoculated at a concentration of 1 × 104 cells per 
well in standard 12-well plate (well area 3.8 cm2) at 6% or 21% oxygen. Cell growth was 
monitored every 24 h using manual counts. Cell proliferation was also monitored via 
immunohistochemical methods using the thymidine analog 5-bromo-2′-deoxyuridine (BrdU) 
ELISA (Roche). BrdU incorporation was detected using the supplied anti-BrdU antibody. Cells 
were plated at 5 × 104 cells per well in a standard 96-well plate with emECM, SIS or UBM at  
15 μg/mL digest material and labeled with BrdU for 18 h. Relative proliferation was quantified at 
370 and 492 nm in a plate reader (Molecular Devices). Each assay was performed in triplicate on 
three separate occasions. Statistical significance was evaluated by the Student's t-test and a p-
value of 0.05 was considered significant. 
3.2.8  Surgical Procedure and ECM Implantation 
All surgical procedures were approved by the Institutional Animal Care and Use Committee at 
the University of Pittsburgh and the animal care complied with the National Institutes of Health 
Guidelines for the Care and Use of Laboratory Animals. Induction and surgical plane of 
anesthesia were achieved with 2% inhaled isoflurane and the animals were placed on a warming 
pad in supine position. The cervical skin was shaved and aseptically prepared with ethanol and 
betadine. A midline cervical incision was performed above the clavicle and the esophagus 
exposed via blunt dissection. A transverse incision of the muscularis externa layer was 
performed, and a window of full thickness mucosa extending 5-10 mm length including 70% of 
the circumference was resected. Animals treated with ECM received a single layer sheet that was 
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placed over the denuded area and secured in place with interrupted 10.0 prolene sutures (Ethicon, 
Somerville, NJ). The denuded mucosa was left exposed in non-treated control animals. Skin was 
closed with 4.0 Vicryl (Ethicon) and buprenorphine (0.5 mg/kg, Benckiser Healthcare (UK) Ltd, 
Hull, England) was administered intramuscularly immediately postoperatively and twice a day 
for 3 days. Animals were placed on a soft diet for 5 days post operatively. 
3.2.9 Histology and Immunolabeling 
Two histology and immunolabeling studies were performed on the explanted esophageal tissue 
sections. Explanted esophageal tissue sections were fixed in 10% neutral buffered formalin and 
paraffin embedded. 
Serial sections (8 μm) of the samples were stained with hematoxylin and eosin or 
immunolabeled. Antigen retrieval was performed by heating a citrate antigen retrieval buffer (10 
mM citric acid with 0.05% Tween 20, pH 6) until boiling, and incubating the slides in the 
solution until returning to room temperature. Three washes in phosphate buffered saline (PBS) 
for five minutes at room temperature were performed. Tissue sections were permeabilized with 
1x Tris-Buffered Saline with Tween 20 (TBST) for 10 minutes at room temperature. The slides 
were incubated in a blocking solution (5% BSA in 1x PBS) at room temperature to prevent non-
specific binding. The slides were incubated in primary antibody blocking solution at 4°C 
overnight. Five washes in PBS were performed for 5 minutes at room temperature. Slides were 
incubated in secondary antibody in blocking buffer at room temperature for 1 hour. Five washes 
in PBS were performed for 5 minutes at room temperature. The primary antibodies used for the 
immunolabeling studies cytokeratin 14 (1:200; NBP1-67606, Novus Biologicals, Littleton, CO) 
for tissue sections. The secondary antibodies used were Alexa Fluor 488 (1:200; A-11034, 
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Invitrogen) and Alexa Fluor 594 (1:200; A21203, Invitrogen). Sections were counterstained with 
4',6-diamidino-2-phenylindole (DAPI) and mounted in fluorescence mounting medium (Dako). 
Stained sections were visualized on Nikon E600 fluorescence microscope with Cri Nuance FX 
multispectral imaging system. 
3.2.10  Statistical Analysis 
Data sets were analyzed with a one-way analysis of variance (ANOVA) using SPSS Statistical 
Analysis Software (SPSS Inc., IBM, Chicago, IL). A student t-test was used to identify the 
differences between means when the observed F ratio was statistically significant (p < 0.05). 
Data are reported as mean ± standard error. 
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3.3 RESULTS 
3.3.1 Degradation Products from ECM Bioscaffolds Promote Cell Migration 
The chemotaxis of primarily isolated heterogeneous esophageal cell populations was evaluated 
using a Boyden chamber assay. Two concentrations of ECM were chosen to determine whether a 
migration dose response existed. The esophageal cells did not migrate toward serum free media 
or 10% FBS. However, the cells showed an increased migration response towards all the ECM 
groups and the positive control. Quantification of migrating cells (Figure 34) showed no 
statistical significance among groups. 
 
Figure 34. Esophageal cell migration towards ECM degradation products 
Primary heterogeneous esophageal cell populations were exposed to degradation products of emECM, UBM, and 
SIS in a Boyden Chamber assay at concentrations of 25ug/ml and 100ug/ml. No differences were observed between 
the groups.  Equivalent trends have been observed in other studies [359] 
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3.3.2 Degradation Products from ECM Bioscaffolds Promote Cell Proliferation 
Proliferation of cell was assessed via manual counts and by incorporation of EdU. Degradation 
products of ECM were shown to promote cell proliferation when compared to negative controls. 
However, there was no difference among the values for proliferating cells culture in eECM, SIS 
and UBM (Figure 35). 
Figure 35. Degradation products of ECM bioscaffolds promote esophageal cell proliferation 
Esophageal cell populations exhibit increased growth media containing ECM degradation products compared to 
controls. Growth of Cells were plated at an initial seeding density of 1 × 104 per well and triplicate wells harvested 
every 24 h with total cells per well counted. Data presented as means of triplicate determinations with standard 
deviations. Equivalent trends have been observed in other studies [359, 437] 
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3.3.3 ECM-Mediated Esophageal Mucosal Remodeling 
The ability of ECM to mediate tissue repair in the esophageal mucosa was tested in a rat model 
of mucosal resection. Following resection of approximately 7 mm length of esophageal mucosa 
consisting of 70% of the circumference, a size-matched ECM scaffold was placed at the site of 
tissue resection (Figure 36). Rats weighed 228 ± 2.5g prior to operation, and all animals lost 
weight following mucosal resection. The ECM treated rats gradually gained weight over time. 
Eighty-three percent (5 out of 6) of the untreated control animals showed anorexia and 
complications secondary to anastomotic leaks and stricture formation that required removal from 
the study prior to the predetermined experimental endpoint. The remaining control rat showed no 
signs of mucosal coverage of the implant site (Figure 38A). The emECM treated rats lost -7.4 ± 
1.3% vs. -11.9 ± 2.5% for the UBM treated rats by 3 days post surgery compared to the UBM 
treated rats although the difference was not significant (p=0.243). By 14 days post surgery both 
groups had recovered from the weight loss and exceeded their initial weight (emECM +2.4 ± 
2.7% vs UBM +1.4 ± 2.6%) (Figure 37). All of the ECM treated rats recovered from surgery and 
survived to the experimental endpoint (14 days) without complications. Representative images 
show that remodeling of the esophageal mucosa was indistinguishable in rats treated with UBM 
(Figure 40B) vs. emECM (Figure 38C).  Positive staining for CK14, a marker of basal 
esophageal epithelium, was absent in the control animals (Figure 38D) but was shown in cells 
lining the basement membrane of the esophageal mucosa in rats treated with both UBM (Figure 
40E) and emECM (Figure 38F). 
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Figure 36. Esophageal mucosal resection in the rat model 
(A) Mucosal resection in the rat is performed by exposing the esophagus around the trachea and performing a 
mucosectomy through a horizontal incision in the muscularis layer of the esophagus. (B) Once the mucosa is 
removed, an extracellular matrix (ECM)-derived biomaterial is delivered in situ to facilitate constructive tissue 
remodeling. (C) Masson’s trichrome stain of native esophageal mucosa (arrow) and (D) remodeled esophageal 
mucosa after biomaterial-mediated repair showing intact keratinized epithelium (arrowhead). 
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Figure 37. Post-Operative weight of animals undergoing ECM-mediated mucosal repair. 
Animals in the no treatment control group present clinical stricture formation and fall below 20% pre-op weight or 
expire within 4 days and are therefore excluded from the study. 
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Figure 38. ECM mediated esophageal mucosal repair 
Histologic images showin ECM mediated esophageal mucosa repair at 14 days post implantation. A) No treatment 
control shows an inflammatory cell infiltrate in the esophageal lumen devoid of a normal esophageal mucosa and 
consistent early stages of collagen deposition and scar tissue formation. B) and C) show a histologically 
unremarkable neo-mucosa in the groups treated with UBM and emECM respectively. Immunolabeling with 
cytokeratin 14 stain show no site appropriate differentiated cells in the no treatment control group and positive cells 
in both UBM and emECM treatment groups. 
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3.4 CONCLUSION AND DISCUSSION 
The clinical translation of successful regenerative medicine strategies for tissue repair is 
contingent on the implementation of adequate and relevant animal models that permit both the 
investigation of the mechanisms of tissue repair and the evaluation of the safety and efficacy of 
these therapies.  
Animal models are important tools to predict in vivo human behavior [133]. However, 
the term has often been used inappropriately to imply that only work with species that closely 
duplicate human physiology can be useful. Instead, it is important to recognize that there is both 
a unity and a diversity within animal models [187] and that both differences and similarities can 
and should be exploited in the development of regenerative medicine strategies for tissue repair.  
Results of the present aim indicate that while a homologous emECM preferentially 
enhances the migration of esophageal stem cells and supports the formation of 3D organoids in 
culture - as shown in previous studies by Keane et al[275],  there seems to be no difference in the 
ability to attract heterogeneous esophageal cell populations, or in the ability to promote non-stem 
cell proliferation in vitro. In line with these findings, in-vivo remodeling events of the 
esophageal mucosa were found to be similar with the use of heterologous (UBM) vs. 
homologous (emECM) scaffolds. These collective results suggest that although the mucosa of 
the esophagus might contain favorable tissue-specific properties that are retained following the 
decellularization process, the contribution of these properties may only be relevant under specific 
circumstances involving stem cell activity.  In contrast, in vitro work with heterogeneous stem 
cell populations and the overall in-vivo remodeling process are either not identifiable with these 
experiments or not necessary for the process of constructive remodeling to occur. These findings 
are in line with other published studies that suggest that tissue specificity of ECM-derived 
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biomaterials is particularly relevant in specific in vitro experiments involving isolated stem cell 
and fully differentiated cell types[9, 106, 397, 398].  
 
Furthermore, while the cells that contribute to esophageal remodeling following mucosal 
resection in the present study are not completely identified, the resident esophageal stem cell 
population represents a plausible and logical candidate [121]. These cells are present in the basal 
layer of the esophageal mucosa and following tissue resection must migrate the length of the 
mucosal resection to aid in tissue repair. Results of the present study show that ECM constituents 
facilitate the migration and proliferation of esophageal cells 
 
A key indicator of the success or failure of an ECM scaffold to facilitate constructive and 
functional tissue repair is the host response to the material following implantation. While a 
distinct and tissue-specific ECM-dependent stem cell response has been observed in-vitro in, the 
in-vivo remodeling outcome at 14 days post surgery yielded an indistinguishable constructive 
outcome regardless of which ECM scaffold was used. The fate of the control animals clearly 
indicated that the mucosal defect was critically sized and both ECM scaffolds promoted a 
constructive remodeling response compared to the healing response of the untreated control 
animals. Whether the temporal remodeling response differed between UBM and emECM is 
unknown since only a single post-operative time point was studied.  
 
Previous studies in the esophageal location suggest constructive tissue remodeling occurs 
with the use of UBM and SIS [27, 33, 316], incidentally, both heterologous forms of ECM. The 
use of heterologous ECMs has been well documented in other anatomic locations. In these 
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studies, all ECMs were successful in reducing stricture formation but the remodeled tissue did 
not fully reconstitute all components of normal esophageal tissue; for example, glandular tissue 
was absent . The present study showed that heterologous source ECM scaffolds were inferior to 
site-specific ECM in-vitro but in-vivo differences in outcomes in eECM vs. UBM at 14 days post 
mucosectomy were not identified. Species differences in the rat and human esophageal histology, 
namely the lack of submucosal glands in the rat esophagus, would require testing in a large 
animal model to determine whether eECM may have clinical benefits.  
 
A variable in the present study that should be noted is that the ECM materials were 
derived from xenogeneic tissues. However, this is quite representative of the clinical scenario, 
where a large majority of commercial scaffolds composed of ECM are from a porcine source 
[229]. Practical considerations favor the use of xenogeneic tissues as they are in abundant supply 
through the agricultural supply chain. More importantly, the constituent molecules of ECM are 
some of the most highly evolutionarily conserved proteins across species [210, 212, 250]. The 
present study shows that porcine eECM regulates murine esophageal stem cell behavior and also 
mediates esophageal remodeling in the rat, consistent with known species homology of ECM 
constituents. 
 
There were limitations to the present study. First, the response of only one cell type was 
evaluated. Esophageal stem cells are not the only cell population that may contribute to 
remodeling of the esophageal mucosa. Another potential contributing cell population is the 
multipotent perivascular stem cell [5, 108]. Perivascular stem cells are found surrounding 
endothelium of normal tissue and are likely to be present in the vasculature within the esophagus. 
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A number of studies have reported the chemotactic and mitogenic potential of ECM for the 
perivascular stem cell population [5, 437]. Another limitation of the present study was the use of 
different decellularization protocols for preparing the ECM scaffolds. Decellularization protocols 
are typically dictated by tissue-specific characteristics, which almost always differ to achieve 
effective decellularization. Use of a single decellularization protocol for all tissues in the present 
study would have resulted in ECM scaffolds with a different content of cell remnants and thus 
would have added a major variable [231]. The effects of the different decellularization protocols 
upon the results in the present study are unknown, but protocols similar or identical to those in 
the present study would likely be used in the clinical setting and therefore have potential clinical 
relevance. 
 
In conclusion, the present study showed a superior in-vitro response of esophageal stem 
cells to homologous ECM vs. heterologous ECM. Surgical placement of the scaffold into a 
rodent mucosal defect, however, showed no differences in remodeling response for homologous 
vs. heterologous ECM. A single time point limited conclusions from the in-vivo portion of the 
present study and the preference of homologous ECM in the esophageal location is worthy of 
further investigation considering the unmet clinical need for therapeutic options for esophageal 
pathology. 
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4.0  A CARIDAC-ECM COATING TO MODULATE THE HOST RESPONSE TO A 
SYNTHETIC CARDIAC PATCH ON A MURINE MODEL OF MYOCARDIAL 
INFARCTION 
 
Aim3: To evaluate the ability of cardiac-ECM to modify the host response to an implanted 
cardiac patch in a preclinical murine model of myocardial infarction.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 143 
4.1 BACKGROUND 
 
The human heart is a complex organ that unlike the dermis, bone marrow, and the epithelium 
from the gut, does not have the ability to significantly regenerate.  However, recent studies have 
reported the existence of stem cell populations in the heart, and have suggested that the 
possibility of recovery in fact exists [43, 259]. Despite these findings, the regenerative capacity 
of the heart has not yet been deciphered. Nonetheless, different regenerative medicine 
approaches are currently being developed for cardiac repair, and of these, the manipulation of 
host cell populations and modulation of the wound healing response are the most promising 
strategies[319]. 
 Mortality rates from myocardial infarction have decreased significantly in the last few 
decades due to advancements in quick detection, the establishment of rapid emergency triage and 
treatment algorithms [356], and better management/medications for risk factors associated with 
CAD, including hypertension and dyslipidemia[449] (Figure 39). 
 
 
Figure 39. Decrease in MI Mortality. Adapted from [356] 
A) The decrease in mortality associated with MI has steadily decreased due to B) therapeutic improvements.    
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However, due to unprecedented MI survival rates, more and more patients are now living 
with a partially dysfunctional myocardium with different degrees of severity often times leading 
to ventricular remodeling and heart failure[245]. In an attempt to prevent these events, several 
attempts to create cardiac patches to physically restrain the ventricular remodeling by providing 
additional support to the infarcted region [17, 153]. 
Our group has reported the implantation of an elastic and biodegradable polyester 
urethane urea (PEUU) cardiac patch onto a region of myocardial infarct can prevent adverse 
ventricular remodeling, altered LV wall thickness, and can promote compliance toward normal 
levels at the site of implantation.[178]  The PEUU patch prevents myocardial encapsulation and 
provides temporary elastic support that mechanically alters the wall stress experienced by the 
infarcted region resulting in changes in the remodeling course pursued by the tissue towards a 
more desirable end. In addition, the degradable patch also avoids the existence of a permanent 
foreign body on the myocardial surface.  
However, the host immune response to synthetic biomaterials is well described[13] and 
these materials lack the bioactivity present in natural ECM[271]. ECM-derived scaffolds contain 
bioactive molecules that exert in vivo mimicking effects as applied for soft tissue engineering, 
yet do not possess the same flexibility in mechanical property control as some synthetics[424]. 
Furthermore, studies have found that an ECM coating can mitigate the chronic inflammatory 
response and associated scar tissue deposition associated with synthetic meshes[136, 466](Figure 
43) and therefore, we hypothesize that a biohybrid patch of PEUU-cardiac ECM is able to
modify the host response to an implanted cardiac patch in a murine model of MI. 
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Figure 40. ECM coating of synthetic devices modulates the host response[136] 
A) Gross morphology images of non-coated and ECM-coated polypropylene mesh. B)Six months after implantation,
the constructs present different size and orientation of collagen fibers. C) ECM coating decreases the M1 
macrophage (orange) – response typically associated with synthetic material fibers and promotes a pro-remodeling 
M2 phenotype (green). Nuclei – blue, DAPI stain. 
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4.2 MATERIALS AND METHODS 
4.2.1 Overview of Experimental Design 
A myocardial infarction (MI) was induced in Sprague Dawly rats via coronary artery ligation. 
Two weeks post MI the size of the infarction was assessed and any animals with smaller infarcts 
were removed from the study. Those with large infarcts were divided in three groups and 
implanted with patch composed of either PEUU alone, a biohybrid of PEUU and Cardiac ECM, 
or received no treatment. Eight weeks post implantation the animals were sacrificed and the 
tissue was processed for histology.  
4.2.2 Cardiac Decellularization 
 
This protocol for decellularization is available at[360] 
4.2.2.1 Tissue Preparation and Experiment Setup 
Porcine whole hearts were harvested immediately after euthanasia from an abattoir 
excess blood was rinsed off. Excess fat and tissue were trimmed off keeping the atria and aorta 
intact. The tissue was then frozen in a -80 °C freezer for at least 24 hr to ensure complete 
freezing. 
When ready for decellularization, the tissue was thawed in Type 1 water overnight 
submerged in a 4 L beaker at 4 °C, patted dry, and its weigh was recorded. The heart of a market 
weight pig should weigh approximately 375-450 g.  The heart was then connected to a  size 18 
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Masterflex tubing to the ¼" end of a barbed reducer remaining above the aortic valve, so the 
coronary arteries can be perfused. 
The tubing was filled with Type I water and inserted within the cartridge of a Masterflex 
roller pump at its approximate midpoint. The inflow end of the tubing was submerged in the 
bottom of a 4 L beaker filled with 2.5 L of water and secure the tubing. 
The heart was placed in the beaker filled with water, and prime the pump to remove air 
bubbles. If bubbles were observed coming from the aorta where the tubing is inserted, the aorta 
may need to be repositioned or secured with additional ties. An airtight seal is important to 
maintain adequate pressure during the decellularization process. The 4 L beaker containing 3 L 
of a 0.2% Trypsin/0.05% EDTA/0.05% NaN3 solution was placed on a stir plate and warmed to 
37 °C in preparation of the decellularization process. 
 
4.2.2.2 Tissue Rinses 
The pump was set to a flow rate of 400 ml/min, ensuring that the correct tubing size is selected. 
The heart was flushed with Type I water for 15-25 min. As the pump is started, the heart should 
swell and effuse blood from the ventricles. Fresh solution should be substituted every 5-10 min, 
or as needed based on the amount of blood removed from the heart. If blood is not effused from 
the heart, adjust the tubing and clamps as necessary. 
The pump was stopped and the heart was transferred to a separate beaker filled with 2X 
Phosphate Buffered Saline (PBS). After the tubing was submerged in solution, the pump was 
started and increased the flow rate to 700 ml/min. The heart should remain in solution for 15 
min, changing the solution every 5 min. Each solution change requires the pump to be stopped 
temporarily while the tissue and tubing is moved to the new beaker. 
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The heart was then transferred to Type I water for 10 min and increase the flow rate to 
750 ml/min. 
4.2.2.3 Decellularization and Solution Perfusion  
The heart was transferred to the beaker containing 0.2% Trypsin/0.05% EDTA/0.05% NaN3 at 
37 °C. The pump speed was increased to 1,200 ml/min and the pump stared  using a stir bar 
placed at the bottom of the beaker to circulate solution in the beaker. The heart should remain in 
the 0.2% Trypsin/0.05% EDTA/0.05% NaN3 solution at 37 °C for a total of three hours. After 1 
hr, the pump speed was increased to 1,500 ml/min. After an additional hour, the pump speed was 
increased to 1,800 ml/min. The tissue was slowly subjected to increased perfusion speeds to 
condition the tissue and prevent rupture of the vessels. The heart swells and nearly doubles in 
size during this step of the protocol. The tissue loses its natural color, progressing from the atria 
to the apex throughout the protocol. 
After each solution perfusion, a two step rinse was performed to remove cellular debris, 
chemical residue, and aid cell lysis. Each rinse consisted of a 10 min rinse in Type I water 
followed by a 10 min rinse with 2X PBS solution at room temperature. Each wash consisted of 
removal of solution from the original beaker, adding rinse solutions, and circulating the perfusate 
within the beaker containing the submerged heart. After the 0.2% Trypsin/0.05% EDTA/0.05% 
NaN3 solution, water was perfused at 1,900 ml/min and then 2X PBS at 1950 ml/min. 
The heart was transferred to a solution of 3% Triton X-100/0.05% EDTA/0.05% NaN3 at 
room temperature. Increase the pump speed to 2,000 ml/min and perfuse solution for one hour. 
The solution was removed from the beaker and replaced with fresh solution, the pump speed was 
increased to 2100 ml/min, and the fresh solution was perfused for an additional hour and a half, 
bringing the total time in 3% Triton X-100/0.05% EDTA/0.05% NaN3 to 2.5 hr. 
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The tissue was rinsed in Type I water at 2150 ml/min and 2X PBS at 2180 ml/min for 10 
min each and transferred to a 4% Sodium Deoxycholate solution at room temperature. The pump 
speed was increased to 2,200 ml/min and perfuse solution for 3 hr. The tissue was rinsed in Type 
I water at and 2X PBS at 2,200 ml/min for 15 min each, changing the solutions after 5-10 min 
for each solution. The described perfusion steps may be split over multiple days by performing 
the rinse step twice and storing the heart with attached tubing overnight at 4 °C and submerged 
in Type I water. 
The following day, a 5 min rinse with Type I water at 750 ml/min was performed,  
followed by a 5 min rinse in 1X PBS at 1,500 ml/min. The protocol may then be continued at the 
described flow rate in the proper solution. 
4.2.2.4 Disinfection and Final Processing 
The heart was transeferred to a 0.1% peracetic acid/4% ethanol solution and perfused in solution 
for 1.5 hr at 2,200 ml/min. The final rinses for the tissue were all performed at 2,200 ml/min. 
The tissue was perfused with 1X PBS for 15 min, followed by two 5 min washes in Type I water. 
This series of rinses is repeated once more in order to complete the solution perfusion procedure. 
After most of the water is removed, the weight of the cardiac extracellular matrix (C-ECM) was 
recorded. The heart can be expected to lose approximately 20-25% of its initial weight during the 
decellularization process (Figure 41). 
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Figure 41. Porcine heart before and after decellularization 
4.2.3 Preparation of Cardiac Patch 
Polymer patches were were synthesized from soft segments of polycaprolactone (PCL, MW = 
2000, Sigma) and diisocynantobutane (BDI, Sigma) hard segment with chain extension by 
putrescine (Sigma) according to a previous report. The soft segment:hard segment:chain extender 
molar ratio was set as 1:2:1. For scaffold fabrication, polymer samples were completely 
dissolved in hexafluoroisopropanol (HFIP) to obtain a 40% (w/v) solution. This solution (1 mL) 
was blended uniformly with 5 g salt particles (NaCl, Sigma), which had particle sizes of 75–100 
µm obtained by serial treatment with American standard sieves. The polymer/salt mixture was 
poured into a 1 cm diameter cylindrical glass mold. After complete solvent evaporation, the 
mixture was immersed in an excess of 30% ethanol solution to remove the salt particles from the 
scaffold with frequent solution changes over 2 d of immersion. The scaffold was then placed in 
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pure deionized water to exchange the ethanol solution for 3 h, and then frozen at −80 °C, 
followed by lyophilization for 2 d to obtain a porous scaffold for implantation[202]. The material 
was sized to circular patches 6 mm in diameter and 300 µm in thickness. The patches were 
immersed in 70% ethanol for 30 min, followed by washing in phosphate-buffered saline and 
exposure to the ultraviolet light source for 1 h before implantation. [202]. Hybrid bioscaffolds 
were manufacter through electrospinning polymer and cardiac-ECM using a proprietary process.   
 
4.2.4  Surgical Procedure 
Adult female syngeneic Lewis rats (Harlan Sprague Dawley Inc.) 10–12 wk old, weighing 160–
210 g were used for this study. The research protocol followed the National Institutes of Health 
guidelines for animal care and was approved by the Institutional Animal Care and Use 
Committee of the University of Pittsburgh (#0903312A-3). 
4.2.4.1 Myocardial Infarction Model 
The detailed procedure for creating the rat MI model has been described previously [150]. 
Briefly, rats were anesthetized with 3.0% isoflurane inhalation with 100% oxygen followed by 
intubation and respiratory support with a rodent volume-controlled mechanical ventilator (683 
Ventilator, Harvard Apparatus, Holliston, MA) at a tidal volume of 3 mL and 80 breaths/min. 
Rats were placed in the right decubitus position, and the chest was shaved and prepared with 
povidone-iodine solution. Procedures were performed in a sterile environment on a heating 
blanket. The heart was exposed through a 4th left thoracotomy, monitoring electrocardiogram. 
The proximal left anterior descending (LAD) coronary artery was ligated with 7-0 
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polypropylene. Myocardial ischemia was confirmed by decreased movement in the left ventricle 
(LV) free wall, regional cyanosis and ST-segment elevation. The incision was closed in layers 
with 5-0 polypropylene continuous sutures. The animals were allowed to recover from anesthesia 
and returned to their cages. For prophylaxis of lethal ventricular arrhythmia, 10 mg/kg of 
lidocaine was administered intramuscularly once prior to surgery. For postoperative analgesic 
treatment, 0.1 mg/kg of buprenorphine was administered subcutaneously 3 times daily for 3 d 
after surgery. For prophylaxis of surgical site infection, 100 mg/kg of cefuroxime was 
administered intramuscularly twice daily for 3 d after surgery [183]. 
4.2.4.2 Patch implantation 
Two weeks after coronary artery ligation, animals were anesthetized and examined 
echocardiographically for infarct size as estimated by the percentage of scar area (akinetic or 
dyskinetic regions) to LV free wall area. Animals with infarcts greater than 25% of the LV free 
wall were randomly divided into 3 groups: 1) PEUU patch orthogonal repair, 2) PEUU patch 
longitudinal repair, and 3) PEUU-Cardiac ECM patch repair (Figure 42). Through a 5th left 
thoracotomy, the infarcted anterior wall was exposed. Before affixing the patch, the surface of 
the infarcted area (less than 0.1 mm thickness), including the remnant epicardium and some of 
the integrated fibrous tissue, was scraped and removed at the patch implant site. Subsequently, 
the anterior infarcted myocardium was covered with a patch, using 7-0 polypropylene with over-
and-over peripheral continuous sutures. For the infarction control group, a thoracotomy was 
performed 2 weeks after coronary ligation, but no scraping or patch placement was performed.  
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4.2.4.3 Determination of infarction size, scar area, and LV anterior wall thickening 
The cross-sectional surface during sectioning was digitally photographed at the level of the 
center of patches. Infarction size was defined as a percentage of the sum of the epicardial and 
endocardial infarct circumference divided by the sum of the total LV epicardial and endocardial 
circumferences[266]. Scar area was measured as an infarction scar area using computer-based 
planimetry. LV anterior wall thickness was expressed as follows: scar area/[(epicardial 
circumference + endocardial circumference)/2]. Measurement of each parameter (n = 6 per each 
group) was performed using ImageJ analysis software on Masson’s trichrome stained sections. 
Figure 42. Experimental Groups 
Implantation orientation according the orientation of the polymer fibers. 3 groups were used in this study: 1) PEUU 
patch orthogonal repair, 2) PEUU patch longitudinal repair, and 3) PEUU-Cardiac ECM patch repair. 
4.2.5 Specimen Harvest and Histology 
The heart (n = 6 per each group) was explanted and fixed in 2% paraformaldehyde for 2 h 
at 4 °C and then embedded with optimal cutting temperature compound (Tissue-Tek, Torrance, 
CA) followed by freezing at −80 °C. Embedded, frozen LV tissues were serially sectioned at 8 
µm in the LV transverse direction at the center of patched area and mounted on microscopic 
glass slides and stained with Masson’s trichrome.  
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4.2.5 Sample Analysis 
Slides were examined with an Olympus IX51 microscope and images captured using DP2-BSW 
software (Olympus America Inc.). For each retrieved sample, 10 different microscopic fields at 
200× magnification were photographed for αSMA or CD163 positive structures. To determine 
quantity of vessels or arterioles, the number of αSMA-positive structures was measured using a 
digital image analyzer (ImageJ v.1.41, National Institutes of Health, Bethesda, Maryland) at 
200× magnification. Vessels were identified as tubular structures positively stained for αSMA. 
Arterioles were defined as αSMA-positive structures, having visible lumen, and more than 10 
µm in diameter. All measurements and assessments were performed using a digital image 
analyzer (ImageJ). Values are reported as the area (µm2) per 200× magnification of high-
powered filed (HPF, approximately 0.581mm2) for non-vascular αSMA and as numbers per HPF 
for αSMA-positive vessels and arterioles, and CD68- and CD163-positive structures. The 
number of structures positive for a specific antibody was counted for vessel, arteriole, and 
CD163 evaluation, while the area expressed in pixels was measured for the evaluation of non-
vascular αSMA, CD68, elastin, collagen type I, and collagen type III. 
4.2.6 Statistical Analysis 
 
Statistical evaluations were performed using Prism version 4.0c (GraphPad Software Inc.). 
Results are listed as mean ± standard error of the mean. The Komolgorov–Smirnov test for 
normality was performed for each data set to determine the appropriate statistical testing. One-
way ANOVA followed by Bonferroni multiple comparison testing was applied where multiple 
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comparisons were made at the same time point. For the temporal analysis of echocardiography 
including EDA and %FAC, two-way repeated measures analysis of variance (ANOVA) was 
performed using the Bonferroni correction. Differences were considered to be statistically 
significant at p < 0.05. 
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4.3 RESULTS 
4.3.1 Cardiac Decellularization  
The left ventricular wall was effectively decellularized via perfusion decellularization. H&E 
stains show no visible nuclei. 
 
Figure 43. Cardiac Decellularization 
A) Whole heart post decellularization. B) Gross image of cross section of the left ventricular wall. H&E cross 
sectional images show no visible nuclei at C) 100x and D) 400x magnification.   
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4.3.2 Preparation of Cardiac Patch   
Cardiac patches for implantation measuring 0.5cm by 0.5cm were manufactured via 
electrospinning with either one polymer layer composed of PEUU, or with two layers: a polymer 
side with PEUU, and a cardiac-ECM rich side (Figure 44). Cardiac patch in situ after 
implantation (Figure 45). 
 
Figure 44. Cardiac Patch for Myocardial Repair 
A) Macroscopic image of polymer (top) and hybrid patch (bottom). B) Trichrome stain of hybrid patch containing 
polymer layer (top) and cardiac ECM-rich layer (bottom). 
 
 
Figure 45. Cardiac patch implanted in situ [183]. 
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4.3.3 Macroscopic Findings 
Macroscopic inspection of the ventricular wall showed increased wall thickness in the cardiac 
ECM-PEUU patch treatment group (2.3cm) compared to PEUU patches implanted in the 
longitudinal and orthogonal direction (1.2cm and 1.4cm respectively). The left ventricular 
thickness of the cardiac ECM-PEUU not was statistically different from healthy controls (Figure 
46). 
 
Figure 46. Gross examination of left ventricular wall thickness 
Long: patch implanted in the longitudinal direction, Ortho: patch implanted in orthogonal orientation. C-ECM: 
cardiac ECM-PEUU patch, MI: myocardial infarction, HC: healthy control, pre-L-O: pre longitudinal and 
orthogonal implantation, Prec-ECM pre cardiac ECM-PEUU patch implantation. 
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4.3.4 Histomorphology 
Microscopic examination of the explanted samples and quantification of the area covered by 
muscle and scar tissue thickness showed the cardiac ECM-PEUU patch treatment group was able 
to reduce scar tissue thickness compared to PEUU patches implanted in the orthogonal direction. 
Thickness of muscle tissue was unchanged among treatment groups. (Figure 47). 
 
Figure 47. Histologic Examination 
Histologic examination of H&E stained tissue sections showed a reduction of scar tissue formation in the cardiac 
ECM-PEUU patch treatment group. 
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4.4 DISCUSSION AND CONCLUSIONS 
Remodeling events observed in the myocardium following infarction are the result of 
compensatory mechanism secondary to ischemic cardiomyopathy. These remodeling events are 
characterized by thining and bulging of the ventricular walls and ultimately lead to heart 
failure.PREvious studies report that polymer patches composed of PEUU can act as temporary 
mechanical barrier that can mitigate the amount of ventricular wall remodeling and functional 
loss following myocardial infarction [139, 182]. 
However, the host response to synthetic biomaterials is a well described event that in the 
case of degradable materials, does not lead to constructive tissue remodeling [271, 470]. The 
data in the current study demonstrated that the addition to of cardiac ECM component to the 
polymer patch can modify the host response and lead to less scar tissue formation per histologic 
analysis, and prevention of ventricular wall thining. 
Synthetic biodegradable material implantation induces an inflammatory response[13]. 
However, ECM-derived biomaterials are immunomodulatory [136, 207, 244, 466]. The 
magnitude of inflammatory response associated with synthetic biomaterials depends upon the 
specific material chemistry and other physical parameters. As the primary cell type of the post-
acute foreign body response, macrophages produce a spectrum of enzymes and cytokines that 
facilitate tissue remodeling in terms of matrix degradation, cell recruitment, proliferation and 
extracellular matrix formation for new tissue regeneration. Extracellular matrix-derived 
biomaterials have been show to modulate these processes both in vivo[408] and in vitro[359]. 
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The addition of a cardiac ECM component to cardiac polymer patches is efficacious in 
reducing ventricular wall thining and reducing scar tissue formation when compared to polymer 
patches without an ECM component. These results indicate that a hybrid patch provides a greater 
benefit in treating ischemic cardiomyopathy than morphologically similar PEUU patches in the 
rat model. This conclusion was supported gross morphology findings and histological assessment 
which showed superior performance of the hybrid patch. These results are in line with findings 
of hybrid bioscaffolds used in other applications [136, 466] and support a tuned biomaterial 
approach to modulate the remodeling process that occurs in ischemic cardiomyopathy.  
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5.0  DISSERTATION SYNOPSYS  
 
The work presented in this dissertation focused on the development and characterization of ECM 
bioscaffolds derived from esophageal tissues and the examination of homologous tissue 
specificity upon constructive tissue remodeling both in vitro and in vivo models of tissue repair. 
This work showed that porcine esophageal and cardiac tissues can be decellularized and that the 
resulting scaffolds are compliant with criteria for decellularization. Furthermore, the resulting 
scaffolds are able to promote chemotaxis and mitogenesis in vitro, as well as macrophage 
differentiation into the M2-proremodeling phenotype. Surgically placed ECM-derived 
bioscaffolds in a model of esophageal mucosal repair are able to promote constructive tissue 
remodeling. This work also showed that contrary to other studies, homologous site specificity 
does not play a role in heterogeneous cell population migration and proliferation, or in the host 
response following in vivo implantation. Modification of existing polymer based scaffolds with 
the addition of a cardiac-ECM component was able to modify the host response to an implanted 
cardiac patch following ischemic events in a murine model of myocardial infarction. The major 
findings for each specific aim are outlined below. 
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5.1 MAJOR FINDINGS 
 
The major findings of the present work were: 
 
Aim 1: To develop and characterize extracellular matrix based bioscaffolds from the mucosal 
layer and muscularis externa of the porcine esophagus.  
ECM-derived bioscaffolds can be derived from the esophageal mucosa and the 
muscularis externa, and these bioscaffolds are compliant with proposed decellularization criteria. 
Perfusion decellularization can maintain the ultrastructure of the original ECM in the muscularis 
layer of the esophagus. The bioscaffolds are cytocompatible and their degradation products 
promote and M2-modulatory macrophage phenotype in vitro.  
 
Sub-Aim 1: To characterize the host response to implanted esophageal mucosa ECM-
derived bioscaffolds in a preclinical murine model of abdominal wall defect.  
When used to repair an abdominal wall defect in the rat, bioscaffolds derived from the 
extracellular matrix of the esophageal mucosa can modulate the host response and promote a 
pro-remodeling environment as indicated by M2/M1 macrophage ratios and histologic 
examination.  
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Aim 2: To evaluate the tissue specific effects of biologic scaffolds derived from esophageal 
tissues in vitro and in a preclinical murine model of esophageal mucosal resection  
Porcine heterogeneous cell populations isolated from murine esophageal tissue and 
exposed to degradation products from esophageal ECM show no preference over degradation 
products from ECMs derived from UBM or SIS. Furthermore, when implanted in a model of 
esophageal mucosal repair, esophageal ECM, UBM and SIS present the same performance under 
the evaluated criteria.  
 
Aim3: To evaluate the ability of cardiac-ECM to modify the host response to an implanted 
cardiac patch in a preclinical murine model of myocardial infarction. 
Modification of a PEUU cardiac patch with a cardiac-ECM enriched layer can modify the 
host response following implantation 2-weeks post MI in a rat model. Findings include increased 
ventricular wall thickness over infarcted region compared to non-modified PEUU control, and 
reduce area of scar tissue formation. 
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